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Background: Cardiovascular magnetic resonance (CMR) is increasingly used in patients who activate
the primary percutaneous coronary intervention (PPCI) pathway to assess heart function. It is uncertain
whether having CMR influences patient management or the risk of major adverse cardiovascular events
in these patients.
Objective: To determine whether or not it is feasible to set up a national registry, linking routinely
collected data from hospital information systems (HISs), to investigate the role of CMR in patients who
activate the PPCI pathway.
Design: A feasibility prospective cohort study.
Setting: Four 24/7 PPCI hospitals in England and Wales (two with and two without a dedicated
CMR facility).
Participants: Patients who activated the PPCI pathway and underwent an emergency coronary angiogram.
Interventions: CMR either performed or not performed within 10 weeks of the index event.
Main outcome measures: A. Feasibility parameters – (1) patient consent implemented at all hospitals,
(2) data extracted from more than one HIS and successfully linked for > 90% of consented patients at all
four hospitals, (3) HIS data successfully linked with Hospital Episode Statistics (HES) and Patient Episode
Database Wales (PEDW) for > 90% of consented patients at all four hospitals and (4) CMR requested
and carried out for ≥ 10% of patients activating the PPCI pathway in CMR hospitals. B. Key drivers of
cost-effectiveness for CMR (identified from simple cost-effectiveness models) in patients with (1) multivessel
disease and (2) unobstructed coronary arteries. C. A change in clinical management arising from having
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CMR (defined using formal consensus and identified using HES follow-up data in the 12 months after the
index event).
Results: A. (1) Consent was implemented (for all hospitals, consent rates were 59–74%) and 1670 participants
were recruited. (2) Data submission was variable – clinical data available for ≥ 82% of patients across all
hospitals, biochemistry and echocardiography (ECHO) data available for ≥ 98%, 34% and 87% of patients in
three hospitals and medications data available for 97% of patients in one hospital. (3) HIS data were linked
with hospital episode data for 99% of all consented patients. (4) At the two CMR hospitals, 14% and 20% of
patients received CMR. B. In both (1) multivessel disease and (2) unobstructed coronary arteries, the difference
in quality-adjusted life-years (QALYs) between CMR and no CMR [‘current’ comparator, stress ECHO and
standard ECHO, respectively] was very small [0.0012, 95% confidence interval (CI) –0.0076 to 0.0093 and
0.0005, 95% CI –0.0050 to 0.0077, respectively]. The diagnostic accuracy of the ischaemia tests was the key
driver of cost-effectiveness in sensitivity analyses for both patient subgroups. C. There was consensus that CMR
leads to clinically important changes in management in five patient subgroups. Some changes in management
were successfully identified in hospital episode data (e.g. new diagnoses/procedures, frequency of outpatient
episodes related to cardiac events), others were not (e.g. changes in medications, new diagnostic tests).
Conclusions: A national registry is not currently feasible. Patients were consented successfully but
conventional consent could not be implemented nationally. Linking HIS and hospital episode data was
feasible but HIS data were not uniformly available. It is feasible to identify some, but not all, changes in
management in the five patient subgroups using hospital episode data. The delay in obtaining hospital
episode data influenced the relevance of some of our study objectives.
Future work: To test the feasibility of conducting the study using national data sets (e.g. HES, British
Cardiovascular Intervention Society audit database, Diagnostic Imaging Dataset, Clinical Practice
Research Datalink).
Funding: The National Institute for Health Research (NIHR) Health Services and Delivery Research
programme. This study was designed and delivered in collaboration with the Clinical Trials and Evaluation
Unit, a UK Clinical Research Collaboration-registered clinical trials unit that, as part of the Bristol Trials
Centre, is in receipt of NIHR clinical trials unit support funding.
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Plain English summary
Cardiovascular magnetic resonance (CMR) is a non-invasive test that can be used to assess damageto the heart and help guide treatment in people who have had a suspected heart attack. CMR is
expensive (≈£300), so it is important to know whether or not it benefits patients or the NHS.
This study had two aims. The first was to find out whether or not it is feasible to create a database of
patients who had a suspected heart attack by bringing together information collected routinely during
patients’ hospital care. The second was to determine the ways in which CMR changes treatment.
A registry database could be used to test whether or not patients who undergo CMR do better than
those who do not undergo CMR.
Attempts were made to identify all eligible individuals at four hospitals, obtain their consent to participate,
collect information from the hospital where they were treated, including whether or not they had CMR,
and combine this with other information collected routinely during patients’ hospital care over the
following year.
A group of experts discussed and agreed in whom, and in what ways, CMR can influence treatment. Some
of these treatments could be identified in the data about participants’ care in the year after their heart
attack. However, most hospitals were unable to provide all the information requested about the suspected
heart attack. Using conventional ways of recruiting participants, it was not possible to invite many patients
who would have been eligible. Therefore, it is not currently feasible to establish the database.
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Scientific summary
Background
Cardiovascular magnetic resonance (CMR) is a non-invasive imaging technique that assesses heart structure
and function with high spatial and temporal resolution. The use of CMR has increased in all subgroups of
acute coronary syndrome (ACS) patients, including those who activate the primary percutaneous coronary
intervention (PPCI) pathway. It is unknown if undergoing CMR influences patient management or reduces
the length of hospital stay or the risk of major adverse cardiovascular events (MACEs) in these patients.
Objectives
l To determine whether or not it is feasible to set up a national registry linking routinely collected data
from hospital information systems (HISs) for the index event (emergency angiography with or without
PPCI) with hospital episode data [from Hospital Episode Statistics (HES) and Patient Episode Database
Wales (PEDW), which collects equivalent information for the NHS Wales hospitals] and death registration
data [from the Office for National Statistics (ONS)] for follow-up in the 12 months after the index event,
in order to investigate the role of CMR in patients who activate the PPCI pathway.
l To describe resource use and associated costs of having CMR and to identify key drivers of
cost-effectiveness for CMR.
l To identify an outcome measure representing a definitive change in clinical management, conditional
on having undergone CMR, that would be credible to cardiologists and other stakeholders as an
interim measure of the ‘value added’ by doing CMR.
Design
The study included three components to address the objectives listed in the preceding section:
1. Feasibility prospective cohort study – we established if we could implement patient consent, extract data
about the index event from multiple HISs and link these data with hospital episode data for follow-up.
We also quantified the proportion of patients who undergo CMR. We explored whether or not the
cohort study could be set up using only hospital episode data.
2. Simple cost-effectiveness models – we developed economic decision models in two subgroups of
patients who activate the PPCI pathway: (1) patients with multivessel disease and (2) patients with
unobstructed coronary arteries. These subgroups were identified in the protocol (before commencing
work on the study) as having the potential to benefit from CMR.
3. Formal consensus study – we defined important changes in management resulting from CMR and
subgroups of patients to whom these changes relate. Potential changes in management were described
from literature review and cardiologist expert opinion and were reviewed by a consensus panel and
additional cardiologists (from across the UK). We determined whether or not changes in management
defined as being important by formal consensus could be identified in hospital episode data in the
12 months following the index event, with the intention to formulate an ‘interim’ outcome measure
representing a definitive change in clinical management that could be used for a future registry.
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Setting
l Feasibility prospective cohort study: four 24/7 PPCI hospitals in England and Wales (two with and two
without a dedicated CMR facility, both representing usual care in the NHS).
l Cost-effectiveness models: usual care (with or without CMR) in the NHS.
l Formal consensus study: secondary care (cardiology departments) across the UK.
Study population
Feasibility prospective cohort study
This comprised patients who activated the PPCI pathway and underwent an emergency coronary
angiogram whether or not they received PPCI. We included patients if they were aged ≥ 18 years and
underwent an emergency angiogram, defined as taking place within 2 hours of arrival at the hospital,
unless specified otherwise by local protocols. We excluded patients if they were prisoners or lacked mental
capacity to consent.
Cost-effectiveness models
l Model 1 (multivessel disease): patients who activate the PPCI pathway, have their index angiography
and PPCI and are identified as having multivessel disease (commonly defined as stenosis of > 50% from
the angiogram) in two or more coronary arteries.
l Model 2 (unobstructed coronary arteries): patients who activated the PPCI pathway, had their index
angiography and were found to have unobstructed coronary arteries.
Formal consensus study
This comprised consultant cardiologists with CMR, interventional, echocardiography (ECHO), electrophysiology
and heart failure expertise from across the UK.
Intervention(s)
Feasibility prospective cohort study
Cardiovascular magnetic resonance performed/not performed within 10 weeks of the index event (whether
during the index admission or subsequently as an outpatient). All patients were assumed to receive
standard ECHO as part of usual care.
Cost-effectiveness models
l Model 1 (multivessel disease): three different ischaemia testing methods; CMR versus stress ECHO
versus pressure wire.
l Model 2 (unobstructed coronary arteries): CMR and standard ECHO versus standard ECHO alone.
Formal consensus study
For each statement, CMR was considered alongside standard or stress ECHO as appropriate.
Main outcome measures
Feasibility prospective cohort study
l Patient consent implemented at all four hospitals.
l Data linkage and extraction from multiple local HISs achieved for > 90% of consented patients at all
four hospitals.
l Local data successfully linked with hospital episode data for > 90% of consented patients at all
four hospitals.
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l CMR requested and carried out for ≥ 10% of patients activating the PPCI pathway in CMR hospitals.
l Whether or not the registry could be compiled from hospital episode data rather than from multiple HISs.
Cost-effectiveness model
The main outcomes were key drivers of cost-effectiveness for CMR in patients with (1) multivessel disease
(model 1) and (2) unobstructed coronary arteries (model 2).
Formal consensus study
l Identification, through formal consensus, of the important changes in management resulting from
CMR and the subgroups of patients to whom these changes relate.
l Identification of relevant subgroups of patients in the data sets obtained (local HISs and follow-up
hospital episode data).
l Ascertainment of the consequences of important changes in management from hospital episode data.
Data sources
Feasibility prospective cohort study
l Index procedure: local HIS at each participating hospital –
¢ basic demography [local Patient Administration System (PAS)/British Cardiovascular Intervention
Society – Central Cardiac Audit Database (BCIS-CCAD)]
¢ clinical characteristics on presentation at the index admission, peri- and post-procedural (PPCI)
characteristics (local catheter laboratory database/BCIS-CCAD)
¢ ECHO and CMR reports (local imaging databases)
¢ biochemistry (local biochemistry databases)
¢ medications on discharge (one hospital only).
l Follow-up: hospital episode data. We requested inpatient, outpatient, accident and emergency and
critical care data sets.
Cost-effectiveness models
Data were sourced from a literature review for model parameter estimates and NHS Reference Costs
(Department of Health and Social Care. NHS Reference Costs 2015 to 2016. London: Department of
Health and Social Care; 2016) for unit costs.
Formal consensus study
For the formal consensus study, data were sourced from a literature review and cardiologist expert opinion.
In-hospital data were sourced from local HIS data and follow-up data were sourced from HES data.
Results
Feasibility prospective cohort study
l Consent using conventional methods was successfully implemented (across all hospitals, consent rates
were 59–74%); 2462 patients were screened (May 2013–September 2014) but only 1670 participants
(68%) were recruited.
l Hospitals submitted varying numbers of requested data: clinical data (for ≥ 82% of patients across all
hospitals), biochemistry data (three hospitals, for ≥ 98% of patients), ECHO data (three hospitals,
for 34–87% of patients) and medications data (for 97% of patients in one hospital). Imaging data
(ECHO and CMR data from one hospital) were submitted as free-text reports extracted from radiology
databases.
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l HIS data were linked with hospital episode data for 99% of all consented patients. We identified an
admission that matched the index admission within ± 1 day for 93% and 97% of consented patients.
l At the two CMR hospitals, 14% and 20% of patients received CMR.
l We identified 98% of patients who underwent PPCI and 85% of patients who had an emergency
angiogram but no PCI in hospital episode data. We could identify CMR exposure in hospital episode
data for only 29% (55/189) of patients who had a CMR in our cohort.
Cost-effectiveness models
l In both model 1 (multivessel disease) and model 2 (unobstructed coronary arteries), the difference in
quality-adjusted life-years (QALYs) between CMR and no CMR was very small (0.0012, 95% CI –0.0076
to 0.0093 and 0.0005, 95% CI –0.0050 and 0.0077, respectively) (the ‘current’ comparator for model 1
is stress ECHO; the ‘current’ comparator for model 2 is standard ECHO). The diagnostic accuracy of
the ischaemia tests was the key driver of cost-effectiveness in sensitivity analyses for both model 1 and
model 2.
Formal consensus study
l There was consensus that CMR leads to clinically important changes in management in five patient
subgroups, namely those with: (1) out-of-hospital cardiac arrest, (2) unobstructed coronary arteries,
(3) left ventricular (LV) thrombus, (4) multivessel disease and (5) PPCI with CMR markers indicating
poor prognosis.
l Patients with unobstructed arteries and PPCI patients could be identified from both the local HIS data
set and hospital episode data. Patients with an out-of-hospital cardiac arrest and PPCI patients who
developed a LV thrombus could not be identified from the local HIS data set, but could be identified in
hospital episode data. Patients with multivessel disease could be identified only from the local HIS data
set, not from hospital episode data.
l We identified the following changes in management in hospital episode data: new diagnoses and
procedures (those that resulted in hospital admission and were recorded in outpatient visits) and the
frequency of outpatient appointments related to cardiac events. We could not identify changes in
medications because there were no medication data in the hospital episode data.
Limitations
Feasibility prospective cohort study
We could not identify all eligible patients from local HISs. The conventional consent model failed to
capture a sizeable proportion of the eligible population, but we could not identify and test a more efficient
model of obtaining consent. The study population did not include patients presenting with a broader
diagnosis of ACS but not requiring emergency coronary angiography (e.g. those with non-ST elevation
myocardial infarction), who may also benefit from CMR.
The study took longer than anticipated to complete after the end of recruitment because our application
for hospital episode data coincided with the moratorium on all data requests imposed by NHS Digital
(formerly known as the Health and Social Care Information Centre). During this time, data availability/quality is
likely to have changed/improved given the rapidly evolving NHS information technology (IT) systems/platforms.
New diagnostic tests for detecting ischaemia (e.g. pressure wire), directly competing with CMR, were also
introduced during the time frame of the study and were rapidly adopted by many cardiologists. These changes
to usual care weakened the importance of the research question that we described at the outset – the
comparison of CMR versus standard ECHO/stress ECHO (usual care at the start of the study) – but highlighted
the importance of different research questions.
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Cost-effectiveness models
There is uncertainty around the majority of parameter estimates in both models. Many estimates were
based on single studies with small sample sizes. Some of these studies were conducted outside the
UK, where patient pathways differ. In the base-case analyses, CMR and pressure wire were treated as
reference standards and both were assumed to have 100% sensitivity and specificity. This assumption
may not be true and, if not, this will influence findings because the diagnostic accuracy of the ischaemia
tests was found to be the key driver of cost-effectiveness.
Individual patient data on resource use from hospital episode data were not available in time to be used in
the cost-effectiveness analyses. Therefore, we estimated resource use associated with each of the patient
pathways, so, although the standard care pathways have been costed, it is likely that we have underestimated
the variability between individual patients and their actual patient pathways. Finally, there was also uncertainty
about the utility estimates used in the cost-effectiveness models because we did not find good-quality
primary data.
Formal consensus study
The number of panel members in our expert panel was lower than the recommended 8–12 members for a
consensus panel. We extended the survey to other UK cardiologists to compensate for this and prevent
the possibility of introducing bias (given the self-selected nature of the panel). We did not include different
stakeholder groups in the consensus panel because the technical wording of the statements would not
have been easily understood by non-cardiologists. Therefore, we cannot be certain that the changes in
management that were identified are relevant to other stakeholders (e.g. commissioners and patients).
Conclusions
Feasibility prospective cohort study
We did not identify all patients who were eligible for the study; for example, patients with unobstructed
arteries (i.e. those who had an emergency angiogram but did not receive PPCI) were difficult to identify
from catheter laboratory databases. We successfully consented patients but obtaining individual, opt-in
consent would not be feasible for a national registry. We explored several consent models (i.e. opt out on
procedural consent form, standard consent at discharge) but none was implemented because of logistic
difficulties. Linkage of data from HIS with hospital episode data was feasible, but data from HIS are not
uniformly available/exportable. Information about whether or not participants had had CMR in CMR
hospitals was successfully obtained from HIS, although some referrals for CMR were for research rather
than clinical purposes. It is feasible to identify important changes in management in the five patient
subgroups in hospital episode data.
Cost-effectiveness models
For each of the base-case models, the differences in QALYs between strategies were very small; therefore,
the results were largely driven by the differences in costs, although these were also modest. Sensitivity
analyses around the two models identified the diagnostic accuracy of the ischaemia tests as the key driver
of cost-effectiveness.
Formal consensus study
We defined five subgroups of patients who activate the PPCI pathway for whom there was consensus
that CMR changes patient management in a clinically important way. All subgroups could be identified
in either the local HIS data set, hospital episode data or both. Some, but not all, important changes in
management could be identified in follow-up HES/PEDW data. The main constraints on identifying
important changes in management were (1) outpatient hospital episode data were poorly coded with
respect to the diagnosis, (2) medication data were not available at baseline or follow-up (preventing
inspection of/prescription of changes in medication after the index event) and (3) data about diagnostic
investigations were poorly coded in both acute care and outpatient data sets.
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Future work
l Identify/test a more efficient method of obtaining consent.
l Some limitations of our study are now historic and others are being addressed. Therefore, it is
recommended to test the feasibility of conducting the study using national data sets [HES/BCIS/
Diagnostic Imaging Dataset (DID), Clinical Practice Research Datalink (CPRD) for medications], which are
likely to be able to capture all of the eligible population, without the need for individual patient consent;
MACEs could be used as the outcome.
l Cost-effectiveness models suggest that it is important for the NHS to have a definitive answer about
the relative diagnostic accuracy of CMR versus pressure wire, despite the fact that the pressure wire is
rapidly superseding CMR across catheter laboratories.
l A feasible registry is a goal worth pursuing, offering a test bed for the rapid evaluation of changes in
practice in this expensive and fast-moving area of clinical care (often driven by commercial interest).
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research (NIHR). This study was designed and delivered in collaboration with
the Clinical Trials and Evaluation Unit, a UK Clinical Research Collaboration-registered clinical trials unit
that, as part of the Bristol Trials Centre, is in receipt of NIHR clinical trials unit support funding.
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Chapter 1 Introduction
Background and rationale
Cardiovascular magnetic resonance (CMR) is a non-invasive imaging technique that assesses heart structure
and function with high spatial and temporal resolution. The use of CMR has increased in recent years
in all subgroups of acute coronary syndrome (ACS) patients, including those who activate the primary
percutaneous coronary intervention (PPCI) pathway.1 It is not clear whether or not having CMR influences
patient management or reduces the length of hospital stay or the risk of major adverse cardiovascular
events (MACEs) in these patients. Systematic reviews from 2014 highlighted the lack of high-quality,
adequately powered studies to establish the prognostic value of CMR findings in patients who activate
the PPCI pathway.2,3 Similarly, few studies have assessed how CMR changes patient management, despite
the fact that cardiologists believe that CMR brings about important changes in management.4
Primary percutaneous coronary intervention
Primary percutaneous coronary intervention is the primary therapeutic approach for restoring blood flow
to the heart in ACS patients who have had a ST-elevation myocardial infarction (STEMI). Currently, across
the UK ≈97% of patients with a STEMI who received any reperfusion treatment were treated with PPCI.5
Management of the in-hospital stay and follow-up after PPCI is determined by the final infarct size, the
presence or absence of comorbidities and patient characteristics. About 10% of patients with ACS who
activate the PPCI pathway (i.e. those that present with chest pain and ST-elevation or chest pain and
new-onset left bundle branch block on electrocardiogram) are found to have unobstructed coronary arteries
on angiography and, therefore, do not receive PPCI. There are no long-term outcome data from well-designed,
multicentre trials on CMR use in different subgroups of patients who activate the PPCI pathway. There are also
no studies reporting on the cost-effectiveness of CMR in these patients (or indeed patients from other clinical
areas), which makes decision-making regarding the provision of CMR services within the NHS difficult.
Subgroups of patients who activate the primary percutaneous coronary intervention
pathway and may benefit from cardiovascular magnetic resonance
Two subgroups of patients were identified in the protocol as having the potential to benefit from CMR:
(1) patients with multivessel disease and (2) patients with unobstructed coronary arteries on angiography.
It is estimated that 40–65% of the patients presenting with a STEMI have multivessel disease (depending
on the baseline characteristics, e.g. age, of the population studied).6–11 There is ongoing debate about the
optimal treatment strategy for these patients. Three main treatment management strategies have been
proposed/are currently used: (1) conservative, PPCI of the infarcted artery followed by medical therapy
(unless ischaemia occurs), (2) staged, in which only the infarct-related artery is treated acutely and other
lesions are treated at a later date and (3) aggressive, percutaneous coronary intervention (PCI) of all
significant lesions at the time of PPCI.
The role of CMR in patients with multivessel disease is undefined. CMR allows the volume of ischaemic or
poorly perfused myocardium to be quantified but it is not known whether or not access to CMR to plan
further revascularisation influences management. Since the Primary percutaneous coronary Intervention
Pathway Activation (PIPA) study was commissioned, there has also been a rapid increase in the use of fractional
flow reserve (FFR) testing (a guide wire-based procedure done through a standard diagnostic catheter at the
time of a coronary angiography) to assess ischaemia; this technology is available to interventional cardiologists
in the catheter laboratory. CMR is comparable to FFR for detecting ischaemia; studies have shown excellent
diagnostic accuracy of perfusion CMR to detect areas of ischaemia identified by FFR.12,13 However, while FFR
may be appropriate in symptomatic, high-risk patients for whom the benefit of an invasive approach to
ischaemia testing may outweigh the risks (i.e. the likelihood of revascularisation is high; therefore, lesions can
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be revascularised at the same time as the FFR), the benefit is less clear in asymptomatic multivessel disease
patients. CMR may, therefore, have a role in selecting patients who will receive the greatest benefit from these
invasive procedures. The non-inferiority of CMR in managing patients with multivessel disease is the subject of
the magnetic resonance perfusion imaging to guide management of patients with stable coronary artery
disease (MR-INFORM) trial.14
The reported variation in the incidence of normal coronary angiograms in patients activating the PPCI
pathway is between 3% and 16%.15,16 It is in this group that cardiologists believe that CMR has the
greatest potential to change patient management. In these patients, the lack of an accurate diagnosis may
result in inappropriate treatment and/or follow-up,17,18 associated with a poorer prognosis.19 A definitive
diagnosis of myocardial infarction (MI) or not is also important so that these patients can be managed and
followed up appropriately. Studies have shown that CMR can facilitate differential diagnosis in the context
of a normal coronary angiogram,20–22 providing a definitive diagnosis (e.g. MI, myocarditis, Takotsubo
cardiomyopathy) in 65–90% of these patients.20,23,24 Although the prognostic implications of non-MI CMR
abnormalities are not known, two studies showed that the pattern of CMR abnormalities in myocarditis
was predictive of long-term outcome.25,26
The benefit of CMR to other subgroups of patients who activate the PPCI pathway is less clear. However,
given that not all of these patients will have access to centres with dedicated CMR facilities, there is
potential for health inequality across the UK, which needs to be identified. Therefore, the population of
interest for this study (target population) includes all ACS patients who activate the PPCI pathway,
regardless of whether or not they receive PPCI.
Rationale for the study
We wanted to set up a multicentre, prospective cohort study (registry) in ACS patients who activate the PPCI
pathway by linking routinely collected data from hospital information systems (HISs) with follow-up data
from Hospital Episode Statistics (HES) and the Office for National Statistics (ONS). The aims of the registry
were to document CMR activity in patients who activate the PPCI pathway and to provide information on
CMR use, uptake over time, patients’ characteristics associated with being referred for CMR, the impact of
CMR on patient management (e.g. early discharge of a patient with a normal coronary angiogram or the
placement of an additional stent for a patient with multivessel disease) and the prognostic value of CMR
after PPCI.
We were uncertain whether or not it would be feasible to set up a registry in this patient population
using routinely collected data. In particular, we were uncertain if we could (1) easily identify the eligible
population, (2) implement a ‘light-touch’ consent system across multiple hospitals and (3) extract and link
data sets from multiple HISs in different hospitals. We also wanted (4) to provide a reliable estimate of
the CMR rate in patients who activate the PPCI pathway and (5) to define a ‘proxy’ primary composite
outcome, acceptable to cardiologists and other stakeholders (e.g. clinical commissioners) as representing
a clinically important change in management as a result of an eligible patient having undergone CMR
(e.g. expected to prevent future MACEs). Item number 5 was included so that the registry would be able
to assess effectiveness in the medium term. A long-term objective of the registry would be to compare the
incidence of MACEs in patients who do or do not have CMR after the index event, but the low frequency
of MACEs means that the study would have to accrue over 37,000 subjects to detect a clinically important
reduction in the incidence of MACEs with adequate power.
INTRODUCTION
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Chapter 2 Aims and objectives
The aim of the study was to evaluate the feasibility of setting up a UK multicentre registry study todocument CMR use in patients who activate the PPCI pathway. There were three elements to the study,
listed below with the associated objectives.
A. To determine whether or not it is feasible to set up a CMR registry in this patient population by linking
sources of routinely collected data.
¢ Objective A1: to implement consent and establish patient consent rate.
¢ Objective A2: to provide evidence of whether or not data linkage and extraction can be carried out
across PPCI centres.
¢ Objective A3: to determine whether the registry can be compiled from hospital episode data
[HES and Patient Episode Database Wales (PEDW)] rather than multiple HISs.
B. To estimate the proportion of the target population who have CMR at two centres with dedicated
CMR facilities and to describe resource use and associated costs of having CMR after PPCI.
¢ Objective B1: to estimate the proportion of the target population who get a CMR scan following
PPCI pathway activation.
¢ Objective B2: to develop simple cost-effectiveness models in relevant subgroups of patients who
activate the PPCI pathway in order to identify key drivers of cost-effectiveness for CMR imaging in
patients who activate the PPCI pathway.
C. To identify an outcome measure representing a definitive change in clinical management, conditional
on having undergone CMR, that would be credible to cardiologists and other stakeholders as an interim
measure of the value added by doing CMR.
¢ Objective C1: to define, using formal consensus methods, a treatment/process outcome that will
constitute a definitive change in clinical management arising from having undergone CMR.
¢ Objective C2: to identify patient subgroups in whom CMR use is indicated using formal consensus
methods and illustrative data from the registry.
¢ Objective C3: to determine whether or not hospital episode data adequately capture the main
changes in clinical management that are identified using formal consensus.
¢ Objective C4: to pilot the implementation of a primary outcome that is based on the changes in
management, for which consensus was achieved using hospital episode data.
Conditional on the success of achieving objectives A, B and C, there was a final objective, D, for which we
envisaged that we would define the research objectives and calculate the sample size needed for a cohort
study to achieve the aim of evaluating the clinical effectiveness and cost-effectiveness of CMR after PPCI
pathway activation, with respect to the outcome identified by objective C.
Changes to objectives during the study
The objectives described above comprise all objectives that were studied rather than the objectives at the
outset. The following objectives were added or modified during the course of the study.
With respect to objective A3, we faced several challenges when identifying the eligible population and
implementing patient consent in the PPCI centres. These are described in detail in Chapter 3. We therefore
wanted to determine whether or not we could identify ACS patients who activate the PPCI pathway in
hospital episode data in order to determine whether or not a future registry in this patient population
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could be set up solely from hospital episode data (Chapter 4, Identifying the eligible study cohort and
cardiovascular magnetic resonance exposure in hospital episode data).
With respect to objective B2, we originally planned to identify key cost drivers empirically, by describing
resource use and associated costs of having CMR after PPCI pathway activation from HES and PEDW data
for participants during follow-up of the cohort. We experienced considerable delays in obtaining HES data,
which prevented us from doing this. Therefore, the economists used an alternative approach, seeking
secondary sources of data as inputs into economic decision models to identify the key drivers of
cost-effectiveness, that is the model parameters that most influence estimates.
With respect to objective C4, we had initially intended to collect follow-up data from each participating
hospital to identify the changes in clinical management that could result from CMR (defined through the
formal consensus). However, we realised early on that this would not be possible for a proportion of
our cohort because many patients whom we recruited had their treatment at the PPCI centres but were
quickly repatriated to their local hospital. We therefore decided that following the cohort through hospital
episode data would provide more complete data because follow-up data would be available for all patients
regardless of which hospital (within England or Wales) they attended after their index admission/procedure.
With respect to objective C3, some of the cardiologists in the research team were sceptical about our ability
to pick up potential changes in clinical management resulting from CMR using HES and PEDW data. They
highlighted that changes in clinical management may be too subtle to be captured in a data set that records
only information about inpatient, outpatient and accident and emergency (A&E) attendances. In contrast,
electronic data sources in many hospitals capture a range of additional information, for example prescribing
data and patient-level nursing observation data. We therefore designed a questionnaire requesting specific
information from the referring cardiologists about how CMR changed management in all patients in our
study who were referred for a CMR. We determined whether or not changes in management described in
the questionnaire were adequately reflected in hospital episode data [see Chapter 6, Implementation of a
primary outcome based on the changes in management for which consensus was achieved (objectives C3
and C4)].
Major delays with the study
The major delay to the study was receiving the HES/ONS linked data set from NHS Digital. Below is a
timeline of our data request and the processing of our application:
l 24 June 2013 – application was submitted to NHS Digital. We were told that our application would be
processed closer to the time at which we required the data (September 2014), because our request
was straightforward and the data set would not take long to assemble.
l March 2014 – NHS Digital commissioned an independent review into data release and stopped
processing all applications.
l March 2015 – NHS Digital began processing our application.
l August 2016 – linked HES/ONS data received.
This process added a 23-month delay to the study.
AIMS AND OBJECTIVES
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Chapter 3 Methods
Feasibility prospective cohort study (objectives A1, A2, A3 and B1)
Parts of this text have been reproduced from Brierley et al.27 © Article author(s) (or their employer(s) unless
otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless
otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/.
Study population
We aimed to approach all ACS patients who activated the PPCI pathway. This population included all
patients who underwent an emergency angiogram, whether or not they received PPCI. We included
patients if they were aged ≥ 18 years and underwent an emergency angiogram, defined as taking place
within 2 hours of arrival at the hospital, unless specified otherwise by local protocols. We excluded patients
if they were prisoners or lacked mental capacity to consent. There were no changes to the eligibility criteria
during the study recruitment period. The study was reviewed and approved by the National Research
Ethics Committee South West-Central Bristol (reference number 12/SW/0326).
Setting
Four NHS hospitals in England and Wales hosting 24/7 PPCI centres took part:27 the Bristol Heart Institute
(University Hospitals Bristol NHS Foundation Trust), Leeds General Infirmary (Leeds Teaching Hospitals NHS
Trust), Morriston Hospital (Abertawe Bro Morgannwg University Health Board, Swansea) and University
Hospital of Wales (Cardiff & Vale University Health Board). Two of these hospitals (Bristol and Leeds)
were defined as ‘coronary magnetic resonance (CMR) centres’, that is hospitals that had a dedicated CMR
service. The other two hospitals (Swansea and Cardiff) were defined as ‘non-CMR centres’, that is hospitals
that did not have access to a dedicated CMR service.
Patient identification and consent
Each hospital implemented its own methods for identifying and consenting patients. Most eligible patients
were identified manually (e.g. by checking catheter laboratory records, by checking the local cardiology
database or both). One of the participating hospitals set up a database query (including the search terms
‘PPCI’, ‘QueryNot’ and ‘QuerProc’) in the local cardiology database to flag up eligible patients. However,
the query was broad and relied on data input by staff in the catheter laboratory, which changed in
‘real-time’. This made identification of some eligible patients difficult. For example, if a patient was
originally marked as ‘PPCI’ but was subsequently found to have an unobstructed coronary artery on the
angiogram, the ‘PPCI’ label was removed, but no further information was added, necessitating manual
searches by local research staff to identify whether or not the patient was eligible.
We gave eligible patients information about the study once they had recovered sufficiently from their
angiography and consented them before they were discharged from hospital (see Appendix 1 for a copy
of the consent form). In some hospitals, this was often not possible because of quick repatriation to the
originating hospital or research staff not being available over the weekend. Patients who could not be
approached in person were sent study information and consent forms by post. Postal consents were
managed locally at each hospital. We requested consent to use all the information collected by the
hospital in relation to the patients’ suspected MI (index admission) and all the information related to
subsequent NHS care and vital status in the first 12 months following the index admission.27
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Exposure
Patients were classified as exposed if they received CMR within 10 weeks of the index admission (whether
during the index admission or subsequently as an outpatient). CMR had to be documented (i.e. CMR
report, including the date of the CMR) in the clinical radiology information system (CRIS) or similar imaging
database when the date/time of the CMR was < 10 weeks (70 days) after the date of the index admission.
Data collection: index procedure
We asked each hospital to provide the following data from local HISs for all recruited patients:
l basic demography [local Patient Administration System (PAS)/British Cardiovascular Intervention Society
(BCIS) Central Cardiac Audit Database (CCAD)]
l clinical characteristics on presentation at the index admission, peri- and post-procedural (PPCI)
characteristics {local catheter laboratory database [e.g. Siemens (Munich, Germany) CARDDAS in
Bristol]/BCIS-CCAD}
l echocardiography (ECHO) and CMR reports (local imaging databases, e.g. Picture Archiving and
Communication System, CRIS, CRIS in Bristol)
l biochemistry [local biochemistry databases, e.g. Virtual Pathology Laboratory System/Integrated Clinical
Environment (ICE) in Bristol]
l medications on discharge (local biochemistry database, e.g. ICE in Bristol).
Each hospital had the option to submit a linked data set (i.e. the participating hospital linked data from
different HISs within the hospital) or unlinked data extracts from each of the above categories with a
unique patient identifier in each extract. We established a data linkage model at Bristol (by liaising with
the appropriate HIS managers at University Hospitals Bristol NHS Foundation Trust) and informed the other
hospitals that we would undertake linkage at Bristol based on this model, although the decision about
how to submit the data was left to each participating hospital.27
We collected a limited anonymised data set to characterise the eligible patients who were not recruited, that
is those who declined to consent or did not respond to an invitation to consent before study recruitment
ended. Hospitals were provided with a look-up table containing the Index of Multiple Deprivation (IMD)28
or Welsh Index of Multiple Deprivation (WIMD)29 for English or Welsh postcodes, so that the anonymised
data sets could contain information on deprivation, both as scores and ranks, without including postcodes,
which might have compromised anonymity. IMD and WIMD are calculated from combined information
from several domains (e.g. income, employment, education, health) to produce an overall relative measure
of deprivation.
Data collection: follow-up
For subsequent inpatient and outpatient activity in the 12 months following the index admission, we
applied to NHS Digital to link our data set with HES (i.e. inpatient, outpatient, A&E and critical care data)
for the hospitals in England and to NHS Wales Information Service (NWIS) for PEDW (which collects
equivalent information for NHS Wales hospitals) for the hospitals in Wales. Inpatient episode data (HES
and PEDW) contain details of hospital admissions (including dates of admission and discharge) and main
diagnoses/procedures. Outpatient data contain appointment dates and consultant specialty. A&E data
contain dates, methods and sources of arrival at hospital.
NHS Digital routinely links HES with ONS mortality data. Mortality data were unavailable through NWIS,
so the two Welsh hospitals provided these data for their patients. Identifiers and evidence of signed
consent were submitted via a secure portal to NHS Digital and NWIS; HES, ONS and PEDW data were
received with our unique patient identifier embedded within each file for linkage.
Admissions data were provided as data relating to an episode (i.e. admission under one consultant), but
we restructured the data to relate to a ‘continuous inpatient spell’ regardless of any transfers to another
consultant that may have taken place within the same admission.30 We created a data set containing
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the admissions data that included the index admission and the admissions, outpatient, critical care and
A&E data in the 12 months after the index admission. This was used to characterise the frequency and
duration of outpatient follow-up, unscheduled cardiac-related hospital readmissions and cardiac-related
investigations/procedures, such as diagnostic angiography, repeat PCI or cardiac surgery up to 1 year after
the index admission.
We assumed that, if patients had any HES/PEDW data (e.g. admissions, outpatient and A&E), data not
recorded in any of the data sets were absent (i.e. patient did not have an episode) rather than missing
(i.e. data not entered). In addition, for those patients with a CMR within 10 weeks of their index admission,
outpatient visits that occurred within this window were excluded from any counts.
Main outcome measures
The main prespecified outcome measures were feasibility parameters (criteria that would have to be met
before making the decision to progress to setting up a full registry):
l patient consent implemented at all four hospitals
l data linkage and extraction from multiple local HISs achieved for > 90% of consented patients at all
four hospitals
l local data successfully linked with HES and PEDW for > 90% of consented patients at all four hospitals
l CMR scan requested and carried out for ≥ 10% of patients activating the PPCI pathway in CMR hospitals.27
Feasibility of compiling the registry from hospital episode data
We tested the feasibility of compiling the registry entirely through hospital episode data. We determined
whether or not we could identify the following from hospital episode data:
l the index event (PPCI or emergency angiography, cohort entry)
l CMR within 10 weeks of the index event (exposure)
l relevant subgroups of the population in which CMR may influence clinical management [identified
through formal consensus, see Formal consensus study (objectives C1 and C2)]
l clinical outcomes [MACEs, comprising death, MI, stroke, repeat PCI and a coronary artery bypass
graft (CABG)].
We identified events corresponding to the index admission, exposure or outcome in HES and PEDW data
sets (inpatient and outpatient) using the International Classification of Diseases, Tenth Edition (ICD-10)31 and
the Office of Population Censuses and Surveys (OPCS) classification procedure codes.32 The index admission
was identified from the inpatient data set using the OPCS codes for PCI (K49, K50, K75) and ICD-10 codes
for ST-elevation myocardial infarction (STEMI) (I21.0, I21.1, I21.2, I21.3) to identify PPCI patients, and
OPCS codes for angiography (K63.3, K63.5 or K63.6) with a method of admission coded as emergency to
identify patients who underwent an emergency angiogram. We identified exposure (OPCS code U10.3)
in the inpatient and outpatient data sets. We regarded all procedure codes within 1 day of the index
admission (PCI and emergency angiography) or subsequent CMR to relate to the same event recorded in
our HIS data set. Clinical outcomes were identified using the following codes: ICD-10 I21 for MI and I64
for stroke, and OPCS K49, K50 or K75 for PCI and OPCS K40, K41, K42, K43, K44, K45 or K46 for CABG.
A full list of codes is shown in Appendix 2.
Sample size considerations
This was a feasibility study. We aimed to recruit sufficient patients to address the study objectives,
not to provide a definitive answer to questions about the clinical effectiveness and cost-effectiveness
of CMR in patients who activate the PPCI pathway. None of the objectives was analytic and, therefore,
a power-based sample size justification was not appropriate.
Objective A2 and objective B1 required quantitative estimates to be reported. The target sample size of
1600 patients was assessed as sufficient to allow these proportions to be estimated with satisfactory
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precision. For example, we expected that ≥ 90% of patients who were invited to take part in the study
would give consent; the 95% confidence interval (CI) for this proportion would be 88.4% to 91.4%.
Similarly, we estimated that 12.5% of the target population would have CMR, although this proportion
was less certain. The 95% CIs for proportions 5%, 10% and 15% would be, respectively, 4.0% to 6.2%,
8.6% to 11.6% and 13.3% to 16.8%.
Data analysis
Data were analysed using Stata/IC® version 13 (StataCorp LP, College Station, TX, USA). The analysis
of feasibility outcomes was descriptive, with quantitative results expressed as counts, percentages and
95% CIs. Feasibility was assessed by comparing descriptive statistics with the corresponding criteria. We
compared patients who did not consent (and for whom we received anonymised data) with those who did
consent using standardised mean differences (SMDs).27,33 We used means and standard deviations (SDs),
or medians and interquartile ranges (IQRs), for continuous variables and number (per cent) for categorical
variables to report the demographic variables and baseline characteristics of patients recruited from the
four hospitals.
Clinical events were expressed as rates per 1000 person-years at risk, along with 95% CIs calculated using
the Poisson distribution. Time at risk of death was calculated as the time from index admission to death for
those known to have died within 12 months, or the time from index admission to the calendar date on
which death data were provided for that site. Any time at risk of death of > 12 months was capped at
12 months.
Time at risk for MI, stroke, repeat PCI and CABG was calculated as the time from index admission to the
event, or the time from index admission to the calendar date that follow-up data were provided for that
site. If the patient died before experiencing the event, the time at risk of death was time from index
admission until death. Any time at risk of death of > 12 months was capped at 12 months.
Formal consensus study (objectives C1 and C2)
Parts of this text have been reproduced from Brierley et al.27 © Article author(s) (or their employer(s) unless
otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless
otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.
org/licenses/by/4.0/.
Literature review
We searched for studies reporting the impact of CMR on prognosis, patient management and risk
stratification in the population of patients who activate the PPCI pathway. We intended to identify studies
providing background knowledge to inform the formulation of statements about how CMR could change
patient management in specific subgroups and as supporting evidence for the final consensus statements.
We did not intend to carry out a formal quantitative systematic review of the effectiveness of CMR in the
target population.
We searched without restriction by study design or search terms related to outcomes, so that we could
determine the full extent of the literature in this area and identify all studies that used CMR in our
population. Thus, the search identified studies that had diverse objectives and measured a range of
outcomes (e.g. clinical outcomes, changes in patient management, classifications of patients into prognostic
groups, new diagnoses). The search was conducted on MEDLINE, EMBASE, The Cochrane Library, Web of
Science (Citations Index and Proceedings) and Bioscience Information Service (BIOSIS) (date range for all
searches: 1950 to 16 January 2014). The following search terms were used, both as free text and medical
subject headings (MeSH) when possible: ‘acute coronary syndrome’, ‘myocardial infarction’, ‘angioplasty’,
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‘percutaneous coronary intervention’ and ‘cardiovascular magnetic resonance imaging’. We applied no
restriction on publication date or language. The literature search is shown in Appendix 3.
We included all studies reporting the use of CMR in patients undergoing PPCI or patients who activated
the PPCI pathway but did not proceed to PPCI (e.g. had an emergency angiogram). We excluded studies
investigating the use of CMR in populations with stable coronary artery disease or patients with non-ST
elevation myocardial infarction (NSTEMI), because these patients do not routinely undergo emergency
angiography. One researcher triaged the titles and abstracts identified by the search to remove duplicate
reports of the same study and studies that did not meet the inclusion criteria. Reference lists of full-text
papers were scanned to ensure that no additional studies had been missed during the search.
The broad search identified many different types of study (e.g. diagnostic, prognostic, controlled or
uncontrolled, prospective or retrospective, cohort studies) and case reports. They were grouped as follows:
(1) studies assessing the prognostic value of a comprehensive CMR scan or specific CMR markers, (2) studies
in which CMR was used to ‘diagnose’ a specific feature (e.g. type of MI) or complication arising from the index
MI [e.g. left ventricular (LV) thrombus, ventricular septal defect (VSD)], or procedure-related complications,
(3) studies in which CMR was used to ‘diagnose’ incidental findings or conditions unrelated to MI, (4) studies
in which indices of heart function (e.g. myocardial viability, necrosis, perfusion, myocardium at risk, ischaemia)
assessed by CMR and other imaging modalities [e.g. ECHO and single-photon emission computed tomography
(SPECT)] were compared and (5) other studies not fitting into any of the categories above.
Formulation of consensus statements
An expert group was convened, consisting of two cardiologists with CMR expertise (CBD and JPG), two
interventional cardiologists from sites participating in the feasibility study (SHD and RAA), one cardiac network
director (SB), two methodologists (BCR and MP), two statisticians (CAR and JMH), one health economist (SW
or EAS) and the study manager (RCB). Draft statements were generated independently by three cardiologists
(CBD, JPG and SHD) based on their cardiological expertise and by one methodologist (MP) based on evidence
from the literature review. The cardiologists and methodologist had no prior communication with each other.
The cardiologists were advised to be as inclusive as possible at this stage and to not be concerned about the
strength or quality of the evidence available to support their draft statements.
Three members of the expert group (study manager, RCB; systematic reviewer, MP; and cardiologist
with CMR expertise, CBD) collated the statements, organised them according to patient subgroup and
standardised the wording of each statement. A 1-day meeting was organised for all members of the
group. The structure of the meeting was as follows: an introduction to the aims of the study and the formal
consensus process; a review of each statement in turn, considering the relevance, format and wording of
each statement; and a discussion about the structure of the survey. Key papers from the literature review
were circulated to all members of the group prior to the meeting and these were also considered in
the discussions. At the meeting, it was decided that each statement would benefit from a ‘supporting
paragraph’, citing key references from the literature review, to provide background information and put
the statement in context.
The structure of the process used to generate the statements is summarised in Table 1. We documented
all of the discussions that led to the final statements.
Survey design
Statements and supporting paragraphs were worded in a consistent manner and collated in the form
of a web-based survey (SurveyMonkey®, Palo Alto, CA, USA) (see Appendix 4). The survey included an
introductory page explaining the purpose and layout of the survey and instructions about how to complete
it. Each statement was followed by its supporting paragraph that contained links to Portable Document
Format (PDF) references. Each statement was accompanied by a nine-point Likert scale asking the respondent
to indicate whether or not he/she agreed with the statement (with 1 indicating ‘completely disagree’ and
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9 ‘completely agree’). There was also a free-text box for each statement for respondents to comment in and
justify their score.
Expert panel
Establishing the expert panel
Clinicians in the working group identified consultant cardiologists with CMR, interventional, ECHO,
electrophysiology and heart failure expertise from across the UK (see Acknowledgements). The cardiologists
were invited by e-mail to form an expert consensus panel.
Completion of first survey
The expert panel completed the survey independently. Responses were collated and analysed by members
of the working group.
Face-to-face meeting
The expert panel attended a face-to-face meeting, chaired by a non-cardiology clinician experienced in
facilitating formal consensus panels. The meeting was also attended by non-clinical members of the
working group, whose role was to introduce the study, describe the structure of the formal consensus
process, provide study-related information and take minutes of the meeting. The expert panel discussed
each statement and anonymised responses to the first survey in turn and agreed on modifications to
the survey.
Completion of the modified survey
The survey was modified by members of the working group as agreed in the face-to-face meeting
(see Appendix 4).4 The expert panel completed the modified survey independently and rated the
statements a second time.
Extension of survey to other UK cardiologists
The survey was extended to other UK cardiologists through the British Cardiovascular Society, which
advertised the survey in their monthly newsletter to members (over 2 consecutive months). We offered
an incentive to encourage participation: the option of entering a prize draw for an iPad (Apple Inc.,
Cupertino, CA, USA).
Main outcome measure
A definition of a primary outcome measure (acceptable to cardiologists and other stakeholders) that
represents a definitive change in clinical management arising from a patient having CMR.
TABLE 1 Structure of the process used to generate the survey statements for use in a formal consensus process
Step Description
Literature review Published literature was identified on the use of CMR in patients who activate the PPCI
pathway and the patient subgroups that may benefit from CMR
Generate draft
statements
Statements were generated independently in writing by clinical and non-clinical members of the
internal group using systematic review and clinical expertise
Collate statements Statements were categorised into patient subgroups and reworded into a standard style
Expert group meeting All members of the expert group convened for a 1-day meeting during which the consensus
process was introduced and each statement was discussed in turn. Discussions focused on the
relevance, format and wording of each statement, and on how to structure the online survey
Generate final list of
statements
A final list of statements was produced based on internal group meeting discussions. Each
statement was accompanied by a supporting paragraph presenting ‘key’ supporting references
from the literature
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Criteria for consensus
Data for each statement are shown as medians and IQRs. A median score ≥ 7 and an IQRs 6–9 was
considered to be in agreement, or consensus, that the change in management described by the statement
was clinically important. These statements were used to identify the patient subgroups perceived to benefit
from CMR and define the treatment/process outcome that constitutes a definitive management change as
a result of having CMR. A median score ≤ 3 and an IQR 1–3 was considered to be in consensus that the
statement did not constitute a clinically important change in management. Data were analysed using
Stata/IC version 14.
Implementation of a primary outcome based on the changes in
management for which consensus was achieved (objectives C3 and C4)
Parts of this text have been reproduced with permission from Pufulete et al.68 This article is distributed under
the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
Patient subgroups
Patient subgroups were identified from HIS data extracts provided by hospitals. When this was not
possible, hospital episode data (the admissions data sets) were used to identify the ICD-10 diagnostic
codes associated with the index admission.
Manual review of patient notes
We undertook a review of patient notes because of the uncertainty regarding the identification of the
subgroup of patients with unobstructed coronary arteries. Forty-seven patients were selected, all identified
as having unobstructed arteries in hospital A at the time of the index event. We undertook a thorough
review of their patient notes to identify the reason why they activated the PPCI pathway.
Identifying changes in management
We used HES/PEDW inpatient and outpatient data to identify changes in management defined through
the formal consensus in the 12 months after the index admission (cohort entry). For those patients who
underwent CMR, any outpatient appointments that occurred between the index admission and the
date of CMR were excluded. We decided not to use the A&E data set because most of the changes in
management identified in the formal consensus were unlikely to occur in the A&E setting.
Cardiologist members of the clinical team identified key clinical ‘events’ that they expected to reflect the
important changes in management characterised through the consensus process. For example, new
non-ischaemic diagnoses (an important change in management resulting from CMR) were identified as
Takotsubo cardiomyopathy, myocarditis, pericarditis, endocarditis and coronary spasm.
We then compiled a list of ICD-10 and OPCS codes representing the key clinical events with the help of a
clinical coder. Most changes in management encompassed a number of ICD-10/OPCS codes, for example
the use of additional diagnostic tests during follow-up required OPCS codes for positron emission
tomography (PET), ECHO, intravascular ultrasound (IVUS) or pressure wire. We identified the changes in
management in HES/PEDW for each statement (patient subgroup) separately. The full code list used to
identify changes in management is shown in Appendix 2.
Implementation of the consensus statements
We calculated the frequency of all events representing changes in management (e.g. number of new
diagnoses, additional diagnostic tests, number of outpatient appointments) in patients who did/did not
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receive CMR for each patient subgroup in the 12 months following the index admission. We also calculated
the time to first event for each change in management (e.g. time to first new diagnosis, time to the first
diagnostic test, time to next revascularisation in patients with multivessel disease) and summarised these
with medians and IQRs. We did not compare differences between patients who did/did not receive CMR in
any of the subgroups because we were interested primarily in the feasibility of identifying relevant events;
the number of patients in most subgroups was also small.
Cardiovascular magnetic resonance questionnaire
We determined whether or not the changes in management identified in HES/PEDW accurately reflected
the changes in management implemented by the cardiologists who referred patients in the study for
CMR. We designed a questionnaire based on the patient subgroups identified in the formal consensus
(see Appendix 5) and asked all referring cardiologists to complete it for each patient whom they referred
for CMR. The questionnaire asked about whether or not and how CMR changed management (using tick
boxes and free text). We used the questionnaire to identify whether or not the changes in management
reported by cardiologists were accurately reflected in HES/PEDW, and whether or not there were additional
changes in management that could not be picked up from HES/PEDW.
Health economic study (objective B2)
We built two separate cost-effectiveness models to explore the impact of CMR for two patient subgroups:
(1) multivessel disease and (2) unobstructed (normal) coronary arteries.
l Model 1: simulated the costs and effects of introducing CMR for patients with multivessel disease,
compared with current practice.
l Model 2: simulated the costs and effects of introducing CMR for patients with normal coronary
arteries, compared with current practice.
From these two models, inferences can be made about the likely drivers of the cost-effectiveness of
introducing CMR for all patients who activate the PPCI pathway, because, in practice, this is how CMR
might be introduced, and is, therefore, the key issue for policy-makers.
The decision trees model the patient pathway after PPCI pathway activation to 1 year. Each possible
patient pathway within the model is associated with a probability, and each pathway incurs costs and
outcomes. The analysis was conducted from a NHS and personal social services perspective.34 Outcomes
were measured in quality-adjusted life-years (QALYs), a composite measure of quality and quantity of life.
The structure of the model for patients with multivessel disease is described next, along with the sources
of parameter estimates, before the model for patients with normal coronary arteries is considered.
Model 1: patients with multivessel disease
This model was designed to address the question ‘Which is the most cost-effective type of ischaemia
testing for patients with multivessel disease who activate the PPCI pathway?’
When the study started, stress ECHO was the ischaemia-testing option commonly used and the study was
comparing this with CMR. During the study, the use of FFR increased35 and, therefore, this test was
included as an additional arm in the model. Thus, the model compares the cost-effectiveness of three
ischaemia testing options: (1) CMR, (2) pressure wire and (3) stress ECHO.
The cohort of patients of interest are those who activate the PPCI pathway, have their index angiography
and PPCI, and are identified as having multivessel disease (commonly defined as stenosis of > 50% from
the angiogram). This model considers the patient pathway thereafter: whether or not to treat non-culprit
lesions with a second revascularisation, the need (or not) for ischaemia testing to help determine the need
for the revascularisation of a second vessel and any MACEs that occur. Figure 1 summarises the scenarios
in the patient pathways included in the model structure for one arm of the model (CMR).
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The model structure (shown in detail in Figure 2 splitting into three arms, representing the three different
types of ischaemia testing) considered the following: the top branch models the scenario in which the
ischaemia-testing option available is CMR, the middle branch models the scenario for pressure wire and
the bottom branch models the scenario for stress ECHO. The structure of each of these three main arms is
the same for each scenario, but the associated probabilities, costs and outcomes for each arm vary.
Considering the CMR arm, the decision tree first divides the starting cohort of patients after PPCI in
accordance with the results of their index angiography. A clinician may determine that a patient requires
or does not require the revascularisation of a second vessel directly from their angiogram, without the
need for ischaemia testing; alternatively, there may be uncertainty from the index angiogram of the need
for further revascularisation, and, therefore, ischaemia testing is used, in this case CMR. For each of these
three categories, patients are then divided by whether or not they truly have ischaemia.
Patients whose index angiography leads to a firm decision on revascularisation are then divided by whether
or not they had any MACEs in the 12 months after PPCI. MACE is a composite end point of all-cause
mortality, MI, stroke and revascularisation.
Patients for whom ischaemia testing is needed are divided in accordance with whether that test result
was positive, and therefore assumed to result in the revascularisation of a second vessel, or negative.
Thereafter, patients are divided by whether or not they had a MACE in the 12 months after PPCI.
Although the model structure is the same for each of the ischaemia testing options, there are differences
in the timing of events between these arms for patients who have ischaemia testing that leads to a second
revascularisation. For CMR and stress ECHO, this is a two-step process, that is a patient has the ischaemia
test and then separately has revascularisation of a second vessel. For pressure wire, this all happens in the
catheterisation laboratory at the same time, that is a patient has their diagnostic angiography and pressure
wire, and, if required, has their PCI at the same time (note that this is entirely separate and subsequent to
their index angiography and PPCI). This affects costs, but not the model structure.
Truly
ischaemia
Truly no
ischaemia
Revascularisation of a
second vessel
Truly
ischaemia
Truly no
ischaemia
Test positive,
revascularisation
of a second vessel
Test negative, no
revascularisation
of a second vessel
Ischaemia testing
Ischaemia testing available is CMR
MACE by 1 year No MACE by 1 year
Truly
ischaemia
Truly no
ischaemia
No revascularisation of a
second vessel
FIGURE 1 Scenarios in the patient pathway included in the model structure for patients with multivessel disease.
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Patient pathways for other ischaemia testing options
(pressure wire and stress ECHO) identical to those for
CMR (i.e. these branches continue exactly as above)
Probability here = sensitivity of test
Probability here = specificity of test
Which type of
ischaemia testing?
Pressure wire
is available
CMR is
available
Index angiography leads to
revascularisation of second vessel
(no need for ischaemia testing)
Index angiography leads to no
revascularisation of second vessel
(no need for ischaemia testing)
Uncertain from the index
angiogram of the need for further
revascularisation; therefore,
ischaemia testing used
Stress ECHO is
available
Truly ischaemia
MACE within 12 months
MACE within 12 months
No MACE within 12 months
No MACE within 12 months
Ischaemia test positive, 
so revascularisation of 
second vessel
Ischaemia test positive, so
revascularisation of second vessel
Ischaemia test negative, so no
further revascularisation
Ischaemia test negative, so no
further revascularisation
MACE within 12 months
MACE within 12 months
No MACE within 12 months
No MACE within 12 months
Truly no ischaemia
Truly ischaemia
Truly no ischaemia
Truly ischaemia
Truly no ischaemia
MACE within 12 months
MACE within 12 months
No MACE within 12 months
No MACE within 12 months
MACE within 12 months
MACE within 12 months
No MACE within 12 months
No MACE within 12 months
FIGURE 2 Model 1 structure: patients with multivessel disease.
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Data for the multivessel disease model
Most model parameters were populated with estimates derived from the literature. The following sections
describe how transition probabilities, costs and outcomes were estimated to 1 year.
Probabilities for the multivessel disease model
Table 2 shows the probabilities used in the model and their sources. These are the probabilities associated
with each branch in the model; probabilities along pathways are multiplied together in the analyses. MEDLINE
searching was used to identify relevant papers, and was conducted using MeSH and keywords for each
imaging type (e.g. exp/pressure-wire or pressure-wire.mp or fractional flow reserve.mp and exp/myocardial
infarction). Any relevant reviews were read in order to identify relevant references, and references and
citations of any relevant references were checked for prior or more recent published work.
In the base-case analyses, CMR and pressure wire were treated as reference standards and both were
assumed to have 100% sensitivity and specificity. Therefore, the probabilities and outcomes are the same
in these arms and they differ only in terms of costs.
The probabilities of MACEs were estimated from Smits et al.,38 in which MACE was defined as a composite
end point of all-cause mortality, non-fatal MI, revascularisation and cerebrovascular events at 12 months.
Outcomes for subgroups of patients in the trial were used to estimate MACE for three groups of patients:
(1) truly ischaemic patients who had a second revascularisation (p = 0.09), (2) truly ischaemic patients who
did not have a second revascularisation (p = 0.31) and (3) truly not ischaemic patients, whether or not they
had a second revascularisation (p = 0.13). Based on subgroups of the trial patients, the probability of a
MACE at 12 months for truly ischaemic patients who had a second revascularisation was actually lower
than for patients without ischaemia. This might seem anomalous, but is a genuine finding. Although the
probability estimates for these three subgroups were all based on ≥ 200 patients, only 18 truly ischaemic
patients who had a second revascularisation had a MACE; these findings might be an artefact of modest
numbers, and larger studies might show different results.
Costs for the multivessel disease model
For each ischaemia testing strategy considered, the costs included were the cost of ischaemia testing
(CMR, pressure wire or stress ECHO) if required, the cost of revascularisation of a second vessel, costs
associated with adverse events included in MACEs (both the initial inpatient costs and subsequent costs
post discharge), costs of cardiac medications and cardiac rehabilitation offered to all patients and
additional health-care costs beyond hospital discharge to 1 year, including follow-up outpatient
appointments for all patients.
Unit costs were largely obtained from NHS Reference Costs 2015 to 201640 and are shown in Table 3;
details of assumptions made in estimating unit costs are also provided in Table 3. NHS Reference Costs
provide upper and lower quartiles around mean estimates; the difference between the mean and the
upper quartile was captured and used as a crude estimate of standard error (SE) in the probabilistic
sensitivity analyses (PSAs) (described in Model analyses). When this was not possible, the SE was assumed
to be 20% of the mean cost. All costs were parameterised using a gamma distribution in the PSAs.
Outcomes for the multivessel disease model
Outcomes were measured in QALYs. Estimates of survival and quality of life utility weights were obtained
from the literature and combined to estimate the QALYs gained to 1 year. As death is one of the
components of MACEs, patients without a MACE are all alive at 1 year in the model. The probability of
dying in the first year was taken from the same source as the MACE estimates above, and was 8% for
patients with a MACE.38
The Tufts Cost-effectiveness Analysis Registry46 was searched for appropriate utility weights. This registry
is a database of 5655 cost–utility analyses on a wide variety of diseases and treatments and has 21,900
utility weights. Search terms such as ‘primary percutaneous coronary intervention’ and ‘major adverse
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TABLE 2 Probabilities for the multivessel disease model
Branch of model
Base-case value
(positive/total)
Distribution
for PSA Source
For each ischaemia testing option
Probability that index angiography leads to revascularisation of
second vessel
0.30 (30/100)a Dirichlet Expert opinion
within the PIPA
study teamProbability of uncertainty following index angiography and
need for ischaemia testing
0.60 (60/100)a
Probability that index angiography leads to no revascularisation
of second vessel
0.10 (10/100)a
Index angiography leads to revascularisation of second vessel
Probability of true ischaemia 0.84 (598/709) Beta FAME37
Probability of MACE by 12 months, true ischaemia 0.09 (18/202)b Beta Smits et al.38
Probability of MACE by 12 months, truly no ischaemia 0.13 (54/432)b Beta Smits et al.38
Uncertainty following index angiography and need for ischaemia testing
Probability of true ischaemia 0.35 (218/620) Beta FAME37
Index angiography leads to no revascularisation of second vessel
Probability of true ischaemia 0.35 (218/620) Beta FAME37
Probability of MACE by 12 months, true ischaemia 0.31 (71/231)b Beta Smits et al.38
Probability of MACE by 12 months, truly no ischaemia 0.13 (54/432)b Beta Smits et al.38
CMR or pressure wire
Uncertainty following index angiogram and need for ischaemia testing, true ischaemia
Probability of ischaemia test positive and revascularisation 1c Beta
Probability of MACE by 12 months, revascularisation 0.09 (18/202)b Beta Smits et al.38
Probability of MACE by 12 months, no revascularisation 0.31 (71/231)b,d Beta Smits et al.38
Uncertainty following index angiogram and need for ischaemia testing, truly no ischaemia
Probability of ischaemia test positive and revascularisation 0c Beta
Probability of MACE by 12 months, revascularisation 0.13 (54/432)b,d Beta Smits et al.38
Probability of MACE by 12 months, no revascularisation 0.13 (54/432)b Beta Smits et al.38
Stress ECHO
Uncertainty following index angiogram and need for ischaemia testing, true ischaemia
Probability of ischaemia test positive and revascularisation 0.70 (32/46) Beta Gurunathan et al.39
Probability of MACE by 12 months, revascularisation 0.09 (18/202)b Beta Smits et al.38
Probability of MACE by 12 months, no revascularisation 0.31 (71/231)b Beta Smits et al.38
Uncertainty following index angiogram and need for ischaemia testing, truly no ischaemia
Probability of ischaemia test positive and revascularisation 0.23 (39/171) Beta Gurunathan et al.39
Probability of MACE by 12 months, revascularisation 0.13 (54/432)b Beta Smits et al.38
Probability of MACE by 12 months, no revascularisation 0.13 (54/432)b Beta Smits et al.38
FAME, Fractional Flow Reserve versus Angiography in Multivessel Evaluation; PSA, probabilistic sensitivity analysis.
a To incorporate uncertainty around the percentage of patients in each of these three groups estimated by experts on the
study team, it was assumed that experts were estimating the number of patients out of 100 in each group.
b For further information on the estimates of MACEs, please see the final paragraph in Probabilities for the multivessel
disease model.
c In the base-case analyses, CMR and pressure wire are assumed to have perfect sensitivity and specificity, but these
parameters are incorporated into the model so that alternative assumptions can be tested in sensitivity analyses.
d These probabilities are not required in the base-case analysis (since the probability in the preceding branch is zero),
but are included here as they are required in sensitivity analyses.
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TABLE 3 Costs for the multivessel disease model
Resource
Unit cost,
£ (SE) Source
Revascularisation of second
vessel (assumed to be PCI)
2682 (533) NHS Reference Costs 2015 to 2016.40 Elective Inpatient. Weighted
average of codes EY40 and EY41, Standard/Complex Percutaneous
Transluminal Coronary Angioplasty
CMR 264 (154) NHS Reference Costs 2015 to 2016.40 Diagnostic Imaging. Weighted
average of all Cardiovascular Magnetic Resonance Imaging Scan codes
Angiography and pressure
wire
1340 (374) NHS Reference Costs 2015 to 2016.40 Day case. Weighted average of
code EY42, Complex Cardiac Catheterisation
Angiography, pressure wire
and revascularisation (as a
single catheter laboratory
admission)
2971 (594) Cost of revascularisation above, and angiography and pressure wire
above, minus the cost of an angiography, £1051 (NHS Reference Costs
2015 to 2016.40 Day case. Weighted average of code EY43, Standard
Cardiac Catheterisation)
Stress ECHO 182 (3) NHS Reference Costs 2015 to 2016.40 Outpatient procedures.
Cardiology. EY50Z, Complex Echocardiogram
MACE 3251 (650) The proportion of each component of MACE was taken from Smits
et al.38 and a weighted average of the costs of each component was
calculated, based on the unit costs below
Revascularisation (PCI) 2682 As above
Revascularisation (CABG) 10,944 NHS Reference Costs 2015 to 2016.40 Elective Inpatient. Weighted
average of codes ED26, ED27, ED28 Complex/Major/Standard Coronary
Artery Bypass Graft
MI 2177 NHS Reference Costs 2015 to 2016.40 Non-elective long stay. Weighted
average of code EB10 A, Actual or Suspected Myocardial Infarction
Stroke 3723 NHS Reference Costs 2015 to 2016.40 Non-elective long stay. Weighted
average of code AA22, Cerebrovascular Accident, Nervous System
Infections or Encephalopathy
Death 0 (0)
Cardiac rehabilitation 364 (73) Assume offered eight sessions, but only 50% uptake, so cost four sessions
(one first and three follow-up appointments, individual costs below)
First appointment 97 NHS Reference Costs 2015 to 2016.40 Consultant Led. 327, Cardiac
Rehabilitation. Non-Admitted Face-to-Face Attendance, First
Follow-up appointment 89 NHS Reference Costs 2015 to 2016.40 Consultant Led. 327, Cardiac
Rehabilitation. Non-Admitted Face-to-Face Attendance, Follow-Up
Cardiac medications for
treatment of MI (all once daily
by mouth). Assumed given
for 12 months (or 6 months
for patients who died)
Aspirin (75 mg) 0.04 BNF41
Prasugrel (Efient®; Eli Lilly and
Company, Indianapolis, IN,
USA) (5 mg)
1.70 BNF41
Atorvastatin (80 mg) 0.07 BNF41
Bisoprolol (2.5 mg) 0.02 BNF41
Ramipril (2.5 mg) 0.04 BNF41
Total daily cost 1.87
Total annual cost 683 (137)
continued
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cardiac events’ were used. Estimates from the Swedish Early Decision reperfusion Study (SWEDES) by Aasa
et al.47 were deemed to be the most appropriate; this study measured health status using the EuroQol-5
Dimensions (EQ-5D) in a group of PPCI patients, and quality weights were obtained using the UK EQ-5D
tariff.47 Patients completed the EQ-5D at three time points: baseline (within 3 days of randomisation, at the
end time of index hospitalisation), and at 1 and 12 months. Mean utilities for patients were 0.72, 0.77 and
0.77 at each time point, respectively. Although the patient group included some patients with a MACE,
here the estimates are applied to patients without a MACE.
Quality-adjusted life-years were calculated assuming a patient’s utility changed linearly between each
time point, so between baseline and 1 month, and between 1 and 12 months. Patients who died were
assumed to die midway through the time period (i.e. at 6 months); their utility was assumed to change
linearly between time points up to death, and a value of zero was given from death onwards. A QALY
estimate for patients without a MACE – who, therefore, were all alive at 1 year – was calculated based
on the utilities provided by Aasa et al.47 For the QALY estimate for patients with a MACE 8% of patients
were assumed to die,38 this was used to produce a weighted average for patients alive and dead at 1 year,
based on the utility weights and assumptions above. A utility decrement of 0.05 was then applied to
this weighted average to reflect the reduced quality of life of patients with a MACE compared with
those without a MACE.48 QALY estimates for patients who had revascularisation of a second vessel were
modified to assume their utility for month 1 was repeated for month 2. QALY estimates used in the model
are summarised in Table 4. QALYs were parameterised using a beta distribution in the PSAs and a SD of
0.09 was assumed, as used elsewhere.49
Model 2: patients with normal coronary arteries
For a starting cohort of patients with normal coronary arteries, this model compares standard ECHO and CMR
with standard ECHO only, and is designed to address the question: ‘Is it cost-effective to introduce CMR in
patients with normal coronaries who activate the PPCI pathway?’. For the standard ECHO and CMR arm of
the model, Figure 3 summarises the scenarios in the patient pathways included in the model structure.
TABLE 3 Costs for the multivessel disease model (continued )
Resource
Unit cost,
£ (SE) Source
Outpatient follow-up
appointment (assumed to
occur at 4–6 weeks and
6 months post discharge)
122 (22) NHS Reference Costs 2015 to 2016.40 Consultant-led appointments.
Non-Admitted Face-to-Face Attendance, Follow-Up. Cardiology
Additional health-care costs
to 1 year
2221 (444) The Office of Health Economics’ estimate of the annual cost per
person of NHS care, inflated to 2015/16 prices using the hospital and
community health services inflation index.42,43 For patients who die,
costs are assumed to be half of this (£1111)
Additional health-care costs
to 1 year for those with a
MACE
263 (53) MI and stroke were assumed to be associated with continuing care
costs post discharge. Costs from Greenhalgh et al.44 were inflated
to 2015/16 prices.42 Separate costs were provided for disabling and
non-disabling stroke. According to Davies et al.,45 58% of strokes are
disabling; this percentage was used to weigh the two continuing care
costs for stroke. Additional costs to 1 year associated with a MACE
were calculated by weighting estimates of the annual costs of MI and
stroke by the number of patients with these complications across the
number of patients with a MACE, from Smits et al.38
BNF, British National Formulary.
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The model structure, shown in detail in Figure 4, is split into two main arms (branches): the top branch
represents standard ECHO and CMR and the bottom branch represents standard ECHO only. The structure
is the same in each arm, and starts by dividing patients into those who truly did have a MI and those who
truly did not. Patients are then divided according to their ischaemia test result. For those with a positive
test result, and therefore assumed to have had a MI, treatment for MI in the form of cardiac medications
and cardiac rehabilitation will be given. Those with a negative test result will be treated for other causes
of their chest pain, and given fewer cardiac medications or none at all. Thereafter, patients are divided
into whether or not they had a MACE within 12 months. A MACE is defined in the same way as above:
a composite end point of all-cause mortality, MI, stroke and revascularisation.
Data for the normal coronaries model
The decision tree for patients with normal coronaries was set up in a similar way to the model for patients
with multivessel disease. The following sections describe how transition probabilities, costs and outcomes
were estimated to 1 year, the majority of which were derived from the literature.
Probabilities for the normal coronaries model
Table 5 shows the probabilities used in the model and their respective sources. From initial MEDLINE
searching, a 2016 review paper by Dastidar et al.55 identified the first paper to use CMR for diagnosis in
patients with normal coronaries,20 and this was confirmed by later reviews. All citations of the Assomull
et al.20 paper were reviewed, and relevant (English) results read. Two meta-analyses were identified,50,56
TABLE 4 QALYs for the multivessel disease model
Patient group Mean QALYs to 1 year
No revascularisation of a second vessel and MACE 0.686
No revascularisation of a second vessel and no MACE 0.768
Revascularisation of a second vessel and MACE 0.684
Revascularisation of a second vessel and no MACE 0.766
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Standard ECHO and CMR
Truly MI Truly no MI
No MACE by 1 yearMACE by 1 year
Test positive,
treatment for MI
Test negative, no
treatment for MI
FIGURE 3 Scenarios in the patient pathway included in the model structure for patients with normal coronaries.
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Probability here = sensitivity of test
Probability here = specificity of test
Which type
of ischaemia
testing?
Standard ECHO
and CMR
Truly MI
Truly no MI
Truly MI
Truly no MI
Standard ECHO
MACE within 12 months
No MACE within 12 months
MACE within 12 months
No MACE within 12 months
MACE within 12 months
No MACE within 12 months
MACE within 12 months
No MACE within 12 months
MACE within 12 months
No MACE within 12 months
MACE within 12 months
No MACE within 12 months
MACE within 12 months
No MACE within 12 months
MACE within 12 months
No MACE within 12 months
Test positive, so treatment
for MI (cardiac medications
and cardiac rehabilitation)
Test positive, so treatment
for MI (cardiac medications
and cardiac rehabilitation)
Test positive, so treatment
for MI (cardiac medications
and cardiac rehabilitation)
Test positive, so treatment
for MI (cardiac medications
and cardiac rehabilitation)
Test negative, so no
treatment for MI
Test negative, so no
treatment for MI
Test negative, so no
treatment for MI
Test negative, so no
treatment for MI
FIGURE 4 Model structure for patients with normal coronaries (no blocked arteries).
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and the citations of these papers were also reviewed, as were the references of more recent papers.
In a final check to ensure that key papers had been identified, MEDLINE searching of keywords, such as
‘myocardial infarction with non-obstructive coronary arteries’, and synonyms was conducted (there are
no relevant MeSH terms).
In the base-case analyses, standard ECHO and CMR was treated as a reference standard and assumed to
have 100% sensitivity and specificity. Alternative scenarios were considered in sensitivity analyses.
Although there is evidence in the literature of the probability of a MACE, the definition frequently varies
and studies follow patients for varying lengths of time. Although mortality at 1 year in patients with
normal coronaries is lower than in patients with obstructed vessels,50,57 it is still significant; a recent
systematic review estimated this to be 4.7%.50
For the group as a whole, Kang et al.51 reported MACEs at 12 months in 7.8% of patients with no or
< 50% coronary artery stenosis. Their definition of a MACE included death, MI and ischaemic target vessel
revascularisation, but did not include stroke. It should also be noted that, although the study began with
372 patients with no or < 50% coronary artery stenosis, only 126 had follow-up data at 12 months.
TABLE 5 Probabilities for the normal coronaries model
Branch of model
Base-case value
(positive/total)
Distribution
for PSA Source
For both arms
Probability of truly having had a MI 0.24 (429/1801) Beta Pasupathy et al.50
Standard ECHO and CMR
Probability of ischaemia test positive and treatment for MI | MI 1a Beta
Probability of MACE within 12 months | treatment for MI 0.21 Beta Kang et al.,51 Pathik et al.52
Probability of MACE within 12 months | no treatment for MI 0.26b Beta Kang et al.,51 Pathik et al.52
and Lindahl et al.53
Probability of ischaemia test positive and treatment for MI |
no MI
0a Beta
Probability of MACE within 12 months | treatment for MI 0.03b Beta Kang et al.,51 Pathik et al.52
Probability of MACE within 12 months | no treatment for MI 0.03 Beta Kang et al.,51 Pathik et al.52
Standard ECHO
Probability of ischaemia test positive and treatment for MI | MI 0.47 (25/53)c Beta Dastidar et al.54
Probability of MACE within 12 months | treatment for MI 0.21 Beta Kang et al.,51 Pathik et al.52
Probability of MACE within 12 months | no treatment for MI 0.26 Beta Kang et al.,51 Pathik et al.52
and Lindahl et al.53
Probability of ischaemia test positive and treatment for MI |
no MI
0.62 (93/151)c Beta Dastidar et al.54
Probability of MACE within 12 months | treatment for MI 0.03 Beta Kang et al.,51 Pathik et al.52
Probability of MACE within 12 months | no treatment for MI 0.03 Beta Kang et al.,51 Pathik et al.52
a In the base-case analyses, standard ECHO combined with CMR is assumed to have perfect sensitivity and specificity,
but these parameters are incorporated into the model so that alternative assumptions can be tested in sensitivity analyses.
b These probabilities are not required in the base-case analyses (since the probability in the preceding branch is zero),
but are included here as they are required in sensitivity analyses.
c For further information on how estimates of sensitivity and specificity for standard ECHO were obtained, please see the
final paragraph in Probabilities for the normal coronaries model.
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Three studies52,58,59 were identified that reported MACE for patients with normal coronaries, broken down
by different CMR diagnoses. Pathik et al.52 reported MACE for 0.27 (7/26) patients diagnosed with MI,
and for 0.05 (5/99) patients not diagnosed with MI (diagnosed with myocarditis, cardiomyopathy or
normal CMR) over a median of 24 months (n = 125). In the other two studies58,59 of 124 and 87 patients,
no MACE outcomes were observed in the non-MI patients. The MACE estimates reported in Pathik et al.52
were converted to continuous rates (events were assumed to occur evenly over the median 24 months
of follow-up). The ratio of events in the MI patients compared with the non-MI patients was six, and was
used with the overall estimate of a MACE at 1 year from Kang et al.51 (0.078), and the estimate of the
underlying probability of patients truly having a MI from Pasupathy et al.50 (0.24), to calculate estimates
of the probability of a MACE in patients who truly had a MI and in those who did not have a MI. This
generated probability estimates of a MACE of 0.21 for patients with MI, and 0.03 for patients without a MI.
However, we needed estimates of MACE based not only on whether or not patients had a MI, but also
on whether or not they had treatment for a MI. The estimate generated for patients with MI (0.21) was
assumed to apply to patients who had treatment. The hazard ratio reported by Lindahl et al.53 for a MACE
for patients who were taking statins compared with those who were not (0.77) was used to adjust this
estimate of a MACE for patients who had a MI and treatment, to give a probability of a MACE for those
with MI but without treatment of 0.26. For patients without MI, the probability of a MACE of 0.03 was
assumed to apply regardless of whether or not treatment was given. A SE of 0.10 was assumed for the PSA
for these probabilities. Although Pathik et al.52 was the only source found to estimate the ratio of events in
MI patients compared with non-MI patients (in patients with normal coronaries), it is important to highlight
that the estimated ratio of six raised concerns among the study team as being very high, and that lower
values are explored in sensitivity analyses.
The sensitivity and specificity of standard ECHO were estimated from Dastidar et al.54 The pre-CMR
diagnosis reported was treated as the standard ECHO diagnosis, and the post-CMR diagnosis was assumed
to be the true underlying diagnosis. It was assumed that those with a pre-CMR diagnosis of MI or
uncertain would have been given treatment for MI, and, therefore, patients in these categories were
combined for the purposes of the sensitivity and specificity calculations.
Costs for the normal coronaries model
For each ischaemia testing strategy considered, the costs included were the cost of ischaemia testing
(standard ECHO, CMR), the cost of treatment for MI in the form of cardiac rehabilitation and medications,
the cost of medications for non-MI causes, costs associated with adverse events included in MACEs (both
the initial inpatient costs and subsequent costs post discharge), and additional health-care costs beyond
hospital discharge to 1 year, including a follow-up appointment for all patients. Unit costs were obtained
from national sources40,41 and are shown in Table 6; details of assumptions made in estimating unit costs
are also provided in Table 6. As for the unit costs used in the previous model, when mean and upper
quartile unit costs were available, the difference was used as a crude estimate of SE in the PSAs, otherwise
the SE was assumed to be 20% of the mean cost. Costs were parameterised using a gamma distribution
in the PSAs.
Outcomes for the normal coronaries model
The QALY estimates used in the model are shown in Table 7. Searches of the Tufts Cost-effectiveness
Analysis Registry46 did not yield any utility weights that were specific to patients with normal coronaries;
therefore, the estimates in Aasa et al.47 were also used here. The QALY estimate for patients without a
MACE who were all alive at 1 year was calculated directly from the utilities in Aasa et al.47 For the QALY
estimate for patients with a MACE, 8% of patients were assumed to die based on the same source as
the MACE estimates above;52 this was used to produce a weighted average for patients alive and dead at
1 year, based on the utility weights and assumptions described previously, and a utility decrement of 0.05
was again applied to reflect the reduced quality of life of patients with a MACE.48 The study team felt that
the estimate of the proportion of patients with a MACE who die was low; therefore, a higher proportion
(50%) is explored in the sensitivity analyses.
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TABLE 6 Costs for the normal coronaries model
Resource Unit cost, £ (SE) Source
Standard ECHO 72 (22) NHS Reference Costs 2015 to 2016.40 Diagnostic Imaging. Outpatient.
RD51 A, Simple Echocardiogram, ≥ 19 years
CMR 264 (154) NHS Reference Costs 2015 to 2016.40 Diagnostic Imaging. Weighted
average of all Cardiovascular Magnetic Resonance Imaging Scan codes
Cardiac rehabilitation 364 (73) Assume offered eight sessions, but only 50% uptake, so cost four
sessions (one first and three follow-up appointments, individual costs
below)
First appointment 97 NHS Reference Costs 2015 to 2016.40 Consultant Led. Cardiac
Rehabilitation. Non-Admitted Face to Face Attendance, First
Follow-up appointment 89 NHS Reference Costs 2015 to 2016.40 Consultant Led. Cardiac
Rehabilitation. Non-Admitted Face to Face Attendance, Follow-Up
Cardiac medications
for treatment of MI
(all once daily by mouth)
Aspirin (75 mg) 0.04 BNF41
Clopidogrel (75 mg) 0.05 BNF41
Atorvastatin (80 mg) 0.07 BNF41
Bisoprolol (2.5 mg) 0.02 BNF41
Ramipril (2.5 mg) 0.04 BNF41
Total daily cost 0.22
Total annual cost 80 (16)
Treatment for non-MI
cause (cardiac medications):
total daily cost
0.11 Assume that half of these patients are taken off cardiac medications
above (these medications are given for cardiomyopathy but not for
myocarditis)
Outpatient follow-up
appointment (assumed to
occur at 4–6 weeks post
discharge)
122 (22) NHS Reference Costs 2015 to 2016.40 Consultant-led appointments.
Non-Admitted Face to Face Attendance, Follow-Up. Cardiology
MACE 2808 (562) The proportion of each component of MACE was taken from Pathik
et al.,52 and a weighted average of the costs of each component was
calculated, based on the unit costs provided in Table 2. Given the small
number of MACE events, calculations were based on MI and non-MI
patients combined
Additional health-care costs
to 1 year
2221 (444) The Office of Health Economics’ estimate of the annual cost per
person of NHS care inflated to 2015/16 prices using the hospital and
community health services inflation index.42,43 For patients who die,
costs are assumed to be half of this (£1111)
Additional health-care costs
to 1 year for those with a
MACE
1602 (320) MI and stroke were assumed to be associated with continuing care
costs post discharge. Costs from Greenhalgh et al.44 were inflated
to 2015/16 prices.42 Separate costs were provided for disabling and
non-disabling stroke. According to Davies et al.45 58% of strokes are
disabling; this percentage was used to weigh the two continuing care
costs for stroke. Additional costs to 1 year associated with MACE were
calculated by weighting estimates of the annual costs of MI and stroke
by the number of patients with these complications across the number
of patients with MACE, from Pathik et al.52
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Model analyses
All analyses were conducted in TreeAge Pro 2013 (TreeAge Software Inc., Williamstown, MA, USA). Costs
and QALYs were not discounted, as the time horizon was 1 year. Cost-effectiveness analyses were run,
and the expected costs and QALYs associated with each arm (each ischaemia testing strategy) to 1 year
were calculated. The incremental cost-effectiveness ratio (ICER) was derived from the difference in costs
and QALYs between each ischaemia testing option and current practice. The ICER is the cost per QALY
gained of introducing a different form of ischaemia testing compared with current practice.
As this is a feasibility study, it is not the actual ICER and cost-effectiveness results that are the main interest,
but rather how the results change in response to sensitivity analyses; this will identify the key drivers of
cost-effectiveness that would require detailed measurement and consideration in any subsequent work.
Sensitivity analyses
Both one-way sensitivity analyses and PSAs were conducted. One-way sensitivity analyses were used to
assess the sensitivity of the base-case results to key uncertainties in the model to identify the key drivers
of cost-effectiveness. Tables 8 and 9 describe the key sensitivity analyses that were conducted for each
model. Threshold analyses were also conducted around the costs of CMR, and angiography and pressure
wire to establish the cost of the test at which the costs associated with alternative strategies were the same.
To quantify the uncertainty around the one-way sensitivity analyses, parameters were assigned distributions
(rather than fixed values) so that SEs and CIs could be estimated; this was done in the same way as the PSAs
that were conducted. PSAs were used to investigate the joint impact of results of all uncertain parameters in
the model simultaneously.
TABLE 7 QALYs for the normal coronaries model
Patient group QALYs to 1 year
MACE within 12 months 0.686
No MACE within 12 months 0.768
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TABLE 8 Sensitivity analyses for the multivessel disease model
SA Parameter varied Base case
Alternative strategies
for SA
1 Probabilities associated with decision on
revascularisation from index angiography
Based on expert opinion Based on PIPA data
Probability that index angiography leads to
revascularisation of a second vessel (number of
patients with events/total number of patients)
0.30 (30/100) 0.11 (78/717)
Probability of uncertainty following index
angiography and need for ischaemia testing
(number of patients with events/total number
of patients)
0.60 (60/100) 0.15 (111/717)
Probability that index angiography leads to no
revascularisation of second vessel (number of
patients with events/total number of patients)
0.10 (10/100) 0.74 (528/717)
2 Sensitivity and specificity of CMR 1 and 1 0.8 (SE 0.1) for each
METHODS
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TABLE 8 Sensitivity analyses for the multivessel disease model (continued )
SA Parameter varied Base case
Alternative strategies
for SA
3 Sensitivity and specificity of pressure wire 1 and 1 0.8 (SE 0.1) for each
4 Sensitivity and specificity of stress ECHO 0.70 and 0.77 (reported
1 – specificity = 0.23)
Sensitivity: 0.791 (SE 0.008)
and 1 – specificity 0.129
(SE 0.007)60
5 Probability of MACE for truly ischaemic patients
who had a second revascularisation, truly
ischaemic patients who did not have a second
revascularisation, and truly not ischaemic
patients whether or not they had a second
revascularisation
0.09, 0.31, 0.13 All ± 0.05
6 Cost of CMR £264.00 ± 20%
7 Cost of angiography and pressure wire £1340.00 ± 20%
8 QALYs for patients with MACE with and
without revascularisation of second vessel
0.684, 0.686 Base case –0.2
(0.484, 0.486)
9 QALYs for patients with no MACE with and
without revascularisation of second vessel
0.766, 0.768 Base case +0.2
(0.966, 0.968)
SA, sensitivity analysis.
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TABLE 9 Sensitivity analyses for the normal coronaries model
SA Parameter varied Base case
Alternative strategies
for SA
1 Sensitivity and specificity of standard ECHO
plus CMR
1 and 1 0.8 (SE 0.1) for each
2 Sensitivity and specificity of standard ECHO 0.47 and 0.38 0.7 (SE 0.1) for each
3 Probability of MACE for patients who had a
MI and treatment, for patients who had a MI
and no treatment, and for patients without MI
regardless of whether they had treatment
(ratio of events in MI-to-non-MI group = 4)a
0.21, 0.26, 0.03 0.18, 0.23, 0.05
4 Probability of MACE (ratio = 2) 0.21, 0.26, 0.03 0.13, 0.17, 0.06
5 Probability of MACE (ratio = 1) 0.21, 0.26, 0.03 0.08, 0.10, 0.08
6 Cost of CMR £264.00 ± 20%
7 Cost of additional health-care costs to
1 year for patients with a MACE: increase the
proportion who die from 8% to 50%
£1602.00 £874.00
8 QALYs for patients with MACE 0.686 Base case –0.2 (0.486)
9 QALYs for patients with no MACE 0.768 Base case 0.2 (0.968)
10 QALYs for patients with MACE: increase the
proportion who die from 8% to 50%
0.686 0.525
SA, sensitivity analysis.
a For further information on this ratio, please see the fifth paragraph in Probabilities for the normal coronaries model.
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Model parameters were assigned probability distributions to describe the range of plausible values that
they could take based on the precision of the estimates available. The type of distribution assigned was
matched to the nature of the parameter; for example, a beta distribution lies between zero and one and
is, therefore, appropriate for parameterising the probability of two mutually exclusive events. The type of
distribution assigned to each parameter was described with the model inputs above.
Randomly selected values from each distribution for each model parameter were simultaneously generated
using Monte Carlo simulation; this was repeated 1000 times and the results were calculated for each run
of the model, generating a distribution of costs and effects that were used to calculate 95% CIs around
the cost and QALY differences between testing strategies, enabling the effect of the parameter uncertainty
on results to be investigated.
Changes to study design after commencement of the study
Feasibility prospective cohort study
There were two main changes to the study design, summarised below:
1. We included the option of postal consent to the recruitment protocol, mainly to be able to catch
patients who were repatriated quickly to local hospitals after the index procedure.
2. We followed up patients through routinely collected hospital episode data (HES for English hospitals
and PEDW for Welsh hospitals). We originally intended to obtain follow-up data for 12 months after
the index procedure from each hospital. However, this was not feasible for many patients, given that
they were repatriated to/followed up at a different hospital from where they had their index procedure.
Formal consensus study
There were four main changes related to the formal consensus study, summarised below:
1. We had intended to include different stakeholders [e.g. cardiologists, general practitioners (GPs) and
patient representatives] in the consensus process. However, as the consensus statements developed it
became evident that these were highly specialised and it would have been unreasonable to expect
those without cardiology expertise to rate and discuss them. Therefore, the consensus process included
only cardiologists.
2. We did not originally intend to give the final survey to cardiologists who did not participate in the
consensus process. However, we had fewer than anticipated cardiologists in the consensus panel;
therefore, to avoid any criticism of the number of panel members in our study and to prevent the
possibility of introducing bias (given the self-selected nature of the panel), we decided to extend the
survey to UK cardiologists who did not participate in the formal consensus process.
3. We had originally intended to implement our primary outcome using follow-up data from local HISs.
However, given the difficulties of obtaining local follow-up data (highlighted in Feasibility prospective
cohort study, point 2), we used HES follow-up data instead.
4. We designed and gave a questionnaire to all cardiologists who referred patients for CMR (in our two
centres with dedicated CMR facilities), which requested information about how CMR changed the
management of those patients. We determined whether or not changes in management described in
the questionnaire were adequately reflected in hospital episode data (see Chapter 6, Implementation of
a primary outcome based on the changes in management for which consensus was achieved).
Health economic study
We intended to use data collected as part of the PIPA study, particularly patient episode data from HES
and the PEDW. However, because the HES data were not available in time to do this, an alternative approach
was required. Secondary sources of data were sought and used as inputs into economic decision models
used to identify the key drivers of cost-effectiveness for CMR imaging in patients who activate the PPCI
pathway, that is, the model parameters that have the most influence.
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Chapter 4 Results for aim A: feasibility of setting
up a cardiovascular magnetic resonance registry by
linking sources of routinely collected data
Parts of this text have been reproduced from Brierley et al.27 © Article author(s) (or their employer(s)unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is
permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
Aim A: to determine whether or not it is feasible to set up a cardiovascular
magnetic resonance registry in this patient population by linking sources
of routinely collected data
l Objective A1: to implement consent and establish patient consent rate.
l Objective A2: to provide evidence of whether or not data linkage and extraction can be carried out
across PPCI centres.
l Objective A3: to determine whether or not the registry can be compiled from HES and the PEDW
rather than multiple HISs.
The number of data about ‘usual care’ provided by UK NHS hospitals that are being collected and stored
electronically in HISs is rapidly increasing. Previous studies have shown that it is possible to use multiple
HISs to retrieve and compile these patient-level data into a research database.61–63 This study tested the
feasibility of setting up a large multicentre registry for patients who activate the PPCI pathway by linking
data from multiple HISs within several hospitals. If the registry was feasible, we had the longer-term aim of
using registry data to evaluate the clinical effectiveness and cost-effectiveness of CMR in this population.
Screening and consent
Standard consent was successfully implemented at all participating hospitals. Across the four participating
hospitals, a total of 2462 patients were screened between 13 May 2013 and 4 September 2014. Of these,
1670 (68%) consented to participate in the study. Consent rates ranged from 59% to 74% (an average
of 68% across the four hospitals). We investigated various options for obtaining consent during the study:
obtaining consent at discharge (rather than straight after the procedure), and an opt-out model on the
procedural consent form (adding a paragraph to the procedural consent form explaining that the clinical
data collected would be used for research unless patients ‘opted out’ by ticking a box on the form).
These were not implemented as they were deemed not feasible.
Detailed screening data were available for only one hospital (hospital A, Figure 5). A total of 1210 patients
were screened in hospital A; 856 were identified through the cardiology database ‘query’ that was set up
to identify eligible participants for the study and 354 were identified independently by the research nurse
team. The other hospitals did not provide detailed screening data. We anticipated that local record linkage
between databases held by a hospital would allow patients who gave consent to be distinguished from
those who did not. Thus, it was intended that standard aspects of data collection for prospective studies, for
example a screening log with reasons for ineligibility and a record of consent, would be implemented in our
study as routine reports from the database. In hospital A, we set out to identify eligible patients through a
database ‘query’ set up in the local cardiology database. It was hoped that this screening model would be
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exported to the other participating hospitals. However, when we started recruiting, it became clear that
this screening model did not work, as many patients were identified independently of the database query.
The other hospitals were, therefore, allowed to implement their own methods of screening, involving a
combination of electronic processes (e.g. e-mail alerts or database searches for new potentially eligible
patients) and manual processes (e.g. checking admission books) by the research nurses and/or the local
principal investigator.
Recruitment
A total of 1670 participants were recruited to the study between May 2013 and September 2014.
Cumulative recruitment by hospital is shown in Figure 6. Recruitment over time increased steadily across all
hospitals. Hospital A recruited the largest number of patients.
Because we did not have screening data for three of the hospitals, we estimated the approximate
number of eligible patients over the recruiting period from the data between January and December 2014
provided directly by the BCIS. This registry provides comparative data on the provision of PCI in the UK
and describes the quality and patterns of care, the process of care and outcomes for patients from all PCI
centres. We extrapolated the number of PPCI procedures carried out during the recruitment period at each
of the hospitals from the annual data provided for each hospital. The estimated rate of recruitment at
each hospital is shown in Table 10. The average recruitment rate across the four hospitals was 52%, but
there was large variation between hospitals (22–86%). These recruitment figures do not take into account
(1) patients who did not meet the study eligibility criteria or (2) patients who activated the PPCI pathway
but had emergency angiography only (i.e. patients with unobstructed arteries).
Patients screened
(n = 1210)
Patients excluded
(n = 447, 37%)
Eligible, consented and included in analysis population
(n = 763, 63%)
• Ineligible, n = 58
    Patient died, n = 33
    Mental incapacity, n = 19
    Not in population, n = 4
    No emergency angiography, n = 1 
    Prisoner, n = 1
• Did not consent, n = 76
    Not interested, n = 21
    Personal reasons, n = 8
    Language difficulties, n = 5
    Other reason, n = 17
    No reason given, n = 25
• Not approached, n = 41
• Flagged as not appropriate for inclusion in research, n = 26
• Did not respond to postal invitation, n = 218
• Not included in the cardiology database query, n = 28 
FIGURE 5 Flow chart of patient recruitment in hospital A.
RESULTS FOR AIM A
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Data linkage and extraction across hospitals
Figure 7 shows the flow chart of data availability. Anonymised data were available for 705 out of the
792 (89%) patients who were identified as eligible but who did not consent or were not approached.
Clinical and biochemistry data were most readily available (for > 80% of participants), whereas data on
medications were least readily available (for only 44% of participants).
Figure 8 shows the flow chart of data submitted from each hospital. One of the hospitals (hospital B)
provided the data in a linked format; linkage was undertaken centrally for the other three hospitals with
data linked on a local hospital identifier. Anonymised data were available for > 80% of patients from three
hospitals, but for only 50% of patients from one hospital. Clinical data were available for 93% of patients
at all hospitals (range 82–98%). The availability of ECHO data was variable; one hospital was unable to
submit any ECHO data, one hospital submitted ECHO data for only 34% of patients and two submitted
data for > 75% of patients. ECHO data were submitted as free-text reports, rather than coded data.
Biochemistry data were available for ≥ 98% of patients from three hospitals; one hospital was unable to
submit biochemistry data for any of its patients. Data about medications on discharge were available for
TABLE 10 Estimated recruitment rate, by hospital
Site
Number of months
of recruitment
Estimated number of PPCIsa
during recruitment period
Participants recruited
to studyb (n)
Estimated
% recruited
Hospital A 15.7 765 655 86
Hospital B 12.5 1138 246 22
Hospital C 11.2 392 295 75
Hospital D 13.8 532 280 53
Total 2827 1476 52
a Estimated recruitment over time based on the following annual figures for January–December 2014: hospital A, n = 585;
hospital B, n = 1092; hospital C, n = 420; and hospital D, n = 463.
b Number recruited with BCIS data.
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Did not consent/not approached
(n = 792, 32%)
Patients consented and included in analysis
(n = 1670, 68%)
Clinical data available
(n = 1553, 93%)
Patients eligible
(n = 2462)
Anonymised data available
(n = 705, 89%)
Echocardiography data available
(n = 994, 60%)
Biochemistry data available
(n = 1342, 80%)
Medications on discharge data available
(n = 739, 44%)
CMR data available
(n = 189, 11%)
Any data available
(n = 1649, 99%)
HES/PEDW data linked
(n = 1655,a 99%)
FIGURE 7 Flow chart of data availability.
a, The number of patients with their index procedure identified in hospital episode data (exact match on day or
1 day out) or inpatient or outpatient or A&E data available in the year following the index procedure. Note that
1612 out of 1670 (97%) patients had their index procedure identified in hospital episode data (exact match on day
or 1 day out).
Reproduced from Brierley et al.27 © Article author(s) (or their employer(s) unless otherwise stated in the text of the
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Hospital A
Eligible and approached
(n = 1057)
Consented and included in
analysis population
(n = 763, 70%)
Any data available
(n = 762, 100%)
Clinical data available
(n = 715, 94%)
CMR data available
(n = 151, 20%)
Echocardiography
data available
(n = 664, 87%)
Biochemistry
data available
(n = 762, 100%)
Medications on
discharge data
available
(n = 739, 97%)
Non-consenting patients
(n = 294, 28%)
Anonymised data
available
(n = 274, 83%)
Hospital B
Eligible and approached
(n = 438)
Consented and included in
analysis population
(n = 272, 62%)
Any data available
(n = 272, 100%)
Clinical data available
(n = 224, 82%)
CMR data available
(n = 38, 14%)
Echocardiography
data available
(n = 92, 34%)
Biochemistry
data available
(n = 268, 99%)
Medications on
discharge data
not available
Non-consenting patients
(n = 166, 38%)
Anonymised data
available
(n = 166, 100%)
Hospital C
Eligible and approached
(n = 539)
Consented and included in
analysis population
(n = 320, 59%)
Any data available
(n = 315, 98%)
Clinical data available
(n = 314, 98%)
Echocardiography
data not available
Biochemistry
data available
(n = 312, 98%)
Medications on
discharge data
not available
Non-consenting patients
(n = 219, 41%)
Anonymised data
available
(n = 208, 95%)
Hospital D
Eligible and approached
(n = 428)
Consented and included in
analysis population
(n = 315, 74%)
Any data available
(n = 300, 95%)
Clinical data available
(n = 300, 95%)
Echocardiography
data available
(n = 238, 76%)
Biochemistry
data not
available
Medications on
discharge data
not available
Non-consenting patients
(n = 113, 26%)
Anonymised data
available
(n = 57, 50%)
FIGURE 8 Flow chart of data availability, by hospital. Shading indicates that no data were available.
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97% of patients from one hospital; the other three hospitals were unable to submit these data.27 Although
we requested biochemistry test results relevant to the cardiovascular disease population [creatinine, full
blood count (serial), electrolytes (serial), troponin (admission; 8 hour), cholesterol (on admission), blood
glucose (serial) and C-reactive protein (serial)], the three hospitals that provided biochemistry data sent all
tests conducted during the specified time frame. However, it was feasible to extract specific test results
from the biochemistry data sets and identify specific medications from the medications data sets.
There were a number of issues with data that were provided by hospitals, such as the inclusion of ‘test’
patients at one hospital, discrepancies between hospitals on the format and naming of the fields (e.g. BCIS
fields were provided as: ‘yes/no’, ‘1/2’ or ‘1. yes/2. no’) and the delay in receiving extracts. Once identified,
‘test’ patients were removed at source and discrepancies between formatting and naming of fields were
addressed by hardcoding.
Cardiovascular magnetic resonance exposure
Cardiovascular magnetic resonance reports were submitted for all consented patients who received CMR
in hospitals A and B. Like the ECHO data, CMR data were in free-text format; the hospital that provided
linked data (hospital B) extracted the CMR variables of interest from the free-text reports. Information
about whether or not a CMR was ordered for clinical need or research purposes (i.e. patient participating
in another research study) was not recorded routinely. From information provided by hospital A, the
proportion ordered for clinical need was 67%.
Data linkage with Hospital Episode Statistics and Patient Episode
Database Wales
Hospital Episode Statistics, ONS and PEDW data were provided from the first recruitment date across all
hospitals (May 2013) up to 30 September 2014 (Swansea), 31 March 2015 (Bristol and Leeds) and
30 April 2015 (Cardiff). Data linkage with HES, PEDW and vital status was achieved for 1655 out of
1670 (99%) patients across all hospitals. The linkage for each HES or PEDW data set is shown in Table 11.
No data were supplied for patients for whom the NHS number was not recorded.
A further review of the linked data demonstrated that it was possible to identify an admission that
matched the index admission for 1554 (93%) patients; this increased to 1612 (97%) patients when the
dates of admissions recorded in hospital episode data and the date of the index admission recorded in HISs
TABLE 11 Data linkage for each HES and PEDW data set, by hospital
Site Consented (n)
Patients with, n (%)
Any admissions data Any outpatient data Any A&E data
Admissions,
outpatient
or A&E data
Hospital Aa 763 757 (99) 743 (97) 583 (76) 758 (99)
Hospital B 272 272 (100) 269 (99) 196 (72) 272 (100)
Hospital Cb 320 311 (97) 266 (83) 264 (83) 316 (99)
Hospital Dc 315 309 (98) 292 (93) 191 (61) 309 (98)
Total 1670 1649 (99) 1570 (94) 1234 (74) 1655 (99)
a No NHS number for five patients.
b No NHS number for one patient.
c No NHS number for six patients; no event date for 17 patients.
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were allowed to differ by 1 day. For some patients (n = 22, hospital D), it was not possible to identify the
index admission in HES because the event date was not recorded in the HIS. This also meant that it was
not possible to identify admissions, outpatient appointments or A&E visits in the year after the index
admission for these patients. Data availability is shown in Table 12.
Identifying the eligible study cohort and cardiovascular magnetic
resonance exposure in hospital episode data
We identified 98% (range 92–100% across hospitals) of patients who underwent PPCI and 85%
(range 46–99% across hospitals) of patients who had an emergency angiogram but no PCI in hospital
episode data.
We could not identify all CMR exposure in HES. Admissions including the date of the CMR were identified
for 109 of the 189 patients with CMR recorded in HISs (57%) and a record of CMR was found in the
hospital episode data for 49 of these 109 (45%) patients. Patients who had a CMR dated after discharge,
based on the HIS, were assumed to have had the CMR as an outpatient (n = 81); only 7 (9%) of these
patients had a matching outpatient date in the hospital episode data. None of these seven outpatient
episodes included any code for CMR (procedure codes are not well recorded in the HES outpatients’ data
set). Data availability is shown in Table 13 and the details of CMR identification in the hospital episode
data are shown in Figure 9.
Summary of main findings
Identifying the eligible population
Patients who activated the PPCI pathway and received PCI were easy to identify from catheter laboratory
databases, since consistent terminology was used to define these patients. A proportion of these patients
recruited in the study were identified independently of these databases. Patients who activated the
PPCI pathway but did not receive PPCI were not consistently defined in catheter laboratory databases;
these patients required further manual checks by catheter laboratory staff who assisted the research
nurses in identifying eligible patients. Some of these patients were screened out, possibly because of
(1) misunderstanding by catheter laboratory staff or research nurses over eligibility (especially at the
beginning of the study) and (2) the lack of consistent terminology used to describe these patients in
catheter laboratory databases, leading to confusion about whether or not to include them.
TABLE 12 Data linkage for each HES and PEDW data set, by hospital
Site Consented (N)
n (%)
Admission matching
index admission
date (± 1 day)
Any APC data in
year after index
admission
Any outpatient data
in year after index
admission
Any A&E data in
year after index
admission
Hospital Aa 763 756 (99) 342 (45) 720 (94) 315 (41)
Hospital B 272 269 (99) 115 (42) 258 (95) 116 (43)
Hospital Cb 320 295 (92) 130 (41) 234 (73) 119 (37)
Hospital Dc 315 292 (93) 86 (27) 284 (90) 89 (28)
Total 1670 1612 (97) 673 (40) 1496 (90) 639 (38)
APC, admitted patient care (inpatient).
a No NHS number for five patients.
b No NHS number for one patient.
c No NHS number for six patients; no event date for 17 patients.
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TABLE 13 Consented patients who underwent PPCI and emergency angiography without PCI, identified in hospital episode data
Site Consented (N)
n (%)
Number (out of N)
consented and
matched for
PPCI index date
(CRF and hospital
electronic record)
Number (and %)
of those in the
left adjacent
column also
identified in
national routine
data sets
(HES/PEDW)
Number (out of N)
consented and
matched for
emergency
angiography but
without PPCI (CRF
and hospital
electronic record)
Number (and %)
of those in the
left adjacent
column also
identified in
national routine
data sets
(HES/PEDW)
Number (out of N)
consented and
matched for CMR
(CRF and hospital
electronic record)
Number (and %)
of those in the
left adjacent
column also
identified in
national routine
data sets
(HES/PEDW)
Hospital A 763 655 649 (99) 108 107 (99) 151 49 (32)
Hospital B 272 246 246 (100) 26 23 (88) 38 6 (16)
Hospital C 320 295 273 (92) 25 22 (88) – –
Hospital D 315 280 274 (98) 35 16 (46) – –
Total 1670 1476 1444 (98) 194 168 (85) 189 55 (29)
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Patients underwent CMR
(within a 10-week window)
(n = 189)
CMR within index
admission
(n = 76)
Record of
CMR in HES
(n = 44)
No inpatient data
match; assumed
outpatient
(n = 70)
Outpatient
date match
but no record
of CMR
(n = 2)
No record of
CMR in HES
(n = 22)
Record of
CMR in HES
(n = 6)
No inpatient data
match; assumed
outpatient
(n = 10)
CMR within index
admission
(n = 28)
Hospital B
(n = 38)
Hospital A
(n = 151)
CMR within
later inpatient
admission
(n = 5)
No record of
CMR in HES
(n = 31)
Record of
CMR in HES
(n = 5)
Outpatient
date match
but no record
of CMR
(n = 5)
FIGURE 9 Details of CMR recording in HES/PEDW data.
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Implementing consent
We asked all participating hospitals to implement a conventional system of written consent so that we
could establish a consent rate and ensure that we had consent to obtain follow-up data from HES and
PEDW. We met the feasibility objective of implementing conventional prospective consent at all hospitals.
Consent rates ranged from 59% to 74%27 with respect to numbers considered eligible to participate,
and from 22% to 86% with respect to approximate BCIS volume in the period of recruitment; these
percentages were lower for some hospitals than we had anticipated for a study in which participants have
no active involvement. The main reason for the lower than expected consent rate, and the variation between
hospitals, was that many patients identified as eligible were missed; PPCI patients are asleep immediately
following the procedure, rarely confined to bed after the first 4–6 hours and many are discharged within
24 hours or transferred to referring hospitals. Some of the missed patients activated the PPCI pathway at the
weekend, when research nurses were not always available. In some centres, patients did not get admitted to
the critical care ward or general ward after the PPCI procedure. We implemented postal consent to invite
identified eligible patients who were not approached in hospital, but return rates were low. Some patients
were unable to cope with the emergency nature of their condition and the large amount of new information
they were given as part of their care; for some, the request to participate in a research study seemed to be
yet another thing to think about and it was easier for them to decline to take part.
Data linkage and extraction across hospitals
We did not meet the feasibility criterion for data linkage and extraction from HISs for all of the requested
data sets. We prespecified that, for each participating hospital, the data items requested should be available
(i.e. extracted from sources and linked) for > 90% of patients. Only one hospital provided all of the requested
data sets (anonymised, clinical, ECHO, biochemistry and medication on discharge) for > 80% of eligible (for
the anonymised data set) and consented patients. Some hospitals had entire data sets missing: medications
on discharge were not available from hospitals B, C and D; information about ECHO tests was not available
from hospital B; and biochemistry data were not available from hospital D. There were several reasons for
missing data, for example:
l Some hospitals were unable to extract data from local stand-alone databases that were designed for a
specific purpose, for example logging biochemistry requests or storing and presenting test results.27
Such local databases were typically old and did not have an interface for data extraction; data would
have had to be retrieved manually for each patient in turn, rather than submitting a ‘batch’ query.
The study was not resourced for this activity. Moreover, obtaining data in this way was considered
infeasible for a national registry (as well as time consuming) and hospitals were not requested to do so.
l Some data (e.g. medications on discharge, bedside ECHO) were not recorded electronically and were
available only in paper form (sometimes scanned but not coded/searchable).
l Non-bedside imaging tests (ECHO and CMR) were available electronically but as free-text reports rather
than coded data; variables of interest were impossible to extract from these reports by conventional
text-searching methods because of the variability with which the information was recorded.27
Cardiovascular magnetic resonance exposure
We were able to obtain CMR reports for all consented patients, although imaging reports were largely in
free-text format, so individual CMR parameters would have had to be extracted manually. We concluded
that this would not be feasible for an extended registry.
Follow-up/outcome data
It would be feasible to obtain 12 months’ follow-up data after the index admission through HES in an
extended registry. Admissions (inpatient data set), outpatient appointments and A&E data could be
identified for all patients for whom a NHS number was available and who had a date recorded for their
index admission. Because we obtained hospital episode data only for patients who we believed to be
eligible, we cannot comment on the risk that eligible patients might not have been identified.
RESULTS FOR AIM A
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Compiling the registry from Hospital Episode Statistics
It is not currently feasible to compile the registry from HES data rather than multiple HISs. Although we
could identify the eligible population and obtain follow-up data, we could not identify the CMR exposure
within 10 weeks of the index admission. This was mainly because the CMR is often performed at an
outpatient clinic and the HES outpatient data quality, particularly for clinical information, is poor (i.e. lack
of data on diagnoses or procedures).
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Chapter 5 Results for aim B: cohort
characteristics, exposure and outcomes, and resource
use/cost-effectiveness
Parts of this text have been reproduced from Brierley et al.27 © Article author(s) (or their employer(s)unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is
permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
Aim B: to estimate the proportion of the target population who have
cardiovascular magnetic resonance at two centres with dedicated
cardiovascular magnetic resonance facilities and describe resource use
and associated costs of having cardiovascular magnetic resonance after
primary percutaneous coronary intervention
l Objective B1: to estimate the proportion of the target population who undergo a CMR following PPCI
pathway activation.
l Objective B2: to describe resource use and associated costs of having CMR after PPCI pathway
activation, including cost-effectiveness models.
In Chapter 4, we reported on the feasibility aspects of the study with respect to identifying the eligible
population, implementing consent, and data linkage and extraction across sites and with hospital episode
data. In this chapter, we report on the quantitative characteristics of the cohort with respect to index
admission (baseline) data, follow-up data and the health economic analysis we conducted for this study.
A series of economic decision models were developed to identify the key drivers of cost-effectiveness.
As uncertainty surrounds the performance of CMR imaging in practice and its benefit to patients in terms
of more optimal treatment, a flexible framework was required to facilitate the assessment of uncertainty
around parameter estimates. Models are a simplification of the real world and will never capture every
possible scenario associated with an intervention, but the key consequences need to be included when
models are conceptualised and structured.64 It is helpful if there are clinical events driving the models to
define branches in the decision trees and associated event probabilities. The models were developed in
consultation with clinical experts on the study team.
Two subgroups of patients who activated the PPCI pathway were chosen for the economic decision
models: (1) patients with multivessel disease and (2) patients with unobstructed coronary arteries. Both
subgroups were identified by formal consensus (see Chapter 6, Patient subgroups) as potentially benefiting
from CMR. Patients with multivessel disease are the largest subgroup of patients in the population that
activates the PPCI pathway (40–60%), and there is clinical uncertainty about how to treat this subgroup.
Patients with normal coronary arteries are a distinct group which, at the outset, the research team
expected to benefit most from CMR.
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Characteristics of consented versus non-consented patients
Table 14 shows the baseline characteristics of consented and non-consented patients. The IMD and
WIMD scores were higher among those who consented than those who did not (SMDs 0.31 and 0.27,
respectively). The percentage of patients who underwent PPCI was also higher among those who
consented than those who did not (90% vs. 65%, respectively; SMD 0.70). This imbalance arose primarily
from hospital A.
Characteristics of participants by hospital
Table 15 shows the characteristics of participants by hospital. Participants from the four hospitals were
similar with respect to demographics, comorbidities and previous cardiac interventions, although rates
of hypertension were lower in patients from hospital B than in patients from hospitals A, C and D
(18% vs. 41–52%).
A CMR scan was performed (within 10 weeks of the index admission) for 20% of consented patients in
one CMR centre and for 14% of consented patients in the second CMR centre. CMR data from hospital A
were submitted as free-text reports; individual CMR parameters were difficult to extract electronically from
these. Hospital B extracted CMR parameters of interest from the free-text reports manually. The baseline
characteristics of patients who did and patients who did not receive CMR are shown in Table 16. Patients
referred for CMR were slightly younger than those who did not have CMR. No other differences were noted.
TABLE 14 Baseline characteristics of consenting and non-consenting patients (for whom data were available)
Characteristic Consenting patients (n= 1649) Non-consenting patients (n= 705) SMDa
Age (years), mean (SD)b 64 (12.7) 65 (14.2) 0.06
Male sex, n/N (%) 1159/1516 (76) 481/677 (71) 0.12
Current smoker, n/N (%) 478/1473 (32) 240/602 (40) 0.16
IMD score, median (IQR)c 13.4 (7.7–25.8) 19.9 (10.4–34.9) 0.31
WIMD rank, median (IQR)d 891 (459–1370) 671 (268–1221) 0.27
Diabetes, n/N (%) 231/1536 (15) 134/645 (21) 0.15
Hypertension, n/N (%) 601/1455 (41) 263/663 (40) 0.03
Previous PCI, n/N (%) 157/1552 (10) 73/652 (11) 0.04
Previous CABG, n/N (%) 37/1540 (2) 25/654 (4) 0.09
Previous MI, n/N (%) 193/1547 (12) 101/650 (16) 0.09
PPCI, n/N (%) 1307/1452 (90) 429/664 (65) 0.70
Length of stay (days), median (IQR)e 3 (2–4) 2 (1–4) 0.13
a SMDs can be interpreted as follows: values of 0.20 are ‘small’ in magnitude, those around 0.50 are ‘medium’ and those
around or above 0.80 are ‘large’.65
b Missing data (consented patients, non-consented patients): (8, 5).
c Missing data (consented patients, non-consented patients): (179, 15).
d Missing data (consented patients, non-consented patients): (92, 47).
e Missing data (consented patients, non-consented patients): (250, 78).
Note
Values are numbers (percentages) unless otherwise stated.27
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TABLE 15 Baseline characteristics of participants, by hospital
Characteristic
Hospital A
(n= 762)
Hospital B
(n= 272)
Hospital C
(n= 315)
Hospital D
(n= 300)
Age (years), mean (SD)a 65.1 (12.7) 62.9 (12.5) 63.8 (12.4) 63.4 (13.0)
Male sex, n/N (%) 512/655 (78) 183/246 (74) 238/315 (76) 226/300 (75)
Current smoker, n/N (%) 191/660 (29) 95/240 (40) 95/300 (32) 97/273 (36)
IMD score, median (IQR)b 12.2 (7.1–21.7) 20.5 (10.1–39.2) – –
WIMD rank, median (IQR)c – – 817 (334–1478) 902 (553–1314.5)
Diabetes, n/N (%) 91/700 (13) 33/243 (14) 70/310 (23) 37/283 (13)
Hypertension, n/N (%) 275/663 (41) 42/238 (18) 143/282 (51) 141/272 (52)
Previous PCI, n/N (%) 71/701 (10) 35/242 (14) 27/310 (9) 24/299 (8)
Previous CABG, n/N (%) 21/704 (3) 7/243 (3) 5/308 (2) 4/285 (1)
Previous MI, n/N (%) 88/707 (12) 40/240 (17) 33/312 (11) 32/288 (11)
PPCI, n/N (%) 597/655 (91) 220/243 (91) 267/295 (91) 223/259 (86)
Length of stay (days), median (IQR)d 3 (2–4) 2 (1–3) 3 (1–4) 2 (1–4)
a Missing data by hospital (hospital A, hospital B, hospital C, hospital D): 8 patients (1, 0, 0, 7).
b Missing data by hospital (hospital A, hospital B, hospital C, hospital D): 179 patients (169, 10, not collected for hospitals C or D).
c Data missing for 92 patients (not collected for hospitals A and B, 80, 12).
d Data missing for 250 patients (109, 2, 17, 122). Proportion of eligible population receiving CMR and characteristics of
patients who did/did not receive CMR.
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TABLE 16 Baseline and CMR characteristics of patients who did and patients who did not have CMR in hospitals A
and B
Characteristic
Patients who had
CMR (n= 189)
Patients who did not
have CMR (n= 846) SMDa
Age (years), mean (SD)b 61.8 (11.7) 65.1 (12.8) 0.26
Male sex, n/N (%) 121/154 (79) 574/747 (77) 0.04
Current smoker, n/N (%) 52/168 (31) 234/732 (32) 0.02
IMD score, median (IQR)c 12.4 (7.5–23.5) 13.5 (7.8–26.3) 0.08
Diabetes, n/N (%) 19/176 (11) 105/767 (14) 0.09
Hypertension, n/N (%) 63/166 (38) 254/735 (35) 0.07
Previous PCI, n/N (%) 18/176 (10) 88/767 (11) 0.04
Previous CABG, n/N (%) 3/176 (2) 25/771 (3) 0.09
Previous MI, n/N (%) 20/174 (11) 108/773 (14) 0.07
continued
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Participant follow-up
Table 17 shows the cardiac-related events in the 12 months following the index admission in the entire
cohort. Overall, 55 out of 1670 (3%) patients died during follow-up (median age 73 years, IQR 66–82 years).
MACE rate in this cohort was 13% (219/1670).
The recorded causes of death for patients who died within 1 year of admission are shown in Appendix 6.
Only 32 out of 54 (59%) patients died from causes closely associated with ischaemic heart disease; an
additional 2 (4%) died from other heart conditions and 8 out of 54 (15%) patients died of cancer.
TABLE 17 Rates of death and cardiac-related events in the 12 months following the index admission in the
entire cohort
Event
Number of events,
n/N (%)
Person-years of
observation
Events per 1000 person-years
(95% CI)
Death 55/1638 (3) 1536.33 35.8 (27.0 to 46.6)
MI 74/1638 (5) 1376.04 53.8 (42.2 to 67.5)
Stroke 2/1638 (0.1) 1427.12 1.4 (0.02 to 5.1)
Repeat PCI 117/1638 (7) 1347.76 86.8 (71.8 to 104.0)
CABG 20/1638 (1) 1417.25 14.1 (8.6 to 21.8)
MACE (death, MI, revascularisation) 219/1638 (13) 1311.44 167.0 (145.6 to 190.6)
Note
The denominator is 1638 because the date of index admission was missing for 22 patients and HES/PEDW data were
unavailable for 10 patients.
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TABLE 16 Baseline and CMR characteristics of patients who did and patients who did not have CMR in hospitals A
and B (continued )
Characteristic
Patients who had
CMR (n= 189)
Patients who did not
have CMR (n= 846) SMDa
PPCI, n/N (%) 140/154 (91) 677/744 (91) 0.003
Length of stay (days), median (IQR)d 2 (2–3) 3 (2–3) 0.11
a SMDs can be interpreted as follows: values of 0.20 are ‘small’ in magnitude, those around 0.50 are ‘medium’ and those
around or above 0.80 are ‘large’.65
b Missing data (patients who had CMR, patients who did not have CMR): 2 patients (1, 1).
c Missing data (patients who had CMR, patients who did not have CMR): 180 patients (43, 137).
d Missing data (patients who had CMR, patients who did not have CMR): 112 patients (32, 80).
Note
Values are numbers (percentages) unless otherwise stated.27
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Cost-effectiveness models
Multivessel disease
The expected costs and QALYs gained under each of the ischaemia testing options are shown in Table 18
together with the cost-effectiveness results for CMR and pressure wire, each compared with stress ECHO.
Comparisons are made with stress ECHO because this was the ischaemia test in use at the time of the
study (and is considered the ‘existing’ comparator) and also because CMR and pressure wire were assumed
to be equally effective; these strategies differ only in terms of their costs. Based on the point estimates,
CMR was slightly less costly and more effective than stress ECHO and, therefore, dominated stress ECHO.
Pressure wire was more costly and more effective than stress ECHO: the ICER is considerably higher than
the accepted cost-effectiveness threshold of £20,000–30,000 per QALY, and, therefore, would not be
considered cost-effective relative to stress ECHO. Pressure wire is convenient for cardiologists if the test
identifies the fact that a patient needs revascularisation, as the patient can be treated immediately while
in the catheter laboratory, and the cost of the pressure wire in addition to the revascularisation is modest.
In the base-case analysis, 35% of patients having ischaemia testing were assumed to truly have ischaemia;
the majority of patients are, therefore, having an expensive test without needing further treatment. If a
greater proportion of patients undergoing ischaemia testing required revascularisation, it is likely that the
estimated cost of a pressure-wire strategy would reduce. It would be possible to use a pressure wire on
other vessels at the time of the index angiography and PCI, but it was beyond the scope of this work to
consider the likely costs and consequences of such a strategy. Based on the point estimates, pressure wire
is dominated by CMR, because CMR is less costly and equally as effective. Cost and QALY differences are
small relative to the mean values under each strategy, and none of the differences in costs or QALYs is
close to being statistically significant; indeed, the differences in QALYs were tiny. There is considerable
uncertainty around these base-case results; however, as is clear from the plots of 1000 simulated cost
and QALY differences from the PSA for CMR and pressure wire (each compared with stress ECHO) in
Figures 10 and 11. In each figure, there are a large number of points in two or three quadrants of the
cost-effectiveness plane. The black dot is the point estimate of the cost and QALY difference, and,
in each figure, it is close to the origin.
For this feasibility study, it is not the cost-effectiveness results per se that are of interest, but rather the
way in which they change in response to sensitivity analyses that helps us to determine the key drivers of
cost-effectiveness. Table 19 reports the results of the sensitivity analyses around this model. Sensitivity
analysis one, around the probabilities of ischaemia testing or a decision to revascularise a second vessel
(or not) directly from the index angiography, affects the mean costs and QALYs under each strategy but
does not alter the cost-effectiveness results, because these probabilities are the same under each strategy.
Sensitivity analyses two and three, around the diagnostic accuracy of CMR and pressure wire, had the
TABLE 18 Base-case results from the cost-effectiveness model for multivessel disease
Ischaemia
testing
option
Costs (£),
mean (SE)
QALYs,
mean (SE)
Difference in costs
to stress ECHO,
mean (95% CI)
Difference in QALYs,
compared with stress
ECHO, mean (95% CI)
ICER (£),
compared with
stress ECHO
Stress ECHO 5495 (556) 0.7564 (0.0545)
CMR 5431 (560) 0.7576 (0.0551) –64 (–232 to 187) 0.0012 (–0.0076 to 0.0093) CMR dominant
(–53,563)
Pressure wire 5855 (539) 0.7576 (0.0551) 360 (–116 to 844) 0.0012 (–0.0076 to 0.0093) 300,216
Note
All costs and ICERs are rounded to the nearest pound.
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most effect on results. When the sensitivity and specificity of CMR were reduced to 80%, CMR became
more costly than stress ECHO, rather than dominant, and, at accepted cost-effectiveness thresholds, would
not be considered cost-effective relative to stress ECHO. When the sensitivity and specificity of pressure
wire were reduced to 80%, conclusions did not alter: pressure wire was still more costly and slightly
more effective than stress ECHO, but the ICER quadrupled. The diagnostic accuracy of the ischaemia
tests, in particular CMR, are key drivers of cost-effectiveness. Varying the costs of CMR, angiography
and pressure wire, and varying QALYs for patients with MACE and those without MACE, did cause
cost-effectiveness results to vary, but did not alter cost-effectiveness conclusions.
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FIGURE 11 A plot of the 1000 simulated cost and QALY differences from the PSA for pressure wire vs. stress ECHO.
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FIGURE 10 A plot of the 1000 simulated cost and QALY differences from the PSA for CMR vs. stress ECHO.
Reproduced with permission from Stokes et al.36 © Author(s) (or their employer(s)) 2019. Re-use permitted under
CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons
Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build
upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and
indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
RESULTS FOR AIM B
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TABLE 19 Results of the sensitivity analyses around the cost-effectiveness model for multivessel disease
SA
Ischaemia
testing
option
Costs (£),
mean (SE)
QALYs,
mean (SE)
Difference in
costs, compared
with stress ECHO,
mean (95% CI)
Difference in
QALYs, compared
with stress ECHO,
mean (95% CI)
ICER (£),
compared
with stress
ECHO
Base case Stress ECHO 5495
(556)
0.7564
(0.0545)
CMR 5431
(560)
0.7576
(0.0551)
–64 (–232 to 187) 0.0012
(–0.0076 to 0.0093)
CMR dominant
(–53,563)
Pressure wire 5855
(539)
0.7576
(0.0551)
360 (–116 to 844) 0.0012
(–0.0076 to 0.0093)
300,216
1. Decision from
angiography
Stress ECHO 4575
(449)
0.7537
(0.0654)
CMR 4558
(500)
0.7540
(0.0661)
–17 (–62 to 45) 0.0003
(–0.0022 to 0.0026)
CMR dominant
(–53,563)
Pressure wire 4667
(500)
0.7540
(0.0661)
93 (–21 to 214) 0.0003
(–0.0022 to 0.0026)
300,216
2. CMR test
accuracy
Stress ECHO 5495
(556)
0.7564
(0.0545)
CMR 5558
(600)
0.7567
(0.0572)
63 (–202 to 390) 0.0004
(–0.0119 to 0.0108)
168,453
3. PW test
accuracy
Stress ECHO 5495
(556)
0.7564
(0.0545)
Pressure wire 5944
(568)
0.7567
(0.0572)
449 (–18 to 947) 0.0004
(–0.0119 to 0.0108)
1,207,875
4. ECHO test
accuracy
Stress ECHO 5431
(553)
0.7568
(0.0555)
CMR 5431
(560)
0.7576
(0.0551)
+0 (–128 to 253) 0.0008
(–0.0022 to 0.0036)
201
Pressure wire 5855
(539)
0.7576
(0.0551)
424 (18 to 888) 0.0008
(–0.0022 to 0.0036)
529,193
5. MACE +0.05 Stress ECHO 5674
(586)
0.7520
(0.0566)
CMR 5610
(580)
0.7533
(0.0574)
–65 (–233 to 164) 0.0012
(–0.0078 to 0.0087)
CMR dominant
(–53,434)
Pressure wire 6033
(575)
0.7533
(0.0574)
359 (–85 to 831) 0.0012
(–0.0078 to 0.0087)
296,587
5. MACE –0.05 Stress ECHO 5317
(564)
0.7607
(0.0589)
CMR 5252
(565)
0.7619
(0.0595)
–65 (–244 to 192) 0.0012
(–0.0081 to 0.0097)
CMR dominant
(–53,463)
Pressure wire 5676
(533)
0.7619
(0.0595)
359 (–112 to 830) 0.0012
(–0.0081 to 0.0097)
297,408
6. CMR cost
+20%
Stress ECHO 5495
(556)
0.7564
(0.0545)
CMR 5463
(556)
0.7576
(0.0551)
–32 (–218 to 187) 0.0012
(–0.0076 to 0.0093)
CMR dominant
(–27,021)
6. CMR cost –20% Stress ECHO 5495
(556)
0.7564
(0.0545)
CMR 5399
(551)
0.7576
(0.0551)
–96 (–268 to 159) 0.0012
(–0.0076 to 0.0093)
CMR dominant
(–80,104)
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An alternative way of assessing the sensitivity of results to the cost of an ischaemia test is to consider how
the cost of the test would need to alter for the costs of alternative strategies to be estimated to be equal.
In the base-case analyses, the cost of CMR was £264, and a CMR strategy was less costly than a stress
ECHO strategy. Threshold analyses around the cost of CMR identified that if the cost rose to £371, there
was no difference in the costs between a CMR and a stress ECHO strategy. In the base-case analyses, the
cost of angiography and pressure wire was £1340, and a pressure-wire strategy was more expensive than
a CMR or stress ECHO strategy. Threshold analyses identified that the cost of angiography and pressure
wire would need to reduce to just £250 for there to be no difference in costs between a CMR and a
pressure-wire strategy, and to £415 for there to be no difference between the cost of a stress ECHO
and a pressure-wire strategy.
Normal (unobstructed) coronary arteries
The expected costs, QALYs and cost-effectiveness results under standard ECHO and CMR compared with
standard ECHO alone for patients with normal coronaries are shown in Table 20. The reduction in costs
associated with treating fewer patients for MI with the introduction of CMR testing compensated only
partially for the additional cost of the CMR test. Mean costs and QALYs gained were higher with standard
ECHO and CMR than with standard ECHO alone, and the ICER would not be considered cost-effective at
accepted thresholds. There is considerable uncertainty around these base-case results, however, as is clear
from the plot of the simulated cost and QALY differences from the PSA in Figure 12. There are a large
number of points in three quadrants of the cost-effectiveness plane.
TABLE 19 Results of the sensitivity analyses around the cost-effectiveness model for multivessel disease (continued )
SA
Ischaemia
testing
option
Costs (£),
mean (SE)
QALYs,
mean (SE)
Difference in
costs, compared
with stress ECHO,
mean (95% CI)
Difference in
QALYs, compared
with stress ECHO,
mean (95% CI)
ICER (£),
compared
with stress
ECHO
7. PW cost +20% Stress ECHO 5495
(556)
0.7564
(0.0545)
Pressure wire 6015
(560)
0.7576
(0.0551)
521 (78 to 992) 0.0012
(–0.0076 to 0.0093)
434,425
7. PW cost –20% Stress ECHO 5495
(556)
0.7564
(0.0545)
Pressure wire 5694
(537)
0.7576
(0.0551)
199 (–240 to 622) 0.0012
(–0.0076 to 0.0093)
166,007
8. QALYs for
MACE –0.2
Stress ECHO 5495
(556)
0.7306
(0.0559)
CMR 5431
(560)
0.7346
(0.0565)
–64 (–232 to 187) 0.0040
(–0.0057 to 0.0117)
CMR dominant
(–16,041)
Pressure wire 5855
(539)
0.7346
(0.0565)
360 (–116 to 844) 0.0040
(–0.0057 to 0.0117)
89,907
9. QALYs for no
MACE +0.2
Stress ECHO 5495
(556)
0.9306
(0.0576)
CMR 5431
(560)
0.9346
(0.0587)
–64 (–232 to 187) 0.0040
(–0.0071 to 0.0104)
CMR dominant
(–16,041)
Pressure wire 5855
(539)
0.9346
(0.0587)
360 (–116 to 844) 0.0040
(–0.0071 to 0.0104)
89,907
PW, angiography and pressure wire; SA, sensitivity analysis.
Note
All costs and ICERs are rounded to the nearest pound.
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Table 21 reports the results of the sensitivity analyses around this model, designed to help identify the
key drivers of cost-effectiveness. Sensitivity analysis one (reducing the diagnostic accuracy of CMR) and
sensitivity analysis six (increasing the cost of CMR) had the greatest impact on the mean cost difference
between standard ECHO and CMR and standard ECHO alone. Threshold analyses around the cost of CMR
(£264 in the base-case analyses) identified that, if the cost reduced to £166, there was no difference in the
costs between standard ECHO and CMR and a standard ECHO alone strategy. Sensitivity analyses 8–10,
which all directly varied QALYs, had the greatest impact on the difference in QALYs between the arms.
However, in all cases, standard ECHO and CMR remained both more costly and more effective than
standard ECHO alone, and in none of the sensitivity analyses would standard ECHO and CMR be
considered cost-effective at accepted thresholds. These sensitivity analyses suggest that the diagnostic
accuracy of CMR is again a key driver of cost-effectiveness. Results are also influenced by the cost of CMR,
and the difference between utility values assigned to MACE and no MACE, and the proportion of patients
who have MACE, who are assumed to die.
TABLE 20 Base-case results from the cost-effectiveness model for normal coronaries
Ischaemia testing
option
Costs (£),
mean (SE)
QALYs,
mean (SE)
Difference in costs,
mean (95% CI)
Difference in QALYs,
mean (95% CI) ICER (£)
Standard ECHO 3032
(564)
0.7615
(0.0837)
Standard ECHO and CMR 3130
(589)
0.7620
(0.0844)
98 (–199 to 488) 0.0005 (–0.0050 to 0.0077) 190,114
Note
All costs and ICERs are rounded to the nearest pound.
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FIGURE 12 A plot of the 1000 simulated cost and QALY differences from the PSA for standard ECHO and CMR vs.
standard ECHO.
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TABLE 21 Results of the sensitivity analyses around the cost-effectiveness model for normal coronaries
SA
Ischaemia
testing option
Costs (£),
mean (SE)
QALYs,
mean (SE)
Difference in
costs, mean
(95% CI)
Difference in
QALYs, mean
(95% CI) ICER (£)
Base case Standard ECHO 3032
(564)
0.7615
(0.0837)
Standard ECHO
and CMR
3130
(589)
0.7620
(0.0844)
98 (–199 to 488) 0.0005
(–0.0050 to 0.0077)
190,114
1. CMR test accuracy Standard ECHO 3032
(564)
0.7615
(0.0837)
Standard ECHO
and CMR
3183
(591)
0.7618
(0.0850)
151 (–105 to 523) 0.0003
(–0.0026 to 0.0053)
469,998
2. ECHO test accuracy Standard ECHO 2945
(561)
0.7617
(0.0863)
Standard ECHO
and CMR
3130
(589)
0.7620
(0.0844)
185 (–59 to 581) 0.0003
(–0.0027 to 0.0042)
631,744
3. MACE (ratio = 4) Standard ECHO 3067
(541)
0.7608
(0.0826)
Standard ECHO
and CMR
3165
(559)
0.7614
(0.0830)
98 (–192 to 465) 0.0005
(–0.0043 to 0.0069)
190,154
4. MACE (ratio = 2) Standard ECHO 3043
(573)
0.7613
(0.0829)
Standard ECHO
and CMR
3146
(606)
0.7617
(0.0834)
104 (–162 to 498) 0.0004
(–0.0051 to 0.0063)
250,905
5. MACE (ratio = 1) Standard ECHO 3046
(579)
0.7612
(0.0847)
Standard ECHO
and CMR
3161
(596)
0.7614
(0.0850)
115 (–168 to 492) 0.0002
(–0.0051 to 0.0069)
554,609
6. CMR cost +20% Standard ECHO 3032
(564)
0.7615
(0.0837)
Standard ECHO
and CMR
3183
(579)
0.7620
(0.0844)
151 (–133 to 532) 0.0005
(–0.0050 to 0.0077)
292,836
6. CMR cost –20% Standard ECHO 3032
(564)
0.7615
(0.0837)
Standard ECHO
and CMR
3077
(572)
0.7620
(0.0844)
45 (–229 to 476) 0.0005
(–0.0050 to 0.0077)
87,391
7. Reduce MACE costs Standard ECHO 2974
(548)
0.7615
(0.0837)
Standard ECHO
and CMR
3077
(574)
0.7620
(0.0844)
103 (–159 to 502) 0.0005
(–0.0050 to 0.0077)
198,992
8. QALYs for MACE –0.2 Standard ECHO 3032
(564)
0.7457
(0.0879)
Standard ECHO
and CMR
3130
(589)
0.7474
(0.0886)
98 (–199 to 488) 0.0018
(–0.0091 to 0.0139)
55,281
9. QALYs for no MACE
+0.2
Standard ECHO 3032
(564)
0.9457
(0.0905)
Standard ECHO
and CMR
3130
(589)
0.9474
(0.0911)
98 (–199 to 488) 0.0018
(–0.0094 to 0.0134)
55,281
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Summary of main findings
Cohort characteristics and follow-up
Baseline characteristics were reasonably well balanced between participants who consented and those
who did not consent in the study, but suggested that patients living in less deprived residential areas
were, on average, less willing to take part. Characteristics were better balanced across participants
recruited by the four hospitals, and participants who did and those who did not receive a CMR scan.
Data completeness was good for most variables. Follow-up data were available for the entire follow-up
period (12 months) for only 729 out of 1035 (70%) participants in England and 287 out of 635 (45%)
participants in Wales. This is because data were requested soon after recruitment finished and the Welsh
data were provided rapidly. The data for English hospitals took much longer to be released, resulting in
a longer follow-up period. The limited follow-up was a result of this process being part of the testing
feasibility for a full registry; in the context of a registry, the request for these data would be made at an
appropriate stage of the study to achieve the desired duration of follow-up.
The proportion of the target population that gets cardiovascular magnetic resonance
after activating the primary percutaneous coronary intervention pathway
Although > 10% of patients in hospitals with a dedicated CMR facility were referred for CMR, many of
these referrals were for research (patient participating in a research study) rather than clinical purposes.
It is not clear whether or not this reflects practice in other hospitals with dedicated CMR facilities. Referral
for non-clinical reasons (unless the findings are used to change clinical management) would dilute any
observed effect of CMR on outcomes in an extended registry. It was not possible to determine how many
CMRs that were done for research purposes were subsequently reviewed by the treating clinician and
resulted in changes in patient management.
Cost-effectiveness models
For each of the base-case models, the differences in QALYs between strategies were tiny; therefore, the
results are driven largely by the differences in costs, although these were also modest. Sensitivity analyses
around the two models identified the diagnostic accuracy of the ischaemia tests as the key driver of
cost-effectiveness. In the model for patients with multivessel disease, the costs of ischaemia testing and
the QALYs associated with MACE and no MACE exerted an influence on cost-effectiveness results, but
not to the same extent as the diagnostic accuracy of CMR and pressure wire. Similarly, in the model for
patients with normal coronaries, the cost of CMR, the difference between QALYs associated with MACE
and no MACE, and the proportion of patients who have MACE who are assumed to die, exerted an
influence on the results.
TABLE 21 Results of the sensitivity analyses around the cost-effectiveness model for normal coronaries (continued )
SA
Ischaemia
testing option
Costs (£),
mean (SE)
QALYs,
mean (SE)
Difference in
costs, mean
(95% CI)
Difference in
QALYs, mean
(95% CI) ICER (£)
10. QALYs for MACE
(50% die)
Standard ECHO 2994
(516)
0.7488
(0.0859)
Standard ECHO
and CMR
3095
(542)
0.7503
(0.0864)
101 (–180 to 464) 0.0015
(–0.0090 to 0.0133)
66,040
SA, sensitivity analysis.
Note
All costs and ICERs are rounded to the nearest pound.
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Chapter 6 Results for aim C: formal consensus to
identify clinically important changes in management
resulting from cardiovascular magnetic resonance
patients who activate the primary percutaneous
coronary intervention pathway
Parts of this text have been reproduced from Pufulete et al.4 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Aim C: to identify an outcome measure representing a definitive change
in clinical management, conditional on having had cardiovascular
magnetic resonance, that would be credible to cardiologists and other
stakeholders as a measure of the ‘value-added’ by doing cardiovascular
magnetic resonance
l Objective C1: to define, using formal consensus methods, a treatment/process outcome that will
constitute a definitive change in clinical management arising from having CMR.
l Objective C2: to identify patient subgroups in whom CMR use is indicated, using formal consensus
methods and illustrative data from the registry.
l Objective C3: to determine whether or not hospital episode data adequately capture the main changes
in clinical management identified using formal consensus.
l Objective C4: to pilot the implementation of a primary outcome based on the changes in management
for which consensus was achieved using hospital episode data.
We used a formal consensus method based on the modified nominal group technique66 to identify
important changes in management that can be used to define the composite outcome. Formal consensus
is a method that combines both research evidence and expert opinion. We used this approach because we
knew from a preliminary scoping of the literature that there were few studies that reported the impact of
CMR on patient management.4
We used clinical expertise to define ‘clinical events’ that captured the important changes in management
and a clinical coder to identify collaborated with codes (ICD-1031 and the OPCS Classification of Intervention
and Procedures32) corresponding to these clinical events. We then searched for these codes in hospital
episode data for participants in the cohort study during the 12 months following the index admission
(PPCI pathway activation).
Literature review
We initially examined a small number of key reports, reviews and primary studies to determine the extent
of the literature reporting how CMR influences patient management. There were few studies that directly
reported the impact of CMR on patient management, and none of these related to our population of
interest. Figure 13 shows the flow diagram of the systematic review and the different types of studies
identified. We identified a total of 171 studies reporting the use of CMR in patients with acute MI who
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1.  Prognostic studies (n = 38, some studies contributed data to > 1 subgroup)
     • Comprehensive CMR, n = 12
     • Microvascular obstruction, n = 8
     • Infarct size, n = 4
     • Ejection fraction, n = 4
     • Haemorrhage, n = 4
     • Myocardial salvage, n = 3, two studies were in the same population and reported short- and long-term
        outcome
     • Other CMR parameters, n = 6
2.  CMR used to ‘diagnose’ type of MI and complications arising from MI and PPCI, n = 38
     • Type of MI, n = 13
     • LV thrombus, n = 6
     • Ventricular septal defect, n = 5
     • Ventricular aneurysms, n = 3
     • Pericarditis, n = 4
     • Other, n = 2
     • Injury from PPCI, n = 5
3.  CMR used to ‘diagnose’ conditions unrelated to MI, n = 18
     • Cardiac incidental findings, n = 11
     • Myocarditis, n = 4
     • Takotsubo cardiomyopathy, n = 3
4.  Studies comparing indices of heart function assessed by CMR and other imaging modalities, n = 71
     • Diagnostic test accuracy studies, n = 24
     • Validation/correlation studies, n = 47
5.  Cost-effectiveness, n = 1
6.  Studies assessing timing of CMR after PPCI, n = 5
Duplicate citations
(n = 2170)
Excluded
(n = 1209)
• Studies evaluating CMR parameters, n = 569
• Animal studies, n = 294
• Reviews, n = 141
• Duplicate studies, n = 84
• Editorials/commentaries, n = 34
• Not emergency angiogram population, n = 52
Excluded
(n = 2720)
CMR studies in emergency angiography population
(n = 171)
Records identified through multiple database searching
(n = 6270)
Records screened
(n = 4100)
CMR studies (full text and abstract)
(n = 1380)
FIGURE 13 Flow diagram of the study selection process and types of studies identified.
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activated the PPCI pathway. There were no studies that directly compared groups of patients having CMR
or not with respect to patient management or clinical outcomes in this population.
There were 38 prognostic studies assessing the value of CMR in predicting MACEs; 12 did not distinguish the
contributing CMR markers, and 26 assessed individual CMR markers of myocardial damage [e.g. microvascular
obstruction (MVO), infarct size (IS), LV ejection fraction (EF), myocardial salvage, intramyocardial haemorrhage]
as predictors of MACE. These studies did not all evaluate the prognostic value of CMR indices in addition
to indices available from alternative imaging modalities; most were small (20–1217 patients, median 257),
single centre and heterogeneous in terms of the CMR parameters reported and how these were assessed.
Nevertheless, they showed that CMR markers (particularly MVO, IS and myocardial salvage) were consistently
associated with MACEs in STEMI patients.
There were 38 studies of the role of CMR in ‘diagnosing’ a specific feature of the index MI or complications
arising from the index MI or procedure. CMR was used to investigate the type of MI (i.e. acute, chronic,
aborted) in 13 studies, to detect complications of MI [e.g. LV thrombus, ventricular septal defect (VSD)
ventricular aneurysms and pericarditis] in 19 studies and to detect injury from PPCI in five studies. Many of
these were case reports, some were diagnostic test accuracy studies comparing CMR with ECHO as the
reference standard (e.g. diagnosis of thrombus) and some also followed up patients and assessed the
prognostic implications of the CMR findings (e.g. aborted MI).
There were 18 studies in which CMR was used to ‘diagnose’ conditions other than MI (e.g. myocarditis and
Takotsubo cardiomyopathy in patients with unobstructed arteries on angiography) and incidental cardiac
findings. All but two of these were case reports. There were 71 studies in which CMR was compared with
one or more other imaging modalities [i.e. ECHO, SPECT, computed tomography (CT), angiography or with
standard coronary angiography with respect to indices of heart function (e.g. myocardial viability, necrosis,
perfusion, myocardium at risk, ischaemia)]. Twenty-four of these were diagnostic test accuracy studies
(those that included a reference standard and provided statistics of test performance, i.e. sensitivity,
specificity, positive or negative predictive values, receiver operating characteristic curves) and 47 were
validation or correlation studies. Most focused on infarct characteristics and myocardial viability, but the
definitions and techniques assessing viability were highly variable for both CMR and the comparator,
making it difficult to compare studies.
Formulation of consensus statements
Thirty-seven draft statements were generated by the three cardiologists and one methodologist (see
Appendix 7, Table 31). Examples of draft statements, categorised by patient subgroup, are shown in
Appendix 7, Table 32. Statements relating to the same patient subgroup/condition (e.g. patients at risk of
complications after PPCI who develop LV thrombus) were condensed into one statement. This reduced
the number of statements from 37 to 16. All statements were then reworded to standardise their format.
Examples of reworded statements are shown in Appendix 7, Table 32. The 16 statements were discussed
in turn at the internal group meeting and the following changes were made:
l The total number of statements was reduced from 16 to 12. Two statements relating to device
implantation were condensed into one, three statements were removed because it was felt that their
content was covered adequately by other statements and one statement was removed because it was
felt that it did not relate to a change in patient management.
l A supporting paragraph was drafted to put the statement into context, summarise the research
evidence and include any key references. These references were chosen to reflect the best available
evidence; although, for several statements, the cited studies were small prognostic studies or case
series (i.e. the only available evidence).
l The statements were reworded to clarify the care pathway compared with which the additional benefit
of CMR was anticipated (e.g. alternative imaging modalities such as ECHO or SPECT).
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The final 12 statements are shown in Table 22 and examples of supporting paragraphs are shown in
Appendix 7, Table 33. These 12 statements describe changes in management relating to six
patient subgroups:
1. Patients with a poor prognosis or at risk of complications after PPCI [e.g. those who develop LV
thrombus, those with low EF who require an implantable cardioverter defibrillator (ICD), those at risk of
impending cardiac rupture] whose treatment could potentially be optimised (statements 1, 4, 6, 7 and 9).
2. Patients with a good prognosis after PPCI who could be discharged earlier and followed up less often
(statement 2).
3. Patients with multivessel disease, in whom revascularisation for the additional diseased arteries could be
optimised (statements 8 and 10).
4. Patients with unobstructed arteries on angiography [who may have had a heart attack that resolved
spontaneously (e.g. MI with spontaneous recanalisation/embolic MI) or another condition, such as
myocarditis or cardiomyopathy] for whom treatment planning could be optimised based on a definitive
diagnosis (statement 5).
5. Patients with an out-of-hospital-cardiac arrest (OHCA) in whom the cause could be definitively
identified, leading to appropriate treatment (statement 3).
6. Patients with incidental cardiac (e.g. mitral regurgitation, pericardial effusion, valve disease, papillary
rupture, congenital cardiac anomalies) and extra-cardiac findings (e.g. pleural effusion, lung mass,
mediastinal lymph adenopathy), in whom appropriate treatment could be started (statements 11 and 12).
TABLE 22 Final statements following the expert group meeting
Statement
number Statement Patient subgroup
1 Compared with ECHO, CMR after PPCI allows patients with
CMR markers that indicate a poor prognosis (e.g. impaired LV
function, large infarct size, MVO) to be followed up more
appropriately and undergo more aggressive medical therapy for
secondary prevention
Poor prognosis/risk of complications
after PPCI
2 Compared with ECHO, CMR after PPCI allows patients with
CMR markers that indicate a good prognosis (e.g. normal LV
function, high myocardial salvage, no MVO, no residual
ischaemia) to be discharged earlier and followed up less
frequently
Good prognosis after PPCI
3 Compared with ECHO, CMR better identifies the cause of
OHCA (e.g. large MI, arrhythmogenic right ventricular
cardiomyopathy, aberrant coronary arteries, hypertrophic
cardiomyopathy) to optimise further treatment for the patient
(e.g. defibrillator for primary arrhythmia or PCI) or family
members
Out-of-hospital cardiac arrest
4 CMR after PPCI identifies patients at high risk of having a
ventricular septal defect or impending cardiac rupture, who may
require a ventricular patch or other urgent cardiac surgery, and
guides the optimal management of these patients
Poor prognosis/risk of complications
after PPCI
5 In patients with a ‘normal’ (unobstructed) coronary angiogram,
CMR can differentiate patients who have had a MI with
spontaneous reperfusion or distal embolisation from patients
with a non-ischaemic diagnosis (e.g. myocarditis, Takotsubo
cardiomyopathy, aortic dissection), resulting in a patient
treatment plan appropriate for the definitive diagnosis
Unobstructed arteries on angiogram
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The expert panel
Nineteen consultant cardiologists were invited to participate in the consensus process. Seven cardiologists
(37%) agreed to participate. Of these, two had CMR, three had interventional, one had ECHO and one
had heart failure expertise. All seven cardiologists completed the first survey independently.
First survey
Figure 14 shows the distribution of responses for the first survey. There was consensus for three of the
12 statements (25%) regarding the change in management being clinically important: statement 3,
relating to the ability of CMR to identify the cause of OHCA and, therefore, optimise treatment for the
patient; statement 5, relating to the ability of CMR to provide a definitive diagnosis in patients found to
have unobstructed arteries on angiography; and statement 9, relating to the ability of CMR to identify
patients with LV thrombus and initiate treatment with anticoagulation therapy. There was no consensus
for any statement that the change in management was not clinically important.
Examples of respondents’ comments to the first survey regarding individual statements are shown in
Appendix 7, Table 34. Consensus was sought on the importance of the change in management and most
respondents commented on this issue. However, some respondents also considered other factors when
rating statements, for example the quality of the supporting evidence, the proportion of patients likely to
benefit, the ability of the NHS to provide a service in line with the statement and whether or not the cost
of CMR justified the perceived benefit.4
TABLE 22 Final statements following the expert group meeting (continued )
Statement
number Statement Patient subgroup
6 Compared with ECHO, CMR after PPCI better identifies patients
at high risk of sudden cardiac death who would benefit most
from an implantable cardiac device (e.g. ICD or CRT)
Poor prognosis/risk of complications
after PPCI
7 Compared with ECHO, CMR after PPCI better identifies patients
who would not benefit from cardiac resynchronisation therapy
Poor prognosis/risk of complications
after PPCI
8 Compared with stress ECHO or SPECT, CMR after PPCI in
patients with multivessel disease better assesses ischaemia and
viability of the myocardium to optimise the revascularisation
strategy for the patient and avoid additional diagnostic tests
Multivessel disease
9 Compared with ECHO, CMR after PPCI better identifies patients
with LV thrombus for treatment with anticoagulation therapy
Poor prognosis/risk of complications
after PPCI
10 Compared with other imaging modalities, in patients with
multivessel disease, CMR after PPCI better identifies the artery
that caused the MI and guides the subsequent treatment plan in
relation to additional revascularisation (e.g. PCI or coronary
artery bypass graft surgery)
Multivessel disease
11 Compared with ECHO, CMR after PPCI better identifies
incidental cardiac findings that may need further investigation
and treatment
Incidental cardiac findings
12 Compared with ECHO, CMR after PPCI identifies significant
incidental non-cardiac findings (e.g. oesophageal and lung
tumours, pulmonary embolus, aortic aneurysm) that may need
further investigation and treatment
Incidental non-cardiac findings
CRT, cardiac resynchronisation therapy.
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Face-to-face meeting
The face-to-face meeting was attended by six of the seven cardiologists and three non-clinical members of
the initial working group. As a result of the face-to-face meeting, the survey was modified as follows:
l The number of statements was reduced from 12 to 10. Statement 10 (relating to patients with
multivessel disease) was removed because cardiologists felt that this statement overlapped significantly
with statement 8. Statements 11 and 12 (relating to incidental cardiac and non-cardiac findings) were
combined into one statement.
l Respondents were asked to rate five aspects of each statement, organised hierarchically – (1) whether
or not CMR is better than the comparator (e.g. ECHO), (2) whether or not the information from CMR leads
to a change in management, (3) whether or not the change in management is clinically important (i.e.
likely to reduce risk of MACEs in the long term), (4) whether or not the change in management is likely to
reduce NHS costs in the long term and (5) whether or not the anticipated benefit was sufficiently large to
make CMR cost-effective among the patients in whom it would be indicated. Consensus was based on the
distribution of responses to questions 1–3 of each statement (i.e. median ≥ 7 and IQR 6–9 for clinically
important changes in management, and median ≤ 3 and IQR 1–3 for questions 1, 2 and 3). Responses to
questions 1–3 were used because question 1 was constructed to interrogate the respondent’s appraisal of
the evidence, question 2 was constructed to determine whether or not the respondent believed the NHS
service delivery changed as a result of CMR and question 3 was constructed to determine whether or
not the respondent believed that any change recognised in the response to question 2 was clinically
important. Discussions in the meeting revealed that consideration of costs and cost-effectiveness for the
NHS influenced some panel members’ responses to the initial survey. Questions 4 and 5 were added to
isolate these aspects of consideration and separate them from the question of change in management,
which was the aim of the consensus process.
l The free-text box in which respondents could justify their score was removed.
The modified survey is shown in Table 23.
Strongly disagree 1
2
Moderately disagree 3
4
Neither agree nor disagree 5
6
Moderately agree 7
8
Strongly agree 9
1 2 3 4 5 6 7 8 9 10 11 12
Statement
FIGURE 14 Median and IQR for the 12 statements in the first survey (n= 7). Boxes represent the median and IQR and the
whiskers represent the upper and lower adjacent values (upper quartile + 1.5*IQR, and lower quartile – 1.5*IQR).67 Dots
represent extreme values. Statements 3, 5 and 9 were considered to be in consensus (median score ≥ 7 and IQR 6–9).
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TABLE 23 Consensus statements (modified survey)
Statement
number Statement
1 The following statements relate to the ability of CMR to identify patients who have a poor prognosis after PPCI:
l CMR markers (e.g. impaired LV function, large infarct size, MVO) better identify patients with a poor
prognosis after PPCI than markers based on ECHO
l Better identification of patients with a poor prognosis after PPCI allows these patients to be followed up
more appropriately and treated more aggressively
l More appropriate follow-up and more aggressive treatment in these patients is expected to lead to a
reduced risk of MACEs in the long term
2 The following statements relate to the ability of CMR to identify patients who have a good prognosis after PPCI:
l CMR markers (e.g. normal LV function, high myocardial salvage, no MVO, no residual ischaemia) better
identify patients with a good prognosis after PPCI than markers based on ECHO
l Better identification of patients with a good prognosis after PPCI allows these patients to be followed up
less frequently
l Less frequent follow-up in these patients is expected to lead to less NHS resource use in the long term
3 The following statements relate to the ability of CMR to identify the causes of OHCA in patients who
undergo an emergency angiogram:
l CMR better identifies the cause of OHCA (e.g. large MI, ARVC, aberrant coronary arteries, HCM)
than ECHO
l Better identification of the cause of OHCA allows treatment to be optimised for these patients
(e.g. defibrillator for primary arrhythmia or PCI) or their family members (e.g. genetic screening and
counselling, primary prevention)
l The ability to optimise treatment for these patients or family members is expected to lead to a reduced
risk of MACEs in the long term
4 The following statements relate to the ability of CMR to identify patients with VSD after MI:
l CMR identifies the location and characteristics of post-infarct VSD better than ECHO
l Better identification of the location and characteristics of post-infarct VSD guides the optimal
management of these patients
l Optimal management of patients with post-infarct VSD is expected to lead to a reduced risk of MACEs
in the long term
5 The following statements relate to the ability of CMR to differentiate MI from other diagnoses in patients
found to have unobstructed coronary arteries on emergency angiography:
l Unlike ECHO, CMR can provide a definitive ischaemic diagnosis (e.g. MI with spontaneous reperfusion
or distal embolisation) or a non-ischaemic diagnosis (e.g. myocarditis, Takotsubo cardiomyopathy, aortic
dissection) in patients with unobstructed coronary arteries on angiography
l A definitive diagnosis results in a patient treatment plan appropriate for that diagnosis
l A treatment plan appropriate for the diagnosis is expected to lead to a reduced risk of MACEs in the
long term
6 The following statements relate to the ability of CMR to identify patients at high risk of sudden cardiac
death after PPCI who would benefit most from an ICD:
l CMR identifies PPCI patients who are at high risk of sudden cardiac death better than ECHO
l Better identification of PPCI patients at high risk of sudden cardiac death allows optimal patient
selection for an implantable cardiac device (ICD or CRT)
l Optimal patient selection for an ICD is expected to lead to a reduced risk of MACEs in these patients in
the long term
7 The following statements relate to the ability of CMR to identify patients who would not benefit from CRT
after PPCI:
l CMR identifies patients who would not benefit from CRT better than echocardiography
l The ability to identify patients who would not benefit from CRT would reduce CRT use in patients who
do not need it
l Reducing CRT use in patients who do not need it is expected to lead to reduced risk of MACEs in these
patients in the long term
continued
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Modified survey
Fifty-four cardiologists (including five of the cardiologists who attended the formal consensus meeting)
completed the survey. There was consensus that five of the 10 statements (50%) described clinically
important changes in management (Figure 15). These were statements 3, 5 and 9 (which were in consensus
in the first survey) and two additional statements: statement 1, relating to the ability of CMR to identify
patients who have a poor prognosis after PPCI, and statement 8, relating to the ability of CMR to assess
ischaemia and viability in patients with multivessel disease. There was no consensus that any of the other
statements described a change in management that was not clinically important.4 The final statements from
the modified survey are in Appendix 8.
Implementation of a primary outcome based on the changes in
management for which consensus was achieved
Parts of this text have been reproduced with permission from Pufulete et al.68 This article is distributed under
the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
TABLE 23 Consensus statements (modified survey) (continued )
Statement
number Statement
8 The following statements relate to the ability of CMR to assess ischaemia and viability in patients with
multivessel disease:
l CMR assesses ischaemia and viability of the myocardium better than ECHO
l Better assessment of ischaemia and viability of the myocardium optimises the revascularisation strategy
for patients with multivessel disease and avoids additional diagnostic tests
l The ability to optimise the revascularisation strategy for patients with multivessel disease is expected to
lead to a reduced risk of MACEs in the long term
9 The following statements relate to the ability of CMR to identify patients with post-infarct LV thrombus:
l CMR identifies post-infarct LV thrombus better than ECHO
l Better detection of post-infarct LV thrombus in PPCI patients allows more affected patients to be treated
with anticoagulation therapy
l Treatment with anticoagulation therapy in patients with post-infarct LV thrombus is expected to lead to
a reduced risk of MACEs in the long term
10 The following statements relate to the ability of CMR to detect incidental cardiac and non-cardiac findings if
offered routinely to patients who undergo an emergency angiogram:
l CMR identifies more incidental cardiac/non-cardiac findings than ECHO
l Improved detection of potentially significant incidental findings allows affected patients to be
investigated further and/or treated
l Further investigation and treatment is expected to reduce the risk of MACE/increase overall survival in
affected patients in the long term
ARVC, arrhythmogenic right ventricular cardiomyopathy; CRT, cardiac resynchronisation therapy; HCM, hypertrophic
cardiomyopathy; VSD, ventricular septal defect.
Reproduced from Pufulete et al.4 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Patient subgroups
We identified five patient subgroups (Table 24) for which there was consensus that CMR changed
management in a clinically important way, either from HISs or from HES/PEDW.
l Patients who underwent PPCI could be identified both from HISs and from HES/PEDW.
l Patients with unobstructed arteries could not be directly identified from either HIS or HES, but they
were indirectly identified from HIS (consented into study and underwent angiography but had no data
in BCIS) and from HES/PEDW (had a record for angiography but no record for PCI).
l Patients with multivessel disease could only be identified reliably from HISs; the presence of disease
in multiple vessels is not coded by ICD-10 but might be inferred from multiple procedure codes in
HES/PEDW for coronary revascularisation (PCI or CABG).
l Patients who experienced OHCA, and PPCI patients who went on to develop LV thrombus, could be
identified only from HES/PEDW.
The proportions of patients in each subgroup (across all hospitals and by hospital) are shown in Table 25.
Across all hospitals, 89% of patients underwent PPCI, 11% were found to have unobstructed coronary
arteries and 44% of patients had multivessel disease. The proportions of patients in each subgroup were
similar between hospitals, except for patients with multivessel disease (19% in hospital D vs. 48%, 51%
and 53% in hospitals A, B and C, respectively).
Strongly disagree 1
2
Moderately disagree 3
4
Neither agree nor disagree 5
6
Moderately agree 7
8
Strongly agree 9
1 2 3 4 5 6 7 8 9 10
Statement
FIGURE 15 Median and IQR for the 10 statements in the modified survey (n= 54). Boxes represent the median and
IQR and the whiskers represent the upper and lower adjacent values (upper quartile + 1.5*IQR, and lower quartile
– 1.5*IQR).67 Dots represent extreme values.
Reproduced from Pufulete et al.4 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon
this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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Manual review of patient notes
We conducted a manual review of patient notes because of the uncertainty regarding the identification of
the unobstructed coronary arteries subgroup from HISs. Only 38 out of 47 (81%) patients were identified
as having unobstructed coronary arteries in the manual review of patient notes (see Appendix 9). Of the
remaining nine patients, six had a culprit lesion identified (therefore, the likely reason for their emergency
angiography was expected to be MI), and the reason for the coronary angiography in the other three
patients was unknown.
We compared the diagnoses from the patient notes with the primary diagnoses recorded in HES for the
index admission (see Appendix 9). Four of the 38 patients identified as having unobstructed coronary
arteries in their medical notes had ‘myocardial infraction’ as a primary diagnosis in HES. Of the six patients
who had a culprit lesion identified in their medical notes, only two had ‘myocardial infraction’ recorded
as their primary diagnosis in HES; two had a diagnosis of ‘chronic ischaemic heart disease’, one had a
diagnosis of ‘pain in throat and chest’ and one had a diagnosis of ‘atrial fibrillation and flutter’.
Identifying changes in management in hospital episode data
The important changes in management identified from the statements in consensus, the patient subgroups
these changes in management refer to, the HES/PEDW data sources used to identify them and the events
identified from hospital episode data sources in the 12 months of follow-up after the index admission
are shown in Appendix 10. Medication data are not available in hospital episode data; therefore, any changes
in medication during follow-up could not be identified. This was particularly relevant for the LV thrombus
TABLE 25 Frequency of patient subgroups by hospital
Patient subgroup
Hospital, n (%)
Total (N= 1655), n (%)A (N= 758) B (N= 272) C (N= 316) D (N= 309)
PPCI 651 (86) 246 (90) 291 (92) 279 (90) 1467 (89)
Multivessel disease 361 (48) 138 (51) 169 (53) 58 (19) 726 (44)
LV thrombus after PPCI 1 (0.1) 0 (0) 0 (0) 0 (0) 1 (0.1)
Unobstructed coronary arteries 107 (14) 26 (10) 25 (8) 30 (10) 188 (11)
OHCA 57 (8) 22 (8) 16 (5) 14 (5) 109 (7)
Note
Percentages do not add up to 100 because some patients were in more than one subgroup.
Reproduced with permission from Pufulete et al.68 This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
TABLE 24 Data sources and definitions used for identifying subgroups of patients
Subgroup Data source Definition
PPCI BCIS BCIS data recorded at site
Multivessel disease BCIS Two or more vessels with > 50% stenosis (pre PCI)
Unobstructed coronary arteries BCIS BCIS data not recorded
OHCA HES/PEDW Index admission includes HES/PEDW diagnosis I46 ‘Cardiac arrest’
LV thrombus HES/PEDW Index admission includes HES/PEDW diagnosis I23.6 ‘Thrombosis
of atrium, auricular appendage and ventricle as current complications
following acute myocardial infarction’
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after PPCI subgroup, for which the start of anticoagulation therapy was identified as the important change
in management. All relevant non-ischaemic diagnoses were identifiable in hospital episode admissions data,
as were procedures, such as implantation of devices, repeat revascularisation and additional diagnostic tests.
In contrast, we could not identify these from the outpatient data set because ICD-10 and OPCS codes
associated with each outpatient episode were missing for a large proportion of patients (25% of patients had
missing diagnoses codes, 74% of patients had missing procedure codes and 74% of patients had ‘unknown
and unspecified causes of morbidity’ as diagnosis). This will lead to an underestimation of diagnostic tests in
the cohort, because most diagnostic tests are carried out on an outpatient basis. However, we could identify
the frequency of outpatient appointments under the cardiology specialty.
Implementation of the consensus statements
The number of events representing changes in management in the relevant patient subgroups, identified in
HES/PEDW up to 12 months after the index admission by CMR status are shown in Table 26. The frequency
of events in patients who did and in those who did not have CMR was similar across all subgroups. Patients
who had CMR had, on average, more outpatient appointments across all subgroups.
Table 27 shows the time to first event for each change in management and for all subgroups, by CMR
status. Except for patients with unobstructed coronary arteries, patients in other subgroups who did
not have CMR had an admission for an additional diagnostic test earlier than patients who had CMR.
In the subgroup of patients with unobstructed coronary arteries, patients who did not have CMR had an
admission related to a new non-ischaemic diagnosis earlier, and an admission for an additional diagnostic
test and implantation of a device later than patients who did get CMR. In the PPCI/multivessel disease
subgroups, time to first cardiology outpatient appointment was earlier for patients who did not have CMR
than for patients who had CMR.
The frequency of events in CMR versus non-CMR hospitals is shown in Table 28. On average, patients in
CMR centres had more outpatient appointments than patients in non-CMR centres. New diagnoses,
additional diagnostic tests, implantation of devices and additional revascularisation in patients with
multivessel disease were more frequent in CMR hospitals than in non-CMR hospitals. Time to the first
event in CMR versus non-CMR centres for all events and by patient subgroup are shown in Table 29.
In CMR centres, patients in most subgroups had an admission for an additional diagnostic test and
implantation of a device later than patients in non-CMR centres. Time to first cardiology outpatient
appointment was earlier for patients in CMR centres across all subgroups.
Cardiovascular magnetic resonance imaging questionnaire
The changes in management identified by the CMR questionnaire and from HES/PEDW data are shown in
Table 30. Changes in management identified by the CMR questionnaire could also be identified in hospital
episode data, although there were clearly some gaps in the data we had available to us, namely: (1) poor
coding of outpatient hospital episode data (diagnoses), (2) failure to obtain medication data and (3) poor
coding of diagnostic tests and investigations (both acute care and outpatient data sets).
Summary of main findings
We identified five subgroups of ACS patients who activate the PPCI pathway and for whom there was
consensus that CMR changes patient management in a clinically important way: (1) patients who have an
OHCA (≈7% of those who activate the PPCI pathway),69 (2) patients who have a ‘normal’ (unobstructed)
coronary angiogram (≈10% of those who activate the PPCI pathway),15,16 (3) patients who develop
LV thrombus (3% overall and 9% in patients with anterior STEMI),70 (4) patients who have multivessel
disease (between 40% and 65% of those who undergo PPCI)7,10,71 and (5) patients in whom CMR
markers indicate a poor prognosis (up to 60% of patients after STEMI).2,72 There was consensus about
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
TABLE 26 Events representing changes in management identified in HES/PEDW inpatient and outpatient data up to 12 months after the index admission, by CMR status
Patient subgroup
n (%)
Cardiology
outpatient
appointments,
median (IQR)
New diagnoses
(non-ischaemic, Takotsubo,
myocarditis, pericarditis,
endocarditis, coronary spasm)
Changes in
medication
Additional diagnostic
tests (PET, ECHO, IVUS,
pressure wire, radionuclide
angiocardiography, CT,
angiography)
Implantation of
devices (CRT or ICD)
Revascularisation
(PCI or CABG)
within 3 months
PPCI
CMR (N = 152) 0 (0) No data available 16 (11) 0 (0) N/A 2 (1–3)
No CMR (N = 1312) 10 (1) No data available 129 (10) 6 (0.5) N/A 1 (1–2)
Multivessel disease
CMR (N = 104) 0 (0) No data available 11 (11) 0 (0) 11 (11) 2 (1–3)
No CMR (N = 622) 4 (1) No data available 61 (10) 4 (1) 64 (10) 1 (1–2)
LV thrombus after PPCI
CMR (N = 1) 0 (0) No data available 0 (0) 0 (0) N/A 3 (3–3)
No CMR (N = 0) 0 (0) No data available 0 (0) 0 (0) N/A –
Unobstructed coronary arteries
CMR (N = 35) 1 (3) No data available 6 (17) 1 (3) N/A 2 (1–3)
No CMR (N = 139) 1 (1) No data available 12 (9) 3 (2) N/A 1 (0–2)
OHCA
CMR (N = 14) 0 (0) No data available 2 (14) 0 (0) N/A 1 (1–3)
No CMR (N = 95) 1 (1) No data available 10 (11) 5 (5) N/A 1 (1–2)
CRT, cardiac resynchronisation therapy; N/A, not available.
Reproduced with permission from Pufulete et al.68 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to
the data made available in this article, unless otherwise stated.
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TABLE 27 Time to first event representing a change in management in HES/PEDW up to 12 months after the index admission, by CMR status
Patient subgroup
Number of days until event after the index admission, median (IQR)
New diagnoses
(non-ischaemic, Takotsubo,
myocarditis, pericarditis,
endocarditis, coronary spasm)
Changes in
medication
Additional diagnostic
tests (PET, ECHO, IVUS,
pressure wire, radionuclide
angiocardiography, CT,
angiography)
Implantation of devices
(CRT or ICD)
Revascularisation
(PCI or CABG)
within 3 months
Cardiology
outpatient
appointments
PPCI
CMR (N = 152) – No data available 107 (50–240) – N/A 64 (34–99)
No CMR (N = 1312) 16 (8–20) No data available 74 (27–171) 147 (48–171) N/A 55 (33–95)
Multivessel disease
CMR (N = 104) – No data available 85 (50–221) – 99 (50–180) 76 (52–116)
No CMR (N = 622) 13 (8–110) No data available 62 (24–130) 147 (84–169) 66 (39–122) 57 (33–95)
LV thrombus after PPCI
CMR (N = 1) – No data available – – N/A 66 (66–66)
No CMR (N = 0) – No data available – – N/A –
Unobstructed coronary arteries
CMR (N = 35) 358 (358–358) No data available 93 (58–140) 78 (78–78) N/A 67 (52–121)
No CMR (N = 139) 180 (180–180) No data available 123 (78–284) 245 (71–262) N/A 67 (44–106)
OHCA
CMR (N = 14) – No data available 110 (79–141) – N/A 65 (61–104)
No CMR (N = 95) 48 (48–48) No data available 62 (48–93) 126 (71–167) N/A 64 (41–99)
CRT, cardiac resynchronisation therapy; N/A, not available.
Reproduced with permission from Pufulete et al.68 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to
the data made available in this article, unless otherwise stated.
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TABLE 28 Events representing changes in management identified in HES/PEDW inpatient and outpatient data up to 12 months after the index admission in CMR vs. non-CMR
centres (hospitals A and B vs. hospitals C and D, respectively)
Patient subgroup
n (%)
Cardiology
outpatient
appointments,
median (IQR)
New diagnoses
(non-ischaemic, Takotsubo,
myocarditis, pericarditis,
endocarditis, coronary spasm)
Changes in
medication
Additional diagnostic
tests (PET, ECHO, IVUS,
pressure wire, radionuclide
angiocardiography, CT,
angiography)
Implantation of devices
(CRT or ICD)
Revascularisation
(PCI or CABG)
within 3 months
PPCI
CMR centres (N = 897) 6 (1) No data available 112 (12) 5 (1) N/A 2 (1–3)
Non-CMR centres (N = 567) 4 (1) No data available 33 (6) 1 (0.2) N/A 1 (0–1)
Multivessel disease
CMR centres (N = 499) 4 (1) No data available 61 (12) 4 (1) 53 (11) 2 (1–3)
Non-CMR centres (N = 227) 0 No data available 11 (5) 0 22 (10) 1 (0–1)
LV thrombus after PPCI
CMR centres (N = 1) 0 No data available 0 0 N/A 3 (3–3)
Non-CMR centres (N = 0) – No data available – – N/A –
Unobstructed coronary arteries
CMR centres (N = 133) 2 (2) No data available 16 (12) 4 (3) N/A 1 (0–2)
Non-CMR centres (N = 41) 0 No data available 2 (5) 0 N/A 0 (0–1)
OHCA
CMR centres (N = 79) 0 No data available 9 (11) 4 (5) N/A 2 (1–3)
Non-CMR centres (N = 30) 1 (3) No data available 3 (10) 1 (3) N/A 1 (0–1)
CRT, cardiac resynchronisation therapy; N/A, not available.
Reproduced with permission from Pufulete et al.68 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to
the data made available in this article, unless otherwise stated.
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TABLE 29 Time to first event representing a change in management in HES/PEDW up to 12 months after the index admission in CMR vs. non-CMR centres (hospitals A and B
vs. hospitals C and D, respectively)
Patient subgroup
Number of days until event after the index admission, median (IQR)
New diagnoses
(non-ischaemic, Takotsubo,
myocarditis, pericarditis,
endocarditis, coronary spasm)
Changes in
medication
Additional diagnostic
tests (PET, ECHO, IVUS,
pressure wire, radionuclide
angiocardiography, CT,
angiography)
Implantation of devices
(CRT or ICD)
Revascularisation
(PCI or CABG)
within 3 months
Cardiology
outpatient
appointments
PPCI
CMR centres (N = 897) 14 (8–17) No data available 79 (33–205) 167 (126–171) N/A 46 (30–81)
Non-CMR centres (N = 567) 20 (14–34) No data available 45 (24–116) 48 (48–48) N/A 90 (57–126)
Multivessel disease
CMR centres (N = 499) 13 (8–110) No data available 69 (32–159) 147 (84–169) 71 (41–151) 52 (32–87)
Non-CMR centres (N = 227) – No data available 59 (15–122) – 63 (43–88) 95 (68–136)
LV thrombus after PPCI
CMR centres (N = 1) – No data available 0 0 N/A 66 (66–66)
Non-CMR centres (N = 0) – No data available – – N/A –
Unobstructed coronary arteries
CMR centres (N = 133) 269 (180–358) No data available 103 (68–205) 162 (75–254) N/A 65 (46–103)
Non-CMR centres (N = 41) – No data available 184 (69–299) – N/A 89 (54–133)
OHCA
CMR centres (N = 79) – No data available 79 (62–141) 147 (99–169) N/A 63 (42–95)
Non-CMR centres (N = 30) 48 (48–48) No data available 48 (5–74) 48 (48–48) N/A 86 (52–105)
CRT, cardiac resynchronisation therapy; N/A, not available.
Reproduced with permission from Pufulete et al.68 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to
the data made available in this article, unless otherwise stated.
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TABLE 30 Changes in management in patients who received CMR, identified using the CMR questionnaire
administered to cardiologists or HES/PEDW data
Change in management
n/N (%)
CMR questionnaire (n= 187) HIS or HES (n= 185)
Risk stratification after PPCI
Patients with markers of a
good prognosis
102/160 (64) Not possible to identify
Patients with markers of a
poor prognosis
58/162 (36)
Change in management? 55/123 (45) Yes, potentially identifiable in HES by
considering the frequency and timing
of events representing changes in
management
Patients with multivessel
disease
121/165 (73) 104/185 (56)
Change in management
(additional diagnostic
tests)?
18/111 (16) 11/104 (11)
Difficult to identify all diagnostic tests
because procedure codes were not well
recorded in HES/PEDW outpatient data
Change in management
(did CMR optimise
revascularisation)?
95/120 (79) Yes, potentially identifiable in HES by
considering timing of revascularisation and
frequency of additional diagnostic tests
Patients with LV thrombus 9/187 (5) 2/185 (1)
Change in management
(anticoagulation therapy)?
5/9 (60) Not possible to identify in HES as
medications not available
Potentially possible to identify in HIS if
medications on discharge data are
provided
Patients with unobstructed
arteries
19/183 (10) 35/185 (19)
New diagnosis? 13/16 (81) 1/35 (3)
What were the diagnoses? l Myocarditis (n = 4)
l Takotsubo cardiomyopathy (n = 5)
l Heart attack with spontaneous LCX/
DS reperfusion and myocarditis (n = 1)
l Spontaneous LAD reperfusion (n = 1)
l Borderline low normal EF, possibly
consistent with early DCM (n = 1)
l Prior infarcts (n = 1)
l Acute MI (n = 88)
l Acute MI AND cardiac arrest (n = 1)
l Acute MI AND cardiomyopathy (n = 1)
l Acute MI AND chronic ischaemic heart
disease (n = 2)
l Acute MI AND other diseases of the
digestive system (n = 1)
l Acute MI AND pain in throat and
chest (n = 1)
l Angina pectoris (n = 1)
l Chronic ischaemic heart
disease (n = 4)
l Chronic ischaemic heart disease AND
acute MI (n = 2)
l Heart failure AND chronic ischaemic
heart disease AND acute MI (n = 1)
l Other acute ischaemic heart diseases
(n = 1)
l Other diseases of pericardium AND
acute MI (n = 1)
Change in management? 15/19 (79) Yes, potentially identifiable
RESULTS FOR AIM C
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the first three subgroups in both rounds of the survey, and consensus was reached about the remaining
two subgroups in the modified survey. These results suggest that CMR benefits a large proportion of
patients who activate the PPCI pathway.4 The population investigated was generally representative of the
population of patients who activate the PPCI pathway; 11% of patients did not undergo PPCI and were
categorised as having unobstructed coronary arteries, 44% of patients had multivessel disease and 7%
of patients had an OHCA. Fewer patients than reported in the literature were identified as having LV
thrombus (0.3% in our data vs. 3% reported in PPCI populations).
Two subgroups, patients with OHCA and patients who developed LV thrombus after PPCI, could not be
identified from HIS data submitted by hospitals but could be identified in the HES/PEDW admissions data
relating to the index admission. We defined patients as having unobstructed coronary arteries if they had no
BCIS data, because we did not have other information in our HIS data sets for positive identification of this
subgroup. We conducted a manual review of these patients’ medical notes because we were uncertain
whether or not all patients identified as such truly had unobstructed coronary arteries. The majority of
patients (81%) were defined as having unobstructed arteries from their medical notes, although 13% did
have a culprit lesion identified, suggesting that the most likely reason that these patients activated the PPCI
pathway was MI. We also compared the diagnosis from medical notes with the primary diagnosis in HES
for all patients in the unobstructed coronary artery subgroup. Again, there were discrepancies, with some
patients who were identified as having unobstructed coronary arteries in their medical notes having a
primary diagnosis of MI. We conclude that some patients were incorrectly classified as having unobstructed
coronary arteries from HIS, and that classification of this patient subgroup is likely to vary depending on the
data source used (medical notes, HIS or hospital episode data).
Some important changes in management identified through the formal consensus (e.g. additional
revascularisation in the multivessel disease group, implantation of devices) were readily identifiable in HES/
PEDW admission data sets. Some changes in management (e.g. changes in medication) were unavailable
because medications data are not available in HES/PEDW. Other changes in management (e.g. additional
diagnostic tests) were likely to be underestimated because a large proportion of diagnostic tests are
performed on an outpatient basis but procedure codes are not well recorded in outpatient data sets.
When implementing the consensus statements, we considered both the frequency of the events
representing the important changes in management and time to the first event. This is because, for some
changes in management (e.g. additional revascularisation for multivessel disease patients or a new
diagnosis in patients with unobstructed coronary arteries), it is the timing to the event that represents the
main change in management resulting from CMR. Although there were differences by CMR status in both
the frequency and timing of events for all patient subgroups, we chose not to interpret these because of
the small numbers involved and because our main objective was to test the feasibility of implementing the
consensus statements using hospital episode data.
TABLE 30 Changes in management in patients who received CMR, identified using the CMR questionnaire
administered to cardiologists or HES/PEDW data (continued )
Change in management
n/N (%)
CMR questionnaire (n= 187) HIS or HES (n= 185)
Patients with OHCA 24/180 (13) 14/185 (8)
Cause identified by CMR? 19/24 (79) 0/14 (new diagnosis recorded)
Change in management? 11/24 (46) Yes, potentially identifiable
DCM, dilated cardiomyopathy; LAD, left anterior descending artery; LCX/DS, left circumflex artery/diameter stenosis.
Notes
HES/PEDW data were unavailable for two patients with CMR within 10 weeks of the index admission.
Denominators for the CMR questionnaire indicate the number of responses for each question, excluding missing responses.
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The CMR questionnaire highlighted several gaps in hospital episode data (i.e. lack of medications data
and poor coding of diagnostic tests and investigations). Without the former data, it would be difficult to
characterise patients at baseline (index admission), which is important for identifying and controlling for,
confounding, and without the latter data we would be unlikely to have reasonable sensitivity for important
changes in management during follow-up in a registry.
RESULTS FOR AIM C
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Chapter 7 Discussion
Main findings: study results
Parts of this text have been reproduced from Brierley et al.27 © Article author(s) (or their employer(s) unless
otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless
otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/.
Feasibility of setting up a registry using hospital information system data
The outcome measures of the feasibility prospective cohort study were feasibility parameters to establish if
(1) consent can be implemented at all four hospitals, (2) data linkage and extraction from multiple HISs can
be achieved for > 90% of consented patients at all hospitals, (3) local data can be successfully linked with
hospital episode data for > 90% of consented patients at all hospitals and (4) the proportion of patients
activating the PPCI pathway who get a CMR scan is ≥ 10% in hospitals with dedicated CMR facilities.
The results suggest that the registry is feasible with respect to points 1, 3 and 4, albeit with some caveats,
but not point 2. We found that recruitment and consenting of the patient population (using conventional
consent), and linkage of local HIS data with hospital episode/vital status data are feasible. However, we
experienced problems with identifying and approaching all eligible patients across all sites and we could
not obtain all of the requested data from all hospitals. We had envisaged that it would be relatively
straightforward to identify patients meeting the eligibility criteria (i.e. patients who activated the PPCI
pathway, including those who had an emergency angiogram but did not receive PCI) consecutively, given
the emergency nature of PPCI pathway activation. Indeed, we chose this population for a national CMR
registry using routinely collected data because, at the outset, we expected that this population would be
easy to identify from hospital databases. Although patients who received PPCI were easy to identify from
catheter laboratory databases, not all eligible patients were identified in this way and many were identified
manually by the research nurses.
The numbers of PPCI patients identified as eligible and approached at each hospital were lower than
the numbers of PPCIs reported to BCIS by each hospital over the recruiting period (varying from 22% to
86% across the four hospitals; see Table 10). Some PPCI patients were missed because they were quickly
repatriated to their local referring hospital. Other patients who arrived at the PPCI centre via A&E were not
always classified as PPCI (e.g. patients who experienced out-of-hospital cardiac arrest), resulting in many of
them being missed.
Patients who activated the PPCI pathway but had an emergency angiogram without PPCI (i.e. those with
unobstructed coronary arteries) were difficult to identify from catheter laboratory databases. Contrary to
expectation, there was no data field in any database capturing emergency admission to the catheter laboratory.
These patients were also not described consistently in HIS databases and there was misunderstanding over
eligibility (especially at the beginning of the study) by catheter laboratory staff and research nurses. Therefore,
it is unclear what proportion of these patients was identified at each site during the recruiting period and how
the proportion may have changed over time.
We met the feasibility objective of implementing conventional prospective consent at all hospitals, although
consent rates were lower than anticipated for a study in which participants have no active involvement.
The main reason for this was that many patients identified as eligible were missed (because of short
hospital stay, no nurse cover at weekends, quick repatriation to referring hospitals, mobile inpatient
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population, etc.). There was also the issue of competing studies in the hospitals, including the perception
that interventional studies should be given priority over observational studies. We relied on postal consent to
invite patients identified as eligible and who were not approached in hospital, but return rates were low and
we did not have the resources to send reminders or make telephone calls.
We explored alternative methods of obtaining consent as part of the feasibility study. We considered
applying for approval to recruit patients without consent [‘presumed consent’, section 251 (of the NHS
Act 200676) exemption] but concluded that this proposal would be unacceptable legally, given that, in
principle, it is possible for patients to be asked to give consent for their data to be used for the study.73
Exemptions are granted only on a temporary basis (pending implementation of consent) or when consent
is impossible, not just infeasible. We considered the option of requesting consent at the same time as
requesting procedural consent (e.g. by adding a paragraph to the standard NHS form, either opt-in or
opt-out consent), although the emergency nature of the procedure means that written procedural consent
is not always obtained and verbal assent is often recorded by hand in the patient notes.27 Furthermore,
we were unsuccessful previously when trying to introduce a research consent step into usual care; at the
lead hospital, we could not get permission to alter the standard NHS consent form for one specialty and
it was impossible to coordinate a change in the written procedural consent across all specialties. Although
we were aware of at least one instance when a lead consultant had been able to integrate an opt-out
consent model (to allow the use of routinely collected data for research) in the procedural consent form,
this instance related to a diagnostic rather than an interventional context. The former setting has a more
structured environment with fewer consultants and possibly less time pressure and we considered that an
analogous process would be difficult to replicate in the PPCI environment, in which patients are critically ill
and staff are under constant pressure to free beds for incoming patients.
Most prospective registries in the UK require explicit patient consent (e.g. National Joint Registry,74
Inflammatory Bowel Disease registry75), using stand-alone consent forms either with/without an approved
‘short text’ for obtaining consent that can be added to local consent forms. Participating hospitals are
responsible for obtaining and recording patient consent with their uploads. However, the issue of missing
information on consent is recognised and the National Joint Registry, for example, has dispensation
[section 251 (of the NHS Act 200676) exemption] to record patient details when the indication for patient
consent is ‘not recorded’, although this dispensation is granted on an annual review basis. Other registries,
such as the cardiac audits under the umbrella of the National Institute for Cardiovascular Outcomes
Research (NICOR) [which includes the Myocardial Ischaemia National Audit Project (MINAP) and the BCIS
National Audit of Percutaneous Coronary Intervention (NAPCI)], have exemption under section 251 of
the NHS Act 200676 to use patient information for medical research without consent. We cannot discern
a rationale for the inconsistency in the consent arrangements for existing registries. Therefore, we are
uncertain whether or not a future registry would be granted a section 251 (of the NHS Act 200676)
exemption, as it is manifestly possible to implement prospective consent, as evidenced by some but not all
existing registries.
A possible solution to the challenge of obtaining consent in the usual care setting would be to implement
changes in NHS information technology (IT) administrative systems (ideally at the national level) to allow a
record of verbal patient consent to be recorded in patients’ electronic notes (e.g. a ‘consent module’).
The use of a system embedded within the NHS administrative systems could be applied more broadly
to all registry or similar projects seeking to exploit routinely collected data, so that patients could be easily
identified as having given or not given consent, having withdrawn consent, or not having been asked for
consent. It could also capture whether or not the patient consents to all data being used and if not, which
data are specifically excluded from the consent. However, we are uncertain whether or not verbal patient
consent recorded in this way would comply with NHS Digital’s requirement for ‘explicit’ patient consent
(the legal basis for accessing HES/ONS data).27,77
Although patients and the public are broadly supportive of the use of electronic patient data for research,78–81
there are concerns about potential breaches of privacy and the misuse of health data.82 The public response
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to the care.data public consulation83 highlighted important challenges in terms of patient confidence and
trust in how electronic health records are used in medical research.84 Newer consent models have been
proposed, including a dynamic consent model, which would allow patients to control consent electronically
over time and receive information about the uses of their data and up-to-date lay summaries of research
projects that have used their data.85 However, such a model would require investment in and maintenance
of an electronic infrastructure, which would be difficult in the current economic climate of the NHS. Others
have called for more adaptive governance models depending on the particular circumstances of the
proposed research.86 It was beyond the scope of this study to explore these possibilities for obtaining
consent.27 The difficulties we experienced in identifying consecutive eligible patients and consenting those
who were identified in the emergency setting of activating the PPCI pathway highlight that the conventional
consent model that we successfully implemented would not be feasible for a national registry.
We did not meet the feasibility criterion for data linkage and extraction (the target was that this should be
achieved for > 90% of patients at all four hospitals) from HIS for all the requested data sets. Reasons for
missing data included the following: difficulties in extracting data from local stand-alone databases, some
of which were old and did not have an interface for data extraction; some data (e.g. medications on
discharge, bedside ECHO) were not recorded electronically; imaging data were available electronically but
only as free-text reports, making individual parameters of interest difficult to extract. The main impacts for
a registry of failing to obtain these HISs is the inability to characterise the registry population in detail,
to adjust any comparisons for patients’ characteristics and to describe changes in these data over time
(potential indicators of the consequences of important changes in management).
We had initially envisaged establishing a data linkage and extraction model in one hospital and using this
to guide data extraction at the other hospitals. We also envisaged that this model would be automated,
with minimal IT support beyond the set-up phase. However, this was not possible because HIS for each
data set differed across hospitals and different hospitals provided different levels of start-up IT support for
the research project.27 We budgeted for only a small amount of funding (£5000) to each hospital to help
with this aspect of the study. Data linkage requires expertise in several areas, including knowledge of the
databases to be linked and skills in creating linkage programmes. This expertise was variable across
hospitals and in-depth knowledge was sometimes lacking; this was perhaps not surprising given the
diversity of the databases involved, and the fact that some of these were old and were being phased out.27
We relied on each hospital identifying key individuals to help with this aspect of the study. In addition,
even in hospital A, the highest priority for the IT team was to maintain the integrity and functionality of
the clinical care systems; in this context, it was difficult for them to prioritise our request to support this
research project, even with the funding that was available.
The complexity of data retrieval from multiple HISs in secondary care in the NHS has been highlighted
previously.61 The government’s vision for the NHS, outlined in the National Information Board’s complex
Personalised Health and Care 2020 framework,87 is that it will be an entirely digital organisation by 2020.
Although such a system, if properly implemented, should provide benefits for research as well as patient
care, it is an ambitious goal given the current financial and operational pressures within NHS organisations.
The earlier (and equally ambitious) National Programme for IT, which aimed to create a single electronic
care record for patients, connect primary and secondary care IT systems and provide a single IT platform
for health professionals, was dismantled, mainly because IT companies could not provide solutions to
match the ambition.27,88 Despite such programmes, our experience from this study has highlighted the
poor-quality electronic infrastructure in hospitals and the multitude of clinical databases that are not
amenable to ‘interoperability’ (i.e. not needing extensive customisation or permission from the database
vendor to provide data flow). Full interoperability for HISs across the majority of hospitals, therefore, still
appears to be a distant goal.89
We met the feasibility criterion of having > 10% of our consented population being referred for CMR in
hospitals with a dedicated CMR facility. However, many of these referrals were for research (patient
participating in a research study) rather than clinical purposes. For example, in the lead hospital, 33%
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of all referrals were for research. It is not clear whether or not this reflects practice in other hospitals with
dedicated CMR facilities. Referral for non-clinical reasons (unless the findings are used to change clinical
management) would dilute any observed effect of CMR on outcomes in an extended registry. Another
challenge was that imaging reports were largely in free-text format, so individual CMR parameters would
have to be extracted manually, which would not be feasible for an extended registry. A registry assessing
the prognostic value of CMR, including individual CMR parameters, such as contractile function, myocardial
oedema, MVO, intracardiac thrombus, myocardial haemorrhage and myocardial scar, would allow for an
assessment of the value added of each parameter on patient outcome. Similarly, ECHO reports were also in
free-text format, and bedside ECHO reports were missing entirely from our data sets because these are not
routinely uploaded to electronic databases.
We made the decision to obtain data about follow-up from hospital episode data rather than from the
source data submitted by participating hospitals, which are used to compile the hospital episode data.
Using hospital episode data has two advantages: (1) follow-up episodes of care can be linked to index
admissions, wherever they occur (not just in the participating hospitals) and (2) the organisations compiling
hospital episode data apply established data management processes to improve data quality. We met the
feasibility objective with respect to linkage of index admission data with hospital episode data. Linkage
was achieved for 99% of patients. We failed to achieve linkage for the remainder mainly because of
missing identifiers (NHS numbers) in the data sets submitted by participating hospitals. We had originally
envisaged collecting information from local HISs on outcomes in the 12 months following the index
procedure. However, we would have been unable to capture these data on every patient included in the
study because many patients were discharged to, and followed up in, different hospitals, and it would
have been difficult to liaise with and obtain data from multiple sites.
Is it feasible to set up a national registry from hospital episode data?
We explored the feasibility of setting up the registry retrospectively entirely by using linked, routinely
collected data sets [e.g. hospital episode data, NHS England’s Diagnostic Imaging Dataset (DID) and
national audits, such as the BCIS’ NAPCI90]. Setting up the registry in this way would avoid the need to
obtain patient consent. This would be deemed appropriate on the basis that all of the information made
available would be anonymised.
We were able to identify patients who activate the PPCI pathway in hospital episode data using the
relevant procedure codes. We identified 98% of patients in our cohort who underwent PPCI and 85%
of patients who underwent emergency angiography without PPCI. We could not, however, identify the
CMR exposure in hospital episode data for the majority of study participants who had a CMR scan. This is
because CMR is carried out mainly as an outpatient investigation and the hospital episode outpatient data
sets do not contain details of the exact nature of the outpatient visit (only the specialty), so the reason for
outpatient visits coded under the cardiology specialty was unclear. One option to consider would be the
use of NHS England’s DID to identify CMR exposure. DID is a central collection of detailed information
about diagnostic imaging tests carried out on NHS patients, extracted from local radiology information
systems and submitted monthly to NHS England.91 The main driver for the creation of the DID was to
assess how the use of diagnostic imaging could contribute to the early diagnosis of cancer (in particular,
GP direct access to these tests). As such, DID has already been linked to cancer registry data, but not
other national audits, and there could be substantial difficulties/delays in applying for linkage permissions
with, for example, the BCIS’ NAPCI data set.90 Although DID captures information about referral
source and patient type, details of the test (e.g. type of test and body site), demographic information
(e.g. GP-registered practice, patient postcode, ethnicity, gender and date of birth), plus items about
waiting times for each diagnostic imaging event (it does not store the images themselves, the individual
parameters measured by the test or the outcomes/diagnoses related to the test). DID could not, therefore,
be used to assess the prognostic value of individual components of a CMR scan, or the extent to which a
CMR scan altered patient management. Nevertheless, it should allow ascertainment of CMR exposure.
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Economic evaluation
We developed a series of economic decision models to identify the key drivers of cost-effectiveness.
To our knowledge, this is the first time the key drivers of the cost-effectiveness of introducing CMR have
been considered. We chose two patient subgroups for our models: patients with multivessel disease
and patients with unobstructed coronary arteries. Both of these subgroups were identified as potentially
benefiting from CMR in the formal consensus study.
Our results showed that, for each of the base-case models, the differences in QALYs between strategies
were very small and, therefore, the results were largely driven by the differences in costs, although mean
differences in cost for different strategies were modest. Sensitivity analyses around the two models
identified the diagnostic accuracy of the ischaemia tests as the key driver of cost-effectiveness. In the
model for patients with multivessel disease, the costs of ischaemia testing and the QALYs associated with
MACEs and no MACEs exerted an influence on cost-effectiveness results, but not to the same extent as
the diagnostic accuracy of CMR and pressure wire. Similarly, in the model for patients with unobstructed
coronary arteries, the cost of CMR, the difference between QALYs associated with MACEs and no MACEs,
and the proportion of patients who have MACEs who are assumed to die exerted an influence on the
results; however, the better diagnostic accuracy of CMR and standard ECHO combined (the reference
standard in the base case) compared with standard ECHO only was more important.
The key drivers of cost-effectiveness highlighted by each model are similar, and, therefore, it is likely that if
CMR was introduced for our entire eligible population (patients who activate the PPCI pathway), it would be
these parameters that would need to be measured accurately in any future study. This work highlights the
importance of having accurate information about the diagnostic accuracy of different tests, as estimates
for these parameters are such key determinants of cost-effectiveness. We have identified some of the key
unknowns in terms of costs and outcomes in the population of patients who activate the PPCI pathway,
which can inform future studies to ensure that important variables are captured in sufficient detail.
Identifying important changes in management resulting from cardiovascular magnetic
resonance and the subgroups of patients to which these refer
Parts of this text have been reproduced from Pufulete et al.4 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/.
A key objective of our feasibility study was to define a primary composite outcome, acceptable to
cardiologists and other stakeholders (e.g. clinical commissioners) as representing a clinically important
change in management (e.g. expected to prevent future MACEs) as a result of an eligible patient having
had CMR, that could be used for the registry in the medium term. Although such a primary outcome is
not typical, it would allow evidence to be obtained more quickly to inform decisions about implementing
CMR than would be possible for an evaluation based on MACEs. In the long term, we envisaged that the
primary outcome for the registry would be MACEs, but addressing relevant research questions using the
registry would need data for a large number of patients. For example, in order to have 90% power to
detect a 1.2% difference in MACEs (4.8% vs. 6.0%) between those having CMR and those not, at the
5% level of statistical significance, and assuming 10% of patients who activate the PPCI pathway receive
CMR and 90% do not, the registry would require > 37,000 patients. This represents 20 hospitals, with
an average of 500 patients giving consent per year per site for > 3.5 years. We expected that important
changes in management would be much more frequent than MACEs, allowing the effectiveness of CMR
with respect to this outcome to be evaluated more quickly with data from fewer patients.
We used a formal consensus approach because there were no studies in the literature that reported the
impact of CMR in our study population, reflecting the fact that changes in clinical management are
difficult to use as end points in trials. This is because some important changes in clinical management
are not easily observed92 and the causal relationship between changes in management and improved
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outcomes is not well defined. Imaging has been identified as one of the key drivers of increased health-care
costs; therefore, the adoption of an imaging modality in a new clinical context should be supported by
evidence of its benefit to specific patient groups or clinical scenarios. Such evidence is difficult to obtain
in practice.
We identified five subgroups of ACS patients who activate the PPCI pathway for whom there was
consensus that CMR changes patient management in a clinically important way: (1) patients who have an
OHCA (≈7% of those who activate the PPCI pathway),69 (2) patients who have a ‘normal’ (unobstructed)
coronary angiogram (≈10% of those who activate the PPCI pathway),15,16 (3) patients who develop LV
thrombus (3% overall and 9% in patients with anterior STEMI),70 (4) patients who have multivessel disease
(between 40% and 65% of those who undergo PPCI)7,10,71 and (5) patients in whom CMR markers indicate
a poor prognosis (up to 60% of patients after STEMI).2,72 There was consensus about the first three subgroups
in both rounds of the survey, whereas consensus was reached about the other two subgroups in the modified
survey. These results suggest that CMR benefits a large proportion of patients who activate the PPCI pathway.
Cardiologists who participated in our research agreed that CMR is superior to ECHO in establishing
a diagnosis in patients who survive an OHCA, which has implications for treatment and prognosis.
Despite this view, there are few studies that have reported the role of CMR in managing these patients.
A retrospective case series of 54 OHCA survivors showed that CMR diagnosed the cause (ischaemic or
non-ischaemic cardiomyopathy) in 40 (74%) of the survivors.93
The cardiologists also agreed that CMR can provide a definitive diagnosis (e.g. acute MI, acute myocarditis
and cardiomyopathy, especially Takotsubo cardiomyopathy) in patients with ACS and unobstructed
coronary arteries. Evidence for the role of CMR in patients with ACS and unobstructed coronary arteries
also comes from small retrospective case series. These suggest that CMR provides a definitive diagnosis in
80–90% of these patients.20,23,94 Without access to CMR, the management of these patients is variable in
clinical practice, which may have long-term implications. A 2015 systematic review50 showed that the
overall all-cause mortality in patients presenting with suspected MI and unobstructed coronary arteries was
≈5% at 12 months.
The cardiologists agreed that CMR identifies LV thrombus better than ECHO, which allows more patients
to be identified and treated appropriately. Accurate identification of a LV thrombus is important because it
often directs subsequent anticoagulation therapy to prevent embolic events. A 2015 systematic review,95
published after we conducted the formal consensus study, showed that late gadolinium enhancement
(LGE) CMR is the most accurate modality for detecting LV thrombus, with 88% sensitivity and 99%
specificity (compared with standard ECHO, which had 24–33% sensitivity and 94–95% specificity, and
contrast ECHO, which had 23–61% sensitivity and 96–99% specificity), although most of the included
studies in this review did not use a pathological or surgical gold standard for the detection of LV thrombus.
There was agreement among cardiologists that CMR-based testing of ischaemia after PPCI would be likely
to optimise the revascularisation strategy for patients with multivessel coronary disease, although they
acknowledged that there is no evidence to support the view that a CMR-based revascularisation strategy
would improve outcomes. Patients with multivessel disease have a two-fold increase in MACEs compared
with patients with single-vessel disease.96 There is continuing debate about the benefits of complete versus
single lesion revascularisation during the index PPCI admission.97 Despite recent evidence from randomised
controlled trials (RCTs) showing improved clinical outcomes when complete revascularisation is undertaken
at PPCI,98 current American99 and European100 revascularisation guidelines for acute MI recommend
revascularisation only of the infarct-related artery at PPCI in patients with multivessel disease.
There was considerable debate about using CMR to identify patients with a poor prognosis after PPCI.
Although there was agreement that CMR parameters of cardiac function (e.g. impaired LV function, large
infarct size, MVO) are useful for risk stratification after STEMI, there was disagreement about whether or
not this would lead to a management change. Some cardiologists felt that there would be no changes to
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prescribing for secondary prevention because all patients should receive aggressive secondary prevention
in accordance with guidelines. It was acknowledged, however, that CMR markers are prognostic for
outcome;4 two recent meta-analyses of prognostic studies (conducted after this formal consensus study)
showed an increased risk of MACE, by 13–15% for every 10% decrease in EF assessed by CMR,2 and in
patients with MVO assessed by CMR [odds ratio (OR) 2.60, 95% CI 1.68 to 4.02 and OR 4.30, 95% CI
2.19 to 8.43, depending on the method of MVO assessment].3
We could not identify all patient subgroups from HIS data sets. Patients with LV thrombus and OHCA were
identifiable only in hospital episode data, from ICD-10 codes for these diagnoses assigned to the index
admission. Patients with unobstructed arteries could not be positively identified from HIS; we identified
them by their exclusion from the hospital BCIS’ NAPCI data sets (as only patients who have a stent
inserted, i.e. have PPCI, or have had an attempt to have a stent inserted, are included in BCIS’ NAPCI).
Given the uncertainty we faced when trying to identify this population prospectively (see Feasibility of
setting up a registry using hospital information system data) and the initial confusion over eligibility at the
beginning of our recruitment period, we decided to review the medical notes (representing the reference
standard) for a subset of these patients to determine the proportion classified correctly according to our
definition of ‘unobstructed coronary arteries’ (exclusion from BCIS’ NAPCI). Although we classified 81%
of patients correctly, some patients we identified as having unobstructed arteries were identified as
having a culprit lesion in the manual review of patients’ notes. Furthermore, there was also a degree of
disagreement between medical notes and the primary diagnosis recorded in hospital episode data for the
index admission of these patients, with 11% of patients who were identified as having unobstructed
coronary arteries in their medical notes having a primary diagnosis of MI in HES. Our investigation using
medical notes highlights a degree of misclassification of this subgroup of patients, although this is not
surprising given the uncertainty in diagnosis during the index admission.
Implementation of a primary outcome based on the changes in management for which
consensus was achieved using hospital episode data
Parts of this text have been reproduced with permission from Pufulete et al.68 This article is distributed under
the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
There was consensus that CMR changes patient management in a clinically important way for five
subgroups of ACS patients. For each group, we listed ‘activities’ (e.g. new diagnoses or procedures,
additional diagnostic tests, changes in medication, outpatient appointments) that reflected a change in
management. Activities were identified from the relevant consensus statements and by looking at care
pathways, when available, to confirm that we captured all aspects of patient management in these
activities. We then compiled a list of the relevant ICD-10 diagnosis codes and OPCS procedure codes
(with help from clinicians on the study team and a dedicated HES coder). We identified these codes in
hospital episode data for participants up to 12 months following the index procedure.
We were able to identify all of the activities that we identified as representing changes in management
in the hospital episode data. Therefore, we conclude that it would be feasible to look for differences
between patients who have and those who do not have CMR within ACS subgroups in terms of frequency
and time to first event for some of the activities. We recognise that some events that were listed as
representing a change in management (e.g. cardiology outpatient appointment, changes in medication)
are not immediately amenable to inclusion in a composite outcome for a time-to-event model.
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This approach to constructing a proxy outcome reflects our original concept and appears to be feasible
when the important changes in management are hypothesised to cause a change in the same direction
in all events/activities included in a composite outcome for a subgroup. However, through the consensus
process, it became apparent that some of the hypothesised changes in management arising from CMR
will not necessarily result in a unidirectional change in the frequency or rate of an activity. In several
instances, an important change in management was more appropriate targeting of a treatment activity
to the patients who were likely to benefit most, without necessarily any change in the overall frequency
of the activity. For example, in patients with multivessel disease, CMR may result in better (i.e. more
cost-effective) targeting of additional revascularisation. In these situations, a simple evaluation of the
frequency or rate of a proxy outcome would not detect any value of CMR to patients and the NHS.
We were unable to identify some important changes in management that could have arisen from CMR.
There are no medication records in hospital episode data, so changes in drug therapy could not be
identified. Initiation, withdrawal or changes in medication represented an important change in management
for all of our patient subgroups and, in particular, patients with LV thrombus, for whom anticoagulation
therapy is the main change in management. A potential solution to this problem is the linkage of HIS and
hospital episode data with data from the Clinical Practice Research Datalink (CPRD), a primary care data set
that has detailed prescription information. However, because not all general practices contribute data to
CPRD, medications data would be available for only a proportion of patients in a registry.
We were also unable to identify additional tests or procedures carried out in the outpatient department
because most outpatient episodes in the HES outpatient data set do not have diagnostic/procedure codes
assigned to them. We are uncertain about the extent to which DID, recently added to the HES portfolio
of data sets, may improve this situation. Finally, hospital episode data alone may not capture all activity
related to changes in management as some patients will be seen multiple times by their GP or in private
facilities. However, as the extent of after care in private facilities in the UK is minimal, it is unlikely to
invalidate a future comparison in a registry.
Patient and public involvement and engagement
The chairperson of the Study Steering Committee (SSC) was a patient representative. We also included on
the SSC a representative from the British Heart Foundation (the Area Development Manager). We felt that
it was particularly important to have members of the public and a previous patient on the SSC because
one of the main objectives of the feasibility study was to investigate the feasibility of consenting patients
into a registry.
We sought the views of both of our lay members about various aspects of the study at all stages. For
example, at the first meeting, we explored the issue of consent. Both our lay members suggested exploring
the possibility of not having consent for the study and confirmed that they did not think using ‘assumed
consent’ would be a problem if it was implemented in routine practice. We did this (as described in Feasibility
of setting up a registry using hospital information system data) but concluded that this viewpoint, although
prevalent among patients and the public, is not currently consistent with the data protection law.101 When
implementing our conventional consent method, we also asked patients who had been in a similar position
to review the patient information leaflet and consent form to ensure that the information was not excessive
but covered all the points that patients would want to know. This input was very useful and helped to guide
some changes during the finalisation of these documents for the Research Ethics Committee submission.
We had planned to hold a focus group with patients and the public to engage with them about developing
the primary outcome as part of the formal consensus process. The lay representatives on the SSC were
consulted at length about this, including reviewing questionnaires that had been drafted for the consensus
meetings. They concluded that, to form an opinion about the importance of the changes in management for
which consensus was obtained, lay people would require an understanding in terms of technical knowledge
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and recent experience and, therefore, it was not reasonable to expect lay people to comment on or refine
the outputs from the consensus process. Throughout the project, the lay representatives on the SSC (and,
in particular, the SSC chairperson) expressed dismay about the lack of availability of HIS and hospital episode
data and the delays this caused to the study. Accepting that our application for these data was held up by
the one-off event of the moratorium in processing applications at NHS Digital (see Chapter 2, Major delays
with the study), lay representatives were surprised that the plan for implementing new governance processes
did not appear to have considered how applications in progress should be handled. The ruling from NHS
Digital and ONS that the wording of the patient information leaflet was not compliant with the new guidance,
after we had completed recruitment, seemed Kafkaesque102 from the perspective of the researcher team.
Strengths and limitations of the study
Feasibility prospective cohort study
We established a successful collaboration among four hospitals and exceeded the recruitment target for the
study of 1600 patients. We also identified the main challenges to establishing a prospective registry in the
way we had envisaged: identifying the eligible population is difficult to do from local HISs; the conventional
consent model fails to capture a sizeable proportion of the eligible population and would be costly to
implement; and, most importantly, the required local data from HISs are not uniformly available/exportable.27
We did not identify or test a more efficient method to obtain consent. The methods used by hospitals for
the study are almost certainly not feasible to implement in the long term for a registry, and are likely to
result in varying completeness across hospitals. However, the barriers to any form of ‘presumed consent’
or ‘opt out’ seemed insurmountable without a long-term plan for implementing consent.
We are aware that CMR may benefit other groups of ACS patients (e.g. those with NSTEMI). However,
we considered at the outset that it would be impossible to identify consecutive patients presenting with a
broader diagnosis of ACS but not requiring emergency coronary angiography; being able to define and
ascertain the entire eligible population is a key requirement of a high-quality database. This was a
particularly important consideration given that the proposed registry was based on the premise of linking
information collected in the course of usual care, avoiding the time and cost burden of primary data
collection.27 Even so, we still encountered difficulties in identifying from electronic records the group of
patients with unobstructed coronary arteries in our eligible population.
We concluded that we could identify our eligible population in hospital episode data, based on the fact
that we identified the index admission for most patients recruited into our study. However, because we
had only hospital episode data for patients in the cohort, we cannot comment on or quantify the risk
that an algorithm designed to identify such patients from hospital episode data could also identify some
patients who would have been ineligible for the registry. Our impression from exploring codes assigned to
hospital episode data for index admissions is that this risk is low and is likely to reduce as the quality of
hospital episode data improves. The only way to quantify the risk would have been to request anonymised
linkage of all HISs and hospital episode data for all cardiology admissions during the study period, with
identification of the study cohort participants as a subgroup.
A major limitation is the length of time it took to complete the study. The main reason for this was because
our application for HES data coincided with the moratorium on data requests by NHS Digital (formerly
known as the Health and Social Care Information Centre), which resulted in a delay of 23 months in
processing our application. This meant that the study took > 4.5 years to complete, whereas we had
projected 1.5 years for completion. During this time, it is likely that data availability and the quality of the
data will have changed/improved, given the rapidly evolving NHS IT systems/platforms. During this time,
new diagnostic tests for detecting ischaemia (e.g. pressure wire), directly competing with CMR, were
introduced and rapidly adopted by some cardiologists. These changes highlight the need for new research
questions; therefore, it is likely that the aims and objectives for a national registry now would be different
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from those we proposed when we set up this study. For example, it may be more relevant to compare
ischaemia testing using pressure wire with CMR, rather than to compare CMR with no CMR, which we
proposed for our registry. We have tried to adapt the study to the current circumstances, for example with
respect to the cost-effectiveness models, but have been unable to do anything about the changes in
practice or the historic nature of the data collected.
Economic evaluation
There is considerable uncertainty around the majority of parameter estimates in both models. In the model
for patients with unobstructed coronary arteries, the probability of patients truly having a MI was obtained
from the results of a systematic review,50 but all other probability estimates in both models are based
on single papers, often on small or modest sample sizes. There was only sparse evidence found in the
literature for many of the probability estimates required. This was particularly true for the probabilities of
MACEs for patients who truly did and those who did not have a MI (and had appropriate treatment or
not), in the model for patients with unobstructed coronary arteries. Members of the study team were
concerned that the estimated ratio of MACEs in MI patients compared with non-MI patients (in patients
with unobstructed coronary arteries) found in Pathik et al.52 was very high; this is why we investigated this
parameter in the sensitivity analyses.
Even when papers reported on the correct patient group and outcomes, studies may have been conducted
in other countries, where practices may differ from those in the UK. For example, Smits et al.38 specifically
reported numbers that could be used to estimate the probability of a MACE by 1 year for those truly with
ischaemia separately for those who were and those who were not revascularised (see Figures 1 and 2, and
Chapter 5, Cost-effectiveness models); however, this study was conducted in Europe and Asia, with no UK
centres included. Occasionally, estimates from a different patient group were the only estimates available.
For example, in the model for patients with multivessel disease, the diagnostic accuracy of stress ECHO
(its sensitivity and specificity) was taken from a paper considering the diagnosis of significant coronary
artery disease, rather than a PPCI population, and estimates are based on the number of vessels rather
than the number of patients.39
In the base-case analyses for multivessel disease, CMR and pressure wire were treated as reference
standards, and both were assumed to have 100% sensitivity and specificity. There are suggestions in the
literature that this is reasonable; for example, Emrich et al.103 found that CMR correctly identified all 20
out of 125 patients with MI in their study. The assumption of equal diagnostic accuracy is critical, because
the sensitivity analyses showed how diagnostic accuracy of the ischaemia tests was the key driver of
cost-effectiveness. Similarly for the unobstructed coronary arteries model, reducing the diagnostic accuracy
of CMR plus standard ECHO compared with standard ECHO alone (sensitivity analysis 1) doubled the ICER.
Individual patient data on resource use were not available from hospital episode data in time to be used in
these analyses; resource use associated with each of the patient pathways was, therefore, estimated based
on discussions with the PIPA study team and costs were largely obtained from NHS Reference Costs.40
These methods have allowed standard care pathways to be costed but will have underestimated the
variability between individual patients and their actual patient pathways.
As well as the costs of initial ischaemia testing (if applicable), and any revascularisation, we included the
costs of follow-up outpatient appointments, medications and rehabilitation over the first year. We also
included additional health-care costs to 1 year based on the Office of Health Economics’ estimate of the
annual cost per person of NHS care.43 It is recognised that there will be an element of double counting
here, as the costs of ischaemia testing, revascularisation and subsequent costs will overlap with these
annual costs, but this will be the same for all strategies and should not affect the comparison of costs
between strategies. These annual costs were included to account for differences in costs for patients who
died; these costs were halved for patients with a MACE who died by 1 year.
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Utility estimates for a PPCI population were found in the literature, but there was uncertainty around the
utility decrement for patients with MACEs compared with those without MACEs. A decrement of 0.05 was
assumed for patients with a MACE compared with those without a MACE.48 Although this decrement has
been used by others, the original reference for this decrement implies that it was a sensitivity analysis, and
was not based on any primary data.104 Utility estimates for patients with unobstructed coronary arteries
were not found in the Tufts Cost-effectiveness Analysis Registry,46 and a recent paper measuring quality of
life in patients with MI with unobstructed coronary arteries reported that no studies measuring quality of life
in these patients have previously been conducted.105 This study measured quality of life using the SF-36 at
3 months post acute event and found similar findings in patients with unobstructed coronary arteries and a
control group of MI patients with coronary heart disease, suggesting that the estimates used in our model
for patients with unobstructed coronary arteries are reasonable.
Formal consensus study
Parts of this text have been reproduced from Pufulete et al.4 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/.
A key strength of the study was the use of a formal consensus approach, based on a systematic search of
the literature as well as expert opinion. The nominal group technique is one of the four well-established
methodologies for formal consensus [the other three are (1) the Delphi method, (2) the Research ANd
Development Corporation (RAND)/University of California, Los Angeles Appropriateness Method (RAM)
and (3) the National Institutes’ of Health consensus development conference methodology].4,106,107 Our
literature review included all study designs to determine the size and nature of the evidence base and
highlight research gaps. The search was systematic and extensive, including five databases and published
abstracts. Four cardiologists contributed expert opinion. Two are UK/European CMR experts. The process
provided evidence for the content validity of each statement. All cardiologists who drafted the statements
proposed the same patient subgroups as potentially benefiting from CMR. There was generally good
agreement between draft statements generated by cardiologists and the non-clinical reviewer.
There were no disagreements in the group meeting regarding the potential management change in each
of the patient subgroups identified. Similarly, the studies identified in our literature review (both prognostic
and diagnostic) were consistent in their findings. The majority of prognostic studies reported that CMR
markers such as EF, MVO and haemorrhage were associated with MACEs, although most did not evaluate
the prognostic value of CMR indices in addition to indices available from alternative imaging modalities.
The evidence supporting many of the statements came from small, retrospective case series. There were
no prospective studies in the literature that reported the impact of CMR on clinical management in our
population or whether or not any changes in management affected patient outcomes.
The main features of a formal consensus method are anonymity (i.e. statements were rated free from
peer-group pressure) and iterative feedback (i.e. participants could adjust their initial rating based on the
feedback of the group rating). We described the supporting evidence for each statement, identified via
the literature review, and fed back qualitative (i.e. panel members’ comments) and quantitative (i.e. group
median ratings of each statement) information at the face-to-face meeting. We also included a varied
group of cardiologists from different specialties in order to encompass diverse perspectives.4
A potential limitation of this study is that we did not perform any formal quality assessment of primary
studies. We made this decision for two reasons. First, the purpose of the review was to identify the
evidence base in order to inform the consensus process, not to use the literature to quantify the
effectiveness of CMR or its diagnostic or prognostic value. Second, no single assessment tool would have
been appropriate for the diverse studies that were identified, hence assessments would not have been
comparable. Therefore, we have not referred to our overall review as being ‘systematic’ (only the search),
although its conduct closely reflected established guidelines for systematic reviews and we believe that
other researchers following the same steps would replicate its findings.
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The number of panel members in our study was lower than the recommended 8–12 members for a
consensus panel.107 Nevertheless, smaller groups are preferable to larger ones because, although having
more group members increases the reliability of group judgement, large groups reduce the ability to
elicit potentially important contributions from every member of the panel.107 To overcome any criticism of
the number of panel members in the study and to prevent the possibility of introducing bias (given the
self-selected nature of the panel), we extended the survey to UK cardiologists who did not participate in
the formal consensus process. Apart from one statement (statement 1, relating to the ability of CMR to
identify patients with a poor prognosis after PPCI), the same statements were in consensus when the
survey was completed by cardiologists external to the consensus process. This indicates that the process
was robust and the survey statements were clear and unambiguous.
A further limitation of the study was that we did not include other stakeholders (e.g. GPs and patient
representatives) in the consensus process.108 Although we had originally planned to do so (see Patient and
public involvement and engagement), we decided that the specialised nature of the statements would not
be easily understood by those without cardiology expertise.4 We did, however, hold a separate meeting
(outside the consensus process) with a GP commissioner and the director of the Southwest Cardiac
and Stroke Network. The conclusion of the meeting was that, given that the cohort is an emergency
population and the consensus process identified that a large proportion of the population would
potentially benefit from scanning, it would be better to offer CMR to the whole population rather than
complicating the patient management strategy by scanning only subsets of patients.
Lessons for the future
Future studies attempting to answer research questions through linkage of routinely collected data sets
(at the local and national level) should consider the following:
l Timeliness – a study must be reported within a reasonable time frame given the rapidly changing
environment (e.g. NHS IT systems, introduction of new diagnostic tests).
l Data availability in hospitals – the HIS available at each hospital and the level of IT support available
to provide the data need to be investigated thoroughly; funding is likely to be required to support
data extraction.
l Data sources in hospitals – the relevant data sources at each hospital need to be identified before
starting a study. For example, we decided to use BCIS/MINAP submission data sets instead of catheter
laboratory databases after the study started; this caused considerable confusion and difficulties over
patient eligibility, given that BCIS/MINAP could provide data only for patients who had STEMI/received
PPCI and not patients with unobstructed coronary arteries.
l Hospital episode data – these data are made available (after ‘cleaning’) by NHS Digital (or Information
Services Division Scotland, PEDW or Northern Ireland Department of Health) for whole financial years.
Our failure to appreciate this meant that only ≈67% of patients had a whole 1 year of follow-up.
Implications for practice
Our experience highlights the need to assess ‘feasibility’ before attempting to set up a new registry.
Although some of the pitfalls we experienced may, in hindsight, be viewed as resulting from a lack
of ‘preparedness’, our experience is not unique. Registries (e.g. national audits) that have managed
to overcome issues with data collection and quality have achieved this through a lengthy process,
necessitating many iterations (and a feedback loop) before attaining any quality targets. This process
requires considerable investment, infrastructure and commitment at the national level, which would be
difficult to achieve in a research setting.4 The process also has drawbacks; for example, iterations add
to the complexity of creating a data set that is consistent over time and that takes into account changes
in the methods of collecting data, which may result in concomitant inadvertent changes in definitions of
the data.
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We consider the following as desirable developments to make it more feasible to construct a registry from
routinely collected data:
l More uniform implementation of IT across acute NHS trusts (e.g. a shortlist of ‘approved’ database
suppliers with compatible features, including features to facilitate data extraction for secondary purposes).
l Lighter touch governance when anonymisation is done centrally. Access to patient data is likely to
remain a challenge, particularly with the introduction of the General Data Protection Regulation
(GDPR).109,110 The lack of clarity over the safe and ethical secondary use of routinely collected data is
currently a major barrier preventing access to routine data for research.
l A method for obtaining consent that is practicable to implement in the busy setting of the NHS.
For example, this could involve an opt-out model of consent or presumed consent, combined with a
national publicity campaign promoting the benefits of using routine data in research. Opt-out models
of consent are currently very difficult to implement because of the specific, and changing, nature of
the instructions for informing affected people. The apparent failure to make provision for analyses of
historic and ongoing data sets, when data collection started before changes in law, is particularly
wasteful and frustrating for researchers.
l Efficient provision of routine data by data guardians, for example NHS Digital.
Future research recommendations
The present study highlighted the difficulties of implementing a conventional consent process for a
registry that recruits patients who undergo an emergency procedure and have a short hospital stay.
An important area of future research should, therefore, be to identify and test a more efficient method
of obtaining consent for similar studies in similar settings that need to link data sources. This issue should
be approached at a national rather than a local level, and involve detailed discussions with all relevant
stakeholders. Critically, clarification is required about whether or not it is possible, given the recent debates
about data sharing and the changes to information governance policies at NHS Digital,111 to obtain
approval (under section 251 of the NHS Act 200676) to use patient information for medical research and
link national data sets without consent. Currently, there is discrepancy between UK national registries, with
many implementing prospective consent,74,75 whereas others, such as the national cardiac audits managed
by NICOR, operate on the basis of section 25176 exemptions.
Alternatively, we need to test the feasibility of conducting the study using linked, anonymised national
data sets (e.g. hospital episode data, BCIS NAPCI, DID, CPRD for medications). This would avoid the need
for obtaining individual patient consent or section 25176 exemption, as data are anonymised when made
available to researchers. Such a linked data set would be able to capture all the eligible population and
could use MACEs as an outcome, although there may still be regulatory hurdles in obtaining permission
to link these data sets and CPRD captures data for only a small proportion of the UK population.
There has been a rapid adoption of pressure-wire testing for detecting ischaemia during this study despite
a lack of evidence of benefit over CMR. Our cost-effectiveness models have highlighted that the diagnostic
accuracies of the CMR versus pressure-wire ischaemia tests are key drivers of the relative cost-effectiveness
of management strategies based on these tests, compared with stress ECHO or each other. Therefore,
future research is needed to quantify the relative diagnostic accuracy of CMR and pressure wire versus
stress ECHO, and versus each other, for ischaemia testing. The fact that both CMR and pressure-wire
testing are regarded as reference standards in clinical practice and no superior standard is recognised may
mean that the cost-effectiveness of CMR versus pressure wire can be tested with respect to effectiveness
only in a large RCT.
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Chapter 8 Conclusion
We conclude that it is not currently feasible to set up a multicentre registry in the way that we hadenvisaged. We did not identify all patients who were eligible for the study: patients with unobstructed
arteries (i.e. those that had an emergency angiogram but did not receive PPCI) were difficult to identify from
catheter laboratory databases. We successfully consented patients but obtaining individual, opt-in consent
would not be feasible for a national registry. We explored several consent models (e.g. opt-out on procedural
consent form and standard consent at discharge) but none was implemented because of logistic difficulties.
Linkage of data from HISs with hospital episode data was feasible, but data from HISs are not uniformly
available/exportable. Information about whether or not participants had had CMR in CMR hospitals
was obtained successfully from HISs, although some referrals for CMR were for research rather than
clinical purposes.27
In the cost-effectiveness models, the differences in QALYs between strategies were very small, and the
results were driven largely by the differences in costs. Sensitivity analyses around the two models identified
the diagnostic accuracy of the ischaemia tests as the key driver of cost-effectiveness.
We defined five subgroups of patients who activate the PPCI pathway for whom there was consensus that
CMR changes patient management in a clinically important way.4 All subgroups could be identified in
either the local HIS data set, hospital episode data or both. It is feasible to identify some, but not all,
important changes in management in follow-up hospital episode data. The main constraints on identifying
important changes in management were as follows: (1) outpatient hospital episode data were poorly
coded with respect to diagnosis, (2) medication data were not available at baseline or follow-up
(preventing inspection of prescription of/changes in medication after the index event) and (3) data about
diagnostic investigations were poorly coded in both acute care and outpatient data sets. More research
would be needed to develop a specific composite outcome for a patient subgroup.68
Any multicentre registry set up in this patient population would need to be able to capture new and
emerging diagnostic/interventional technologies. During the study, priority for CMR decreased because
of the introduction of pressure-wire testing for diagnosing ischaemia in patients with multivessel disease.
However, it is not clear whether or not pressure-wire testing is the optimal management strategy from the
perspective of health services. This question could potentially be answered in a national registry, given that
the use of pressure wire is (currently) driven largely by the preferences of interventional cardiologists rather
than patient characteristics. However, we are uncertain whether or not CMR is used sufficiently to allow
this question to be addressed.
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
83

Acknowledgements
We would like to thank the local research teams that contributed to the study, including Ruth Bowles,Jo Roberts, Alan Davies, Helen Kingsland, Linda Wadey, Petra Bijsterveld, Kathryn Somers,
Richard Gillott, Lesley Davies, Stephen Hiles, Stephen Morris and Clare Fagan. We would also like to
thank Danielle Bargo, for contributions towards the health economic models, and Alice Redfern, who
assisted with the literature searching for the economic models. In addition, we would like to thank
the SSC, including John Walsh, the chairperson of the committee, and our colleagues Lynn Cook,
Peter Brindle, Emma Hopkins and Andreas Baumbach for their contributions to the research. We would
also like to acknowledge the contribution made by the expert cardiology panel for the consensus process.
This study was designed and delivered in collaboration with the Clinical Trials and Evaluation Unit, a UK
Clinical Research Collaboration-registered clinical trials unit that, as part of the Bristol Trials Centre,
is in receipt of National Institute for Health Research clinical trials unit support funding.
Contributions of authors
Jessica M Harris undertook the data handling, linkage and analysis, and prepared the tables and figures
for the report.
Rachel C Brierley conducted the study and conceived some aspects of data collection from
participating hospitals.
Maria Pufulete designed and conducted the study, determined the structure of the consensus process,
conducted the literature review and wrote the report.
Chiara Bucciarelli-Ducci conceived the original research question and provided clinical and CMR expertise.
Elizabeth A Stokes carried out the health economic analyses and wrote the health economics sections of
the report.
John P Greenwood was principal investigator at one of the recruiting hospitals, provided cardiology and
CMR expertise and was a member of the working group in the consensus process.
Stephen H Dorman was principal investigator at one of the recruiting hospitals, provided cardiology
expertise and was a member of the working group in the consensus process.
Richard A Anderson was principal investigator at one of the recruiting hospitals, provided cardiology
expertise and was a member of the working group in the consensus process.
Chris A Rogers provided guidance with respect to statistics and study design.
Sarah Wordsworth provided guidance and oversaw the health economics analysis.
Sunita Berry was a member of the working group in the consensus process and provided expertise with
respect to NHS commissioning of services.
Barnaby C Reeves was chief investigator with overall responsibility for the study, designed the study and
provided strategic direction with the interpretation of study results.
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
Publications
Pufulete M, Brierley RC, Bucciarelli-Ducci C, Greenwood JP, Dorman S, Anderson RA, et al. Formal
consensus to identify clinically important changes in management resulting from the use of cardiovascular
magnetic resonance (CMR) in patients who activate the primary percutaneous coronary intervention (PPCI)
pathway. BMJ Open 2017;7:e014627.
Brierley RC, Pufulete M, Harris J, Bucciarelli-Ducci C, Greenwood JP, Dorman S, et al. Developing a UK
registry to investigate the role of cardiovascular magnetic resonance (CMR) in patients who activate the
primary percutaneous coronary intervention (PPCI) pathway: a multicentre, feasibility study linking routinely
collected electronic patient data. BMJ Open 2018;8:e018987.
Stokes A, Doble B, Pufulete M, Reeves BC, Bucciarelli-Ducci C, Dorman S, et al. Cardiovascular magnetic
resonance in emergency patients with multi-vessel disease or unobstructed coronary arteries: a cost-effectiveness
analysis in the UK. BMJ Open 2019;9:e025700.
Pufulete M, Harris J, Dorman S, Cook L, Bucciarelli-Ducci C, Greenwood JP, et al. Feasibility of identifying
important changes in care management resulting from cardiovascular magnetic resonance (CMR) using
Hospital Episode Statistics data. BMC Med Res Methodol 2019; in press.
Data-sharing statement
Anonymised individual patient data (excluding hospital episode/vital status linked data) may be available for
secondary research, conditional on assurance from the secondary researcher that the proposed use of the
data is compliant with the Medical Research Council Policy on Data Preservation and Sharing regarding
scientific quality, ethics requirements and value for money. All data requests should be submitted to the
corresponding author for consideration and access may be granted following review. The hospital episode
data/vital status data cannot be shared further due to conditions imposed by NHS Digital in the original
data-sharing agreement that covered initial data release.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
References
1. Antony R, Daghem M, McCann GP, Daghem S, Moon J, Pennell DJ, et al. Cardiovascular
magnetic resonance activity in the United Kingdom: a survey on behalf of the British Society of
Cardiovascular Magnetic Resonance. J Cardiovasc Magn Reson 2011;13:57. https://doi.org/
10.1186/1532-429X-13-57
2. El Aidi H, Adams A, Moons KG, Den Ruijter HM, Mali WP, Doevendans PA, et al. Cardiac magnetic
resonance imaging findings and the risk of cardiovascular events in patients with recent myocardial
infarction or suspected or known coronary artery disease: a systematic review of prognostic
studies. J Am Coll Cardiol 2014;63:1031–45. https://doi.org/10.1016/j.jacc.2013.11.048
3. Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of microvascular obstruction and
intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction:
a systematic review and meta-analysis. JACC Cardiovasc Imaging 2014;7:940–52. https://doi.org/
10.1016/j.jcmg.2014.06.012
4. Pufulete M, Brierley RC, Bucciarelli-Ducci C, Greenwood JP, Dorman S, Anderson RA, et al.
Formal consensus to identify clinically important changes in management resulting from the use
of cardiovascular magnetic resonance (CMR) in patients who activate the primary percutaneous
coronary intervention (PPCI) pathway. BMJ Open 2017;7:e014627. https://doi.org/10.1136/
bmjopen-2016-014627
5. National Institute for Cardiovascular Outcomes Research. Myocardial Ischaemia National Audit
Project. URL: www.ucl.ac.uk/nicor/audits/minap/documents/annual_reports/minap-report-2013
(accessed 17 January 2019).
6. Cardarelli F, Bellasi A, Ou FS, Shaw LJ, Veledar E, Roe MT, et al. Combined impact of age and
estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary
intervention for acute myocardial infarction (from the American College of Cardiology National
Cardiovascular Data Registry). Am J Cardiol 2009;103:766–71. https://doi.org/10.1016/j.amjcard.
2008.11.033
7. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW. Multiple complex
coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915–22.
https://doi.org/10.1056/NEJM200009283431303
8. Lee JH, Park HS, Chae SC, Cho Y, Yang DH, Jeong MH, et al. Predictors of six-month major
adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea
Acute Myocardial Infarction Registry). Am J Cardiol 2009;104:182–9. https://doi.org/10.1016/
j.amjcard.2009.03.010
9. Rasoul S, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Marcel Gosselink AT, et al.
Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for
ST-elevation myocardial infarction. Coron Artery Dis 2009;20:415–21. https://doi.org/10.1097/
MCA.0b013e32832e5c4c
10. Toma M, Buller CE, Westerhout CM, Fu Y, O’Neill WW, Holmes DR, et al. Non-culprit coronary
artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction:
insights from the APEX-AMI trial. Eur Heart J 2010;31:1701–7. https://doi.org/10.1093/
eurheartj/ehq129
11. Vlaar PJ, Mahmoud KD, Holmes DR, van Valkenhoef G, Hillege HL, van der Horst IC, et al. Culprit
vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease
in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network
meta-analysis. J Am Coll Cardiol 2011;58:692–703. https://doi.org/10.1016/j.jacc.2011.03.046
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
12. Lockie T, Ishida M, Perera D, Chiribiri A, De Silva K, Kozerke S, et al. High-resolution magnetic
resonance myocardial perfusion imaging at 3.0-Tesla to detect hemodynamically significant
coronary stenoses as determined by fractional flow reserve. J Am Coll Cardiol 2011;57:70–5.
https://doi.org/10.1016/j.jacc.2010.09.019
13. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, et al. Validation of
magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection
of significant coronary heart disease. Circulation 2009;120:2207–13. https://doi.org/10.1161/
CIRCULATIONAHA.109.872358
14. ClinicalTrials.gov. MR INFORM – MR Perfusion Imaging to Guide Management of Patients With Stable
Coronary Artery Disease. URL: https://clinicaltrials.gov/ct2/show/NCT01236807 (accessed April 2018).
15. Larsen AI, Galbraith PD, Ghali WA, Norris CM, Graham MM, Knudtson ML, APPROACH Investigators.
Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal
coronary arteries. Am J Cardiol 2005;95:261–3. https://doi.org/10.1016/j.amjcard.2004.09.014
16. Meryon I, Patel N, Millane T, Varma C. Normal coronary angiography and primary percutaneous
coronary intervention for ST elevation myocardial infarction: a literature review and audit findings.
Int J Clin Pract 2010;64:1245–51. https://doi.org/10.1111/j.1742-1241.2010.02394.x
17. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence
of acute myocardial infarction: incidence and clinical significance. Chest 2004;125:1877–84.
https://doi.org/10.1378/chest.125.5.1877
18. Sarda L, Colin P, Boccara F, Daou D, Lebtahi R, Faraggi M, et al. Myocarditis in patients with
clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol
2001;37:786–92. https://doi.org/10.1016/S0735-1097(00)01201-8
19. Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lotfi A, et al. Prognostic
implications of elevated troponin in patients with suspected acute coronary syndrome but no
critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005;45:19–24.
https://doi.org/10.1016/j.jacc.2004.09.056
20. Assomull RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, et al. The role of cardiovascular
magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed
coronary arteries. Eur Heart J 2007;28:1242–9. https://doi.org/10.1093/eurheartj/ehm113
21. Codreanu A, Djaballah W, Angioi M, Ethevenot G, Moulin F, Felblinger J, et al. Detection of
myocarditis by contrast-enhanced MRI in patients presenting with acute coronary syndrome but
no coronary stenosis. J Magn Reson Imaging 2007;25:957–64. https://doi.org/10.1002/jmri.20897
22. Laissy JP, Hyafil F, Feldman LJ, Juliard JM, Schouman-Claeys E, Steg PG, Faraggi M. Differentiating
acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion
cardiac MR imaging. Radiology 2005;237:75–82. https://doi.org/10.1148/radiol.2371041322
23. Leurent G, Langella B, Fougerou C, Lentz PA, Larralde A, Bedossa M, et al. Diagnostic
contributions of cardiac magnetic resonance imaging in patients presenting with elevated
troponin, acute chest pain syndrome and unobstructed coronary arteries. Arch Cardiovasc Dis
2011;104:161–70. https://doi.org/10.1016/j.acvd.2011.01.005
24. Stensaeth KH, Fossum E, Hoffmann P, Mangschau A, Klow NE. Clinical characteristics and role
of early cardiac magnetic resonance imaging in patients with suspected ST-elevation myocardial
infarction and normal coronary arteries. Int J Cardiovasc Imaging 2011;27:355–65. https://doi.org/
10.1007/s10554-010-9671-7
25. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. Presentation, patterns
of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581–90.
https://doi.org/10.1161/CIRCULATIONAHA.105.606509
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
26. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of
biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol
2012;59:1604–15. https://doi.org/10.1016/j.jacc.2012.01.007
27. Brierley RC, Pufulete M, Harris J, Bucciarelli-Ducci C, Greenwood JP, Dorman S, et al. Developing a
UK registry to investigate the role of cardiovascular magnetic resonance (CMR) in patients who
activate the primary percutaneous coronary intervention (PPCI) pathway: a multicentre, feasibility
study linking routinely collected electronic patient data. BMJ Open 2018;8:e018987. https://doi.org/
10.1136/bmjopen-2017-018987
28. Department of Health and Social Care. NHS Reference Costs. London: Department of Health and
Social Care; 2014. URL: www.gov.uk/government/collections/nhs-reference-costs (accessed
27 October 2015).
29. Welsh Government. Welsh Index of Multiple Deprivation. Cardiff: Welsh Government; 2011.
URL: https://gov.wales/statistics-and-research/welsh-index-multiple-deprivation/?lang=en
(accessed 16 January 2019).
30. NHS Digital. Methodology to Create Provider and CIP Spells from HES APC Data. 2014.
URL: http://content.digital.nhs.uk/media/11859/Provider-Spells-Methodology/pdf/Spells_
Methodology.pdf (accessed 16 January 2019).
31. International Statistical Classification of Diseases and Related Health. URL: https://icd.who.int/
browse10/2016/en (accessed 20 December 2018).
32. OPCS Classification of Interventions and Procedures version 4. URL: www.datadictionary.nhs.uk/
web_site_content/supporting_information/clinical_coding/opcs_classification_of_interventions_
and_procedures.asp (accessed 20 December 2018).
33. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between
treatment groups in propensity-score matched samples. Stat Med 2009;28:3083–107.
https://doi.org/10.1002/sim.3697
34. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology
Appraisal 2013. London: NICE; 2013.
35. National Institute for Health and Care Excellence (NICE). The Pressure Wire Fractional Flow Reserve
Measurement System for Coronary Artery Disease. London: NICE; 2014. URL: www.nice.org.uk/
advice/mib2/chapter/technology-overview (accessed 16 January 2019).
36. Stokes A, Doble B, Pufulete M, Reeves BC, Bucciarelli-Ducci C, Dorman S, et al. Cardiovascular
magnetic resonance in emergency patients with multi-vessel disease or unobstructed coronary
arteries: a cost-effectiveness analysis in the UK. BMJ Open 2019;9:e025700.
37. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic
versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve
versus angiography in multivessel evaluation. J Am Coll Cardiol 2010;55:2816–21. https://doi.org/
10.1016/j.jacc.2009.11.096
38. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al.
Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med
2017;376:1234–44. https://doi.org/10.1056/NEJMoa1701067
39. Gurunathan S, Young G, Parsons G, Karogiannis N, Vamvakidou A, Elghamaz A, et al. 132 diagnostic
accuracy of stress echocardiography compared with invasive coronary angiography with fractional
flow reserve for the diagnosis of haemodynamically significant CAD in patients with known or
suspected CAD. Heart 2016;102:A94–5. https://doi.org/10.1136/heartjnl-2016-309890.132
40. Department of Health and Social Care. NHS Reference Costs 2015 to 2016. London: Department
of Health and Social Care; 2016.
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
41. Joint Formulary Committee. British National Formulary. 73 ed. London: British Medical Association
and Royal Pharmaceutical Society of Great Britain; 2017.
42. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services
Research Unit, University of Kent; 2016.
43. Hawe E, Cockcroft L. OHE Guide to UK Health and Health Care Statistics. London: Office of Health
Economics; 2013.
44. Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, et al. Clopidogrel
and modified-release dipyridamole for the prevention of occlusive vascular events (review of
Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess
2011;15(31). https://doi.org/10.3310/hta15310
45. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage
and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic
review and economic model. Health Technol Assess 2006;10(44). https://doi.org/10.3310/hta10440
46. Tufts Medical Center. Cost-effectiveness Analysis (CEA) Registry. URL: http://healtheconomics.
tuftsmedicalcenter.org/cear4/Home.aspx (accessed 6 April 2017).
47. Aasa M, Henriksson M, Dellborg M, Grip L, Herlitz J, Levin LA, et al. Cost and health outcome of
primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation
myocardial infarction: results of the Swedish Early Decision reperfusion Study (SWEDES) trial.
Am Heart J 2010;160:322–8. https://doi.org/10.1016/j.ahj.2010.05.008
48. Nam J, Briggs A, Layland J, Oldroyd KG, Curzen N, Sood A, et al. Fractional flow reserve (FFR)
versus angiography in guiding management to optimise outcomes in non-ST segment elevation
myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed-trial
and model-based methods. Cost Eff Resour Alloc 2015;13:19. https://doi.org/10.1186/
s12962-015-0045-9
49. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. Management of
non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA
antagonists in the UK National Health Service? Int J Cardiol 2005;100:229–40. https://doi.org/
10.1016/j.ijcard.2004.08.042
50. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting
with suspected myocardial infarction and nonobstructive coronary arteries. Circulation
2015;131:861–70. https://doi.org/10.1161/CIRCULATIONAHA.114.011201
51. Kang WY, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, et al. Are patients with angiographically
near-normal coronary arteries who present as acute myocardial infarction actually safe? Int J
Cardiol 2011;146:207–12. https://doi.org/10.1016/j.ijcard.2009.07.001
52. Pathik B, Raman B, Mohd Amin NH, Mahadavan D, Rajendran S, McGavigan AD, et al.
Troponin-positive chest pain with unobstructed coronary arteries: incremental diagnostic value of
cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging 2016;17:1146–52.
https://doi.org/10.1093/ehjci/jev289
53. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld A, Gard A, Jernberg T. Medical
therapy for secondary prevention and long-term outcome in patients with myocardial infarction
with nonobstructive coronary artery disease. Circulation 2017;135:1481–9. https://doi.org/
10.1161/CIRCULATIONAHA.116.026336
54. Dastidar AG, Rodrigues JC, Johnson TW, De Garate E, Singhal P, Baritussio A, et al. Myocardial
infarction with nonobstructed coronary arteries: impact of CMR early after presentation.
JACC Cardiovasc Imaging 2017;10:1204–6 https://doi.org/10.1016/j.jcmg.2016.11.010
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
55. Dastidar AG, Rodrigues JC, Baritussio A, Bucciarelli-Ducci C. MRI in the assessment of ischaemic
heart disease. Heart 2016;102:239–52. https://doi.org/10.1136/heartjnl-2014-306963
56. Tornvall P, Gerbaud E, Behaghel A, Chopard R, Collste O, Laraudogoitia E, et al. Myocarditis or
‘true’ infarction by cardiac magnetic resonance in patients with a clinical diagnosis of myocardial
infarction without obstructive coronary disease: a meta-analysis of individual patient data.
Atherosclerosis 2015;241:87–91. https://doi.org/10.1016/j.atherosclerosis.2015.04.816
57. Wang ZJ, Zhang LL, Elmariah S, Han HY, Zhou YJ. Prevalence and prognosis of nonobstructive
coronary artery disease in patients undergoing coronary angiography or coronary computed
tomography angiography: a meta-analysis. Mayo Clin Proc 2017;92:329–46. https://doi.org/
10.1016/j.mayocp.2016.11.016
58. Chopard R, Jehl J, Dutheil J, Genon VD, Seronde MF, Kastler B, et al. Evolution of acute coronary
syndrome with normal coronary arteries and normal cardiac magnetic resonance imaging. Arch
Cardiovasc Dis 2011;104:509–17. https://doi.org/10.1016/j.acvd.2011.05.004
59. Gerbaud E, Harcaut E, Coste P, Erickson M, Lederlin M, Labèque JN, et al. Cardiac magnetic
resonance imaging for the diagnosis of patients presenting with chest pain, raised troponin,
and unobstructed coronary arteries. Int J Cardiovasc Imaging 2012;28:783–94. https://doi.org/
10.1007/s10554-011-9879-1
60. Heijenbrok-Kal MH, Fleischmann KE, Hunink MG. Stress echocardiography, stress single-photon-
emission computed tomography and electron beam computed tomography for the assessment of
coronary artery disease: a meta-analysis of diagnostic performance. Am Heart J 2007;154:415–23.
61. Bettencourt-Silva J, De La Iglesia B, Donell S, Rayward-Smith V. On creating a patient-centric
database from multiple Hospital Information Systems. Methods Inf Med 2012;51:210–20.
https://doi.org/10.3414/ME10-01-0069
62. García Álvarez L, Aylin P, Tian J, King C, Catchpole M, Hassall S, et al. Data linkage between
existing health-care databases to support hospital epidemiology. J Hosp Infect 2011;79:231–5.
https://doi.org/10.1016/j.jhin.2011.06.016
63. Torres V, Cerda M, Knaup P, Löpprich M. Assessment of automatically exported clinical data from
a Hospital Information System for clinical research in multiple myeloma. Stud Health Technol
Inform 2016;228:332–6.
64. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M, ISPOR-SMDM Modeling
Good Research Practices Task Force. Conceptualizing a model: a report of the ISPOR-SMDM
Modeling Good Research Practices Task Force – 2. Value Health 2012;15:804–11. https://doi.org/
10.1016/j.jval.2012.06.016
65. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. New York, NY: Lawrence
Erlbaum Associates, Publishers; 1988.
66. Rycroft-Malone J. Formal consensus: the development of a national clinical guideline. Qual Health
Care 2001;10:238–44. https://doi.org/10.1136/qhc.0100238
67. Tukey JW. Exploratory Data Analysis. Reading, MA: Addison–Wesley; 1977.
68. Pufulete M, Harris J, Dorman S, Cook L, Bucciarelli-Ducci C, Greenwood JP, et al. Feasibility of
identifying important changes in care management resulting from cardiovascular magnetic
resonance (CMR) using Hospital Episode Statistics data. BMC Med Res Methodol 2019; in press.
69. Choudry FA, Weerackody RP, Timmis AD, Wragg A, Mathur A, Sporton S, et al. Importance of
primary percutaneous coronary intervention for reducing mortality in ST-elevation myocardial
infarction complicated by out-of-hospital cardiac arrest. Eur Heart J Acute Cardiovasc Care
2015;4:378–85. https://doi.org/10.1177/2048872614555990
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
70. Robinson AA, Jain A, Gentry M, McNamara RL. Left ventricular thrombi after STEMI in the primary
PCI era: a systematic review and meta-analysis. Int J Cardiol 2016;221:554–9. https://doi.org/
10.1016/j.ijcard.2016.07.069
71. Corpus RA, House JA, Marso SP, Grantham JA, Huber KC, Laster SB, et al. Multivessel percutaneous
coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J
2004;148:493–500. https://doi.org/10.1016/j.ahj.2004.03.051
72. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, et al. Prognostic value of
microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC
Cardiovasc Imaging 2014;7:930–9. https://doi.org/10.1016/j.jcmg.2014.05.010
73. NHS Health Research Authority. Confidentiality Advisory Group. 2018. URL: www.hra.nhs.uk/
about-the-hra/our-committees/section-251/ (accessed 16 January 2019).
74. National Joint Registry. Patient Consent. 2017. URL: www.njrcentre.org.uk/njrcentre/Healthcare
providers/Collectingdata/Patientconsent/tabid/101/Default.aspx (accessed 16 January 2019).
75. Inflammatory Bowel Disease (IBD) Registry. Consent and Patient Information Materials. 2018.
URL: http://ibdregistry.org.uk/consent-materials/ (accessed 16 January 2019).
76. Great Britain. National Health Service Act 2006. London: The Stationery Office; 2006.
77. NHS Digital. Obtaining-consent-for-patient-identifiable-and-or-sensitive-data-V2-050613/pdf/
obtaining_consent_for_patient_identifiable_and_or_sensitive_data_V2_050613.pdf (accessed
April 2018).
78. Ipsos Mori. Public Support for Research in the NHS. 2011. URL: www.ipsos-mori.com/research
publications/researcharchive/2811/Public-support-for-research-in-the-NHS.aspx (accessed
16 January 2019).
79. Campbell B, Thomson H, Slater J, Coward C, Wyatt K, Sweeney K. Extracting information from
hospital records: what patients think about consent. Qual Saf Health Care 2007;16:404–8.
https://doi.org/10.1136/qshc.2006.020313
80. Kass NE, Natowicz MR, Hull SC, Faden RR, Plantinga L, Gostin LO, Slutsman J. The use of medical
records in research: what do patients want? J Law Med Ethics 2003;31:429–33. https://doi.org/
10.1111/j.1748-720X.2003.tb00105.x
81. Xafis V. The acceptability of conducting data linkage research without obtaining consent:
lay people’s views and justifications. BMC Med Ethics 2015;16:79. https://doi.org/10.1186/
s12910-015-0070-4
82. Simon SR, Evans JS, Benjamin A, Delano D, Bates DW. Patients’ attitudes toward electronic health
information exchange: qualitative study. J Med Internet Res 2009;11:e30. https://doi.org/10.2196/
jmir.1164
83. NHS England. NHS England Sets Out the Next Steps of Public Awareness About Care.Data. 2013.
URL: www.england.nhs.uk/ourwork/tsd/care-data/ (accessed 16 January 2019).
84. Goldacre B. The NHS plan to share our medical data can save lives – but must be done right.
The Guardian, 21 February 2014. URL: www.theguardian.com/society/2014/feb/21/nhs-plan-
share-medical-data-save-lives (accessed 16 January 2019).
85. Williams H, Spencer K, Sanders C, Lund D, Whitley EA, Kaye J, Dixon WG. Dynamic consent:
a possible solution to improve patient confidence and trust in how electronic patient records are
used in medical research. JMIR Med Inform 2015;3:e3. https://doi.org/10.2196/medinform.3525
86. Laurie G, Ainsworth J, Cunningham J, Dobbs C, Jones KH, Kalra D, et al. On moving targets
and magic bullets: can the UK lead the way with responsible data linkage for health research?
Int J Med Inform 2015;84:933–40. https://doi.org/10.1016/j.ijmedinf.2015.08.011
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
92
87. HM Government, NHS, National Information Board. Personalised Health and Care 2020. 2014.
URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/384650/NIB_Report.pdf
(accessed 16 January 2019).
88. Justinia T. The UK’s National Programme for IT: why was it dismantled? Health Serv Manage Res
2017;30:2–9. https://doi.org/10.1177/0951484816662492
89. Gliklich RE, Dreyer NA, Leavy MB, editors. Chapter 15: Interfacing Registries With Electronic Health
Records. In Registries for Evaluating Patient Outcomes: A User’s Guide [Internet]. 3rd edition.
Rockville, MD: Agency for Healthcare Research and Quality (US); 2014.
90. Ludman PF. BCIS Audit Returns Adult Interventional Procedures Jan 2014 to Dec 2014. 2015.
URL: www.bcis.org.uk/wp-content/uploads/2017/01/BCIS-audit-2014.pdf (accessed 16 January 2019).
91. NHS England. Diagnostic Imaging Dataset. URL: www.england.nhs.uk/statistics/statistical-work-
areas/diagnostic-imaging-dataset/ (accessed 16 January 2019).
92. Royal College of Surgeons. URL: www.rcseng.ac.uk/search/#SearchTerm=pre-operative (accessed
February 2019).
93. Dastidar AG, Ahmed A, McAlindon E, Lawton C, Manghat N, Hamilton M, et al. Incremental
value of cardiovascular magnetic resonance imaging in patients surviving non-traumatic out-of-
hospital cardiac arrest: a tertiary UK centre experience. Heart 2014;100:A79–80. https://doi.org/
10.1136/heartjnl-2014-306118.134
94. Monney PA, Sekhri N, Burchell T, Knight C, Davies C, Deaner A, et al. Acute myocarditis
presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis.
Heart 2011;97:1312–18. https://doi.org/10.1136/hrt.2010.204818
95. Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. cardiac magnetic
resonance imaging for the diagnosis of left ventricular thrombus: a systematic review. Can J
Cardiol 2015;31:785–91. https://doi.org/10.1016/j.cjca.2015.01.011
96. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et al. Impact of
multivessel disease on reperfusion success and clinical outcomes in patients undergoing
primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J
2007;28:1709–16. https://doi.org/10.1093/eurheartj/ehm184
97. Ruggieri A, Piraino D, Dendramis G, Cortese B, Carella M, Buccheri D, et al. STEMI patients and
nonculprit lesions: to treat or not to treat? And when? A review of most recent literature.
Catheter Cardiovasc Interv 2015;87:1258–68 https://doi.org/10.1002/ccd.26236
98. El-Hayek GE, Gershlick AH, Hong MK, Casso Dominguez A, Banning A, Afshar AE, et al.
Meta-analysis of randomized controlled trials comparing multivessel versus culprit-only
revascularization for patients with ST-segment elevation myocardial infarction and multivessel
disease undergoing primary percutaneous coronary intervention. Am J Cardiol 2015;115:1481–6.
https://doi.org/10.1016/j.amjcard.2015.02.046
99. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA
guideline for the management of ST-elevation myocardial infarction: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol 2013;61:e78–140. https://doi.org/10.1016/j.jacc.2012.11.019
100. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC guidelines
for the management of acute myocardial infarction in patients presenting with ST-segment
elevation. Eur Heart J 2012;33:2569–619. https://doi.org/10.1093/eurheartj/ehs215
101. Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998.
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93
102. Kafka F. Metamorphosis, and other stories. Translated by Willa and Edwin Muir. London: Penguin
Modern Classics; no. 1572; 1961.
103. Emrich T, Emrich K, Abegunewardene N, Oberholzer K, Dueber C, Muenzel T, Kreitner KF.
Cardiac MR enables diagnosis in 90% of patients with acute chest pain, elevated biomarkers
and unobstructed coronary arteries. Br J Radiol 2015;88:20150025. https://doi.org/10.1259/
bjr.20150025
104. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. A Cost-effectiveness
Model Comparing Alternative Management Strategies for the Use of Glycoprotein IIbIIIa
Antagonists in Non-ST-Elevation Acute Coronary Syndrome. Report to the National Institute for
Clinical Excellence. London: National Institute of Health and Care Excellence; 2002.
105. Daniel M, Agewall S, Caidahl K, Collste O, Ekenbäck C, Frick M, et al. Effect of myocardial
infarction with nonobstructive coronary arteries on physical capacity and quality of life.
Am J Cardiol 2017;120:341–6. https://doi.org/10.1016/j.amjcard.2017.05.001
106. Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria
and guideline development. Semin Arthritis Rheum 2011;41:95–105. https://doi.org/10.1016/
j.semarthrit.2010.12.001
107. Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, Marteau T. Consensus
development methods, and their use in clinical guideline development. Health Technol Assess
1998;2(3).
108. Hutchings A, Raine R. A systematic review of factors affecting the judgments produced by
formal consensus development methods in health care. J Health Serv Res Policy 2006;11:172–9.
https://doi.org/10.1258/135581906777641659
109. Regulation (EU) 2016/679 of the European Parliament and of the Council. URL: https://eur-lex.europa.
eu/legal-content/EN/TXT/HTML/?uri=CELEX:32016R0679&from=EN (accessed January 2019).
110. European Commission. Data Protection. URL: https://ec.europa.eu/info/law/law-topic/
data-protection_en (accessed January 2019).
111. NHS Digital. Data Access Request Service (DARS). URL: https://digital.nhs.uk/services/data-access-
request-service-dars (accessed 16 January 2019).
112. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-dimensional
echocardiography in measuring left ventricular volumes and ejection fraction: a systematic
review and meta-analysis. J Am Coll Cardiol 2012;59:1799–808. https://doi.org/10.1016/
j.jacc.2012.01.037
113. Eitel I, Desch S, de Waha S, Fuernau G, Gutberlet M, Schuler G, Thiele H. Long-term prognostic
value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused
myocardial infarction. Heart 2011;97:2038–45. https://doi.org/10.1136/heartjnl-2011-300098
114. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H. Prognostic
significance and determinants of myocardial salvage assessed by cardiovascular magnetic
resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010;55:2470–9.
https://doi.org/10.1016/j.jacc.2010.01.049
115. Klug G, Mayr A, Schenk S, Esterhammer R, Schocke M, Nocker M, et al. Prognostic value at 5 years
of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic
resonance. J Cardiovasc Magn Reson 2012;14:46. https://doi.org/10.1186/1532-429X-14-46
116. Wong TC, Piehler K, Puntil KS, Moguillansky D, Meier CG, Lacomis JM, et al. Effectiveness of late
gadolinium enhancement to improve outcomes prediction in patients referred for cardiovascular
magnetic resonance after echocardiography. J Cardiovasc Magn Reson 2013;15:6. https://doi.org/
10.1186/1532-429X-15-6
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
117. Parsai C, O’Hanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular
magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012;14:54.
https://doi.org/10.1186/1532-429x-14-54
118. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in
clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012;5:370–7.
https://doi.org/10.1016/j.jcmg.2011.11.021
119. Artis NJ, Thomson J, Plein S, Greenwood JP. Percutaneous closure of postinfarction ventricular
septal defect: cardiac magnetic resonance-guided case selection and postprocedure evaluation.
Can J Cardiol 2011;27:869.e3–5. https://doi.org/10.1016/j.cjca.2011.01.018
120. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term clinical
course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
Circulation 2004;110:3760–5. https://doi.org/10.1161/01.CIR.0000150390.04704.B7
121. Joshi SB, Connelly KA, Jimenez-Juan L, Hansen M, Kirpalani A, Dorian P, et al. Potential clinical
impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for
cardioverter defibrillator implantation. J Cardiovasc Magn Reson 2012;14:69. https://doi.org/
10.1186/1532-429X-14-69
122. Alexandre J, Saloux E, Dugué AE, Lebon A, Lemaitre A, Roule V, et al. Scar extent evaluated by
late gadolinium enhancement CMR: a powerful predictor of long-term appropriate ICD therapy
in patients with coronary artery disease. J Cardiovasc Magn Reson 2013;15:12. https://doi.org/
10.1186/1532-429X-15-12
123. Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, et al. Cardiac resynchronization therapy
guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn
Reson 2011;13:29. https://doi.org/10.1186/1532-429x-13-29
124. Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac
resynchronization. J Am Coll Cardiol 2002;39:194–201. https://doi.org/10.1016/S0735-1097(01)
01747-8
125. Bilchick KC, Dimaano V, Wu KC, Helm RH, Weiss RG, Lima JA, et al. Cardiac magnetic resonance
assessment of dyssynchrony and myocardial scar predicts function class improvement following
cardiac resynchronization therapy. JACC Cardiovasc Imaging 2008;1:561–8. https://doi.org/
10.1016/j.jcmg.2008.04.013
126. Ellims AH, Pfluger H, Elsik M, Butler MJ, Hare JL, Taylor AJ. Utility of cardiac magnetic resonance
imaging, echocardiography and electrocardiography for the prediction of clinical response and
long-term survival following cardiac resynchronisation therapy. Int J Cardiovasc Imaging
2013;29:1303–11. https://doi.org/10.1007/s10554-013-0215-9
127. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic
response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J
2007;153:105–12. https://doi.org/10.1016/j.ahj.2006.10.015
128. White JA, Yee R, Yuan X, Krahn A, Skanes A, Parker M, et al. Delayed enhancement magnetic resonance
imaging predicts response to cardiac resynchronization therapy in patients with intraventricular
dyssynchrony. J Am Coll Cardiol 2006;48:1953–60. https://doi.org/10.1016/j.jacc.2006.07.046
129. Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M. Prognostic value of stress cardiac
magnetic resonance imaging in patients with known or suspected coronary artery disease:
a systematic review and meta-analysis. J Am Coll Cardiol 2013;62:826–38. https://doi.org/
10.1016/j.jacc.2013.03.080
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
95
130. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, et al. Cardiovascular
magnetic resonance and single-photon emission computed tomography for diagnosis of coronary
heart disease (CE-MARC): a prospective trial. Lancet 2012;379:453–60. https://doi.org/10.1016/
S0140-6736(11)61335-4
131. Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle K, et al. Superior diagnostic
performance of perfusion-cardiovascular magnetic resonance versus SPECT to detect coronary
artery disease: the secondary endpoints of the multicenter multivendor MR-IMPACT II (Magnetic
Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial).
J Cardiovasc Magn Reson 2012;14:61. https://doi.org/10.1186/1532-429X-14-61
132. Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, et al. Noninvasive diagnosis of
ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI:
comparison with dobutamine stress echocardiography. Circulation 1999;99:763–70. https://doi.org/
10.1161/01.CIR.99.6.763
133. Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction.
Heart 2012;98:1743–9. https://doi.org/10.1136/heartjnl-2012-301962
134. Weinsaft JW, Kim RJ, Ross M, Krauser D, Manoushagian S, LaBounty TM, et al. Contrast-enhanced
anatomic imaging as compared to contrast-enhanced tissue characterization for detection of
left ventricular thrombus. JACC Cardiovasc Imaging 2009;2:969–79. https://doi.org/10.1016/
j.jcmg.2009.03.017
135. Srichai MB, Junor C, Rodriguez LL, Stillman AE, Grimm RA, Lieber ML, et al. Clinical, imaging, and
pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced
magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography
with surgical or pathological validation. Am Heart J 2006;152:75–84. https://doi.org/10.1016/
j.ahj.2005.08.021
136. Wong DT, Leung MC, Das R, Liew GY, Williams K, Dundon BK, et al. Diagnostic accuracy of
adenosine stress cardiovascular magnetic resonance following acute ST-segment elevation myocardial
infarction post primary angioplasty. J Cardiovasc Magn Reson 2011;13:62. https://doi.org/10.1186/
1532-429X-13-62
137. Doesch C, Seeger A, Doering J, Herdeg C, Burgstahler C, Claussen CD, et al. Risk stratification
by adenosine stress cardiac magnetic resonance in patients with coronary artery stenoses of
intermediate angiographic severity. JACC Cardiovasc Imaging 2009;2:424–33. https://doi.org/
10.1016/j.jcmg.2008.11.017
138. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, et al. ACCF/ACR/AHA/
NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report
of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
Circulation 2010;121:2462–508. https://doi.org/10.1161/CIR.0b013e3181d44a8f
139. Hoffmann U, Globits S, Schima W, Loewe C, Puig S, Oberhuber G, Frank H. Usefulness of
magnetic resonance imaging of cardiac and paracardiac masses. Am J Cardiol 2003;92:890–5.
https://doi.org/10.1016/S0002-9149(03)00911-1
140. Chan PG, Smith MP, Hauser TH, Yeon SB, Appelbaum E, Rofsky NM, Manning WJ. Noncardiac
pathology on clinical cardiac magnetic resonance imaging. JACC Cardiovasc Imaging
2009;2:980–6. https://doi.org/10.1016/j.jcmg.2009.04.014
141. McKenna DA, Laxpati M, Colletti PM. The prevalence of incidental findings at cardiac MRI.
Open Cardiovasc Med J 2008;2:20–5. https://doi.org/10.2174/1874192400802010020
142. Wyttenbach R, Médioni N, Santini P, Vock P, Szucs-Farkas Z. Extracardiac findings detected by
cardiac magnetic resonance imaging. Eur Radiol 2012;22:1295–302. https://doi.org/10.1007/
s00330-011-2369-y
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Appendix 1 Participant consent form
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
97

Appendix 2 Office of Population Censuses and
Surveys and International Classification of Diseases,
Tenth Edition, codes list
OPCS procedure codes
CMR
U10.3 Cardiac magnetic resonance imaging
PCI
K49 Transluminal balloon angioplasty of coronary artery
K50 Other therapeutic transluminal operations on coronary artery
K75 Percutaneous transluminal balloon angioplasty and insertion of stent into coronary artery
CABG
K40 Saphenous vein graft replacement of coronary artery
K41 Other autograft replacement of coronary artery
K42 Allograft replacement of coronary artery
K43 Prosthetic replacement of coronary artery
K44 Other replacement of coronary artery
K45 Connection of thoracic artery to coronary artery
K46 Other bypass of coronary artery
Angiography, no PCI
K63.3 Angiocardiography of left side of heart NEC
K63.5 Coronary arteriography using single catheter
K63.6 Coronary arteriography NEC
PET
U10.4 Myocardial positron emission tomography
U21.3 Positron emission tomography NEC
U36.2 Positron emission tomography with computed tomography NEC
ECHO
K58.5 Transluminal intracardiac echocardiography
U20.1 Transthoracic echocardiography
U20.2 Transoesophageal echocardiography
U20.3 Intravascular echocardiography
U20.4 Epicardial echocardiography
U20.5 Stress echocardiography
IVUS
K51.2 Intravascular ultrasound of coronary artery
L726 Intravascular ultrasound of artery NEC
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OPCS procedure codes
Pressure wire
K63.4- K63.6 AND Coronary arteriography
K51.8 AND Other specified diagnostic transluminal operations on coronary artery
Y44.2 AND Monitoring of pressure in organ NOC
Y53.- Approach to organ under image control
Radionuclide angiocardiography
U10.5 Radionuclide angiocardiography
Computed tomography angiography
U10.2 Cardiac computed tomography angiography
Single photon emission computed tomography
U21.4 Single photon emission computed tomography NEC
Implantation of ICD
K59 Cardioverter defibrillator introduced through the vein
K72 Other cardioverter defibrillator
Implantation of CRT
K60.7 Implantation of intravenous biventricular cardiac pacemaker system
K61.7 Implantation of biventricular cardiac pacemaker system
K59.6 Implantation of cardioverter defibrillator using three electrode leads
ICD-10 diagnosis codes
OHCA
I46 Cardiac arrest
LV thrombus
I23.6 Thrombosis of atrium, auricular appendage and ventricle as current complications following
acute myocardial infarction
STEMI
I21.0 Acute transmural myocardial infarction of anterior wall
I21.1 Acute transmural myocardial infarction of inferior wall
I21.2 Acute transmural myocardial infarction of other sites
I21.3 Acute transmural myocardial infarction of unspecified site
Takotsubo cardiomyopathy
I42.8 AND Other cardiomyopathies
F43.8 Other reactions to severe stress
Myocarditis
I51.4 Myocarditis, unspecified
Pericarditis
I30 Acute pericarditis
I31.0 Chronic adhesive pericarditis
I31.1 Chronic constrictive pericarditis
I31.9 Disease of pericardium, unspecified
I32.0 Pericarditis in bacterial diseases classified elsewhere
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ICD-10 diagnosis codes
I32.1 Pericarditis in other infectious and parasitic diseases classified elsewhere
I32.8 Pericarditis in other diseases classified elsewhere
I01.0 Acute rheumatic pericarditis
I02.0 Rheumatic chorea with heart involvement
I09.2 Chronic rheumatic pericarditis
Endocarditis
I33.9 Acute endocarditis, unspecified
Coronary spasm
I20.1 Angina pectoris with documented spasm
MI
I21 Acute myocardial infarction
Stroke
I64 Stroke, not specified as haemorrhage or infarction
CRT, cardiac resynchronisation therapy; NEC, not elsewhere classified; NOC, not otherwise classified.
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Appendix 3 Literature search
MEDLINE (via OvidSP)
Date range searched: 1950 to 16 January 2014.
Date searched: 16 January 2014.
Search strategy
1. exp Myocardial Infarction/ (142,973)
2. myocardial infarct$.tw. (134,547)
3. heart attack$.tw. (3601)
4. MI.tw. (25,881)
5. ami.tw. (12,166)
6. stemi.tw. (3663)
7. heart infarct$.tw. (705)
8. Acute Coronary Syndrome/ (6784)
9. acute coronary syndrome$.tw. (15,521)
10. ACS.tw. (9320)
11. or/1-10 (210,783)
12. exp angioplasty/ (53,568)
13. angioplasty.tw. (34,003)
14. percutaneous coronary intervention$.tw. (14,406)
15. exp Percutaneous Coronary Intervention/ (34,668)
16. PCI.tw. (11,157)
17. PPCI.tw. (366)
18. exp Stents/ (50,784)
19. stent$.tw. (56,427)
20. Myocardial Revascularization/ (9079)
21. revasculari$.tw. (37,853)
22. reperfused.tw. (5688)
23. reperfusion.tw. (55,775)
24. or/12-23 (191,056)
25. exp Magnetic Resonance Imaging/ (295,774)
26. Magnetic resonance imag$.tw. (122,420)
27. Cardiovascular magnetic resonance.tw. (1765)
28. cardiac magnetic resonance.tw. (3179)
29. MRI.tw. (121,901)
30. CMR.tw. (3035)
31. or/25-30 (344,849)
32. 24 and 31 (5713)
33. 11 and 32 (1318)
34. exp animals/ not humans/ (3,863,199)
35. 33 not 34 (1051)
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EMBASE
Date range searched: 1980 to 16 January 2014.
Date searched: 16 January 2014.
Search strategy
1. exp heart infarction/ (261,299)
2. myocardial infarct$.tw. (185,732)
3. heart attack$.tw. (4991)
4. MI.tw. (45,694)
5. ami.tw. (19,697)
6. stemi.tw. (10,463)
7. heart infarct$.tw. (1450)
8. exp Acute Coronary Syndrome/ (26,244)
9. acute coronary syndrome$.tw. (28,004)
10. ACS.tw. (17,708)
11. or/1-10 (337,561)
12. exp angioplasty/ (67,762)
13. angioplasty.tw. (47,179)
14. percutaneous coronary intervention$.tw. (27,203)
15. exp Percutaneous Coronary Intervention/ (59,160)
16. PCI.tw. (26,664)
17. PPCI.tw. (1281)
18. Stent/ (64,591)
19. exp cardiovascular stent/ (34,380)
20. stent$.tw. (94,492)
21. heart muscle revascularization/ (21,848)
22. revasculari$.tw. (56,445)
23. reperfused.tw. (7304)
24. reperfusion.tw. (77,453)
25. or/12-24 (298,341)
26. exp nuclear magnetic resonance imaging/ (524,106)
27. Magnetic resonance imag$.tw. (164,672)
28. Cardiovascular magnetic resonance.tw. (3414)
29. cardiac magnetic resonance.tw. (6341)
30. MRI.tw. (203,793)
31. CMR.tw. (7673)
32. or/26-31 (563,445)
33. 25 and 32 (13,408)
34. 11 and 33 (3451)
35. (exp animal/ or nonhuman/) not exp humans/ (5,173,875)
36. 34 not 35 (3048)
37. limit 36 to embase (2864)
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The Cochrane Library
Date range searched: 1950 to 16 January 2014.
Date searched: 16 January 2014.
Search strategy
#1 MeSH descriptor: [Myocardial Infarction] explode all trees
#2 MeSH descriptor: [Acute Coronary Syndrome] explode all trees
#3 myocardial next infarct*
#4 heart next attack*
#5 MI
#6 AMI
#7 STEMI
#8 heart next infarct*
#9 ‘acute coronary syndrome*’
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Angioplasty] explode all trees
#12 MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees
#13 MeSH descriptor: [Stents] explode all trees
#14 MeSH descriptor: [Myocardial Revascularization] this term only
#15 angioplasty
#16 ‘percutaneous coronary intervention*’
#17 PCI or PPCI
#18 stent*
#19 revasculari*
#20 reperfused
#21 reperfusion
#22 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#24 ‘Magnetic resonance imag*’
#25 ‘Cardiovascular magnetic resonance’
#26 ‘cardiac magnetic resonance’
#27 MRI or CMR
#28 #23 or #24 or #25 or #26 or #27
#29 #11 and #22 and #28
Web of Science
Date range searched: 1950 to 16 January 2014.
Date searched: 16 January 2014.
Search strategy
# 4 1,351 #3 AND #2 AND #1
# 3 218,389 TOPIC: (Angioplasty or “percutaneous coronary intervention*” or PCI or PPCI or stent* or
revasulari* or reperfused or reperfusion)
# 2 257,465 TOPIC: (“Magnetic Resonance Imag*” or “Cardiovascular magnetic resonance” or “ cardiac
magnetic resonance” or MRI or CMR)
# 1 273,481 TOPIC: (“myocardial infarct*” or “heart attack*” or “heart infarct*” or “acute coronary
syndrome*” or MI or AMI or STEMI or ACS)
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Bioscience Information Service (BIOSIS)
Date range searched: 1950 to 16 January 2014.
Date searched: 16 January 2014.
Search strategy
# 6 873 #5 AND #4
# 5 TAXONOMIC DATA: (human not (animal* not human))
# 4 #3 AND #2 AND #1
# 3 TOPIC: (Angioplasty or “percutaneous coronary intervention*” or PCI or PPCI or stent* or revasulari*
or reperfused or reperfusion)
# 2 TOPIC: (“Magnetic Resonance Imag*” or “Cardiovascular magnetic resonance” or “ cardiac magnetic
resonance” or MRI or CMR)
# 1 TOPIC: (“myocardial infarct*” or “heart attack*” or “heart infarct*” or “acute coronary syndrome*”
or MI or AMI or STEMI or ACS)
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Appendix 4 First survey (statements, supporting
paragraphs and references)
Benefit to patients and the NHS of cardiac magnetic resonance imaging
after primary percutaneous coronary intervention pathway activation
Thank you for agreeing to complete this survey. We expect the survey to take about 20 minutes of your
time. You are asked to read and rate 12 statements relating to the potential impact of CMR in changing
the management of patients in a clinically important way. The patient population under consideration
includes all patients who activate the PPCI pathway. Please rate your agreement with each statement on
the scale provided. Each statement has a supporting paragraph that provides background information and
links to full-text references. We believe that we have used the best available evidence but we are aware
that the evidence is of variable quality.
In order to progress through the survey, please use the following navigation buttons:
Click the Next button to go to the next page.
Click the Previous button to return to the previous page.
Click the Number buttons in the text to access the full references.
Click the Submit button to submit the survey at the end.
Statement 1. Compared with echocardiography, cardiovascular magnetic resonance
after primary percutaneous coronary a intervention allows patients with cardiovascular
magnetic resonance markers that indicate a poor prognosis (e.g. impaired left ventricular
function, large infarct size, microvascular obstruction) to be followed up more
appropriately and undergo more aggressive medical therapy for secondary prevention
Accurate assessment of infarct characteristics is important for risk stratification after PPCI. CMR can
quantify in a single scan all cardiac markers relevant to PPCI outcomes, with high reproducibility and
accuracy. CMR has high spatial and temporal resolution and is superior to ECHO for measuring LV volumes
and EF.112 Additionally, CMR markers, such as infarct size, MVO and myocardial salvage, have been shown
to have long-term prognostic value.113–115 LGE CMR has added prognostic value over ECHO.116
Statement 2. Compared with echocardiography, cardiovascular magnetic resonance
after primary percutaneous coronary intervention allows patients with cardiovascular
magnetic resonance markers that indicate a good prognosis (e.g. normal left ventricular
function, high myocardial salvage, no microvascular obstruction, no residual ischaemia)
to be discharged earlier and followed up less frequently
Cardiovascular magnetic resonance measures several markers (i.e. infarct size, myocardial salvage index,
MVO, myocardial oedema and haemorrhage) that cannot be measured by ECHO. These markers can be
used to predict cardiac remodelling and prognosis after MI,113–115 determine the optimal therapeutic
pathway for each patient and prevent over- and under-treatment.
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Statement 3. Compared with echocardiography, cardiovascular magnetic resonance
better identifies the cause of out-of-hospital cardiac arrest (e.g. large myocardial
infarction, arrhythmogenic right ventricular cardiomyopathy, aberrant coronary
arteries, hypertrophic cardiomyopathy) to optimise further treatment for the patient
(e.g. defibrillator for primary arrhythmia or percutaneous coronary intervention) or
family members
Out-of-hospital cardiac arrest affects about 60,000 people in the UK each year. Currently, hospital survival
is about 32%. Early identification of the cause is essential to improve survival. Causes of OHCA include
MI (40–90%) and inherited cardiomyopathies, such as arrhythmogenic right ventricular cardiomyopathy
(ARVC) and hypertrophic cardiomyopathy (HCM). Unlike ECHO, CMR allows in vivo tissue characterisation,
which differentiates scarring resulting from MI from other causes of focal fibrosis (e.g. observed in
non-ischaemic cardiomyopathies such as ARVC and HCM).117 LGE on CMR can predict serious cardiac
complications in patients with HCM (e.g. all-cause death, cardiac death and death from heart failure),118
and identifies patients who may need more aggressive medical and device therapy (e.g. renin-aldosterone
system inhibition for prevention of heart failure or ICD placement for primary prevention of sudden
cardiac death).
Statement 4. Cardiovascular magnetic resonance after primary percutaneous coronary
intervention identifies patients at high risk of having ventricular septal defect or
impending cardiac rupture, who may require ventricular patch or other urgent cardiac
surgery, and guides the optimal management of these patients
Ventricular septal defect (VSD) and LV free wall rupture are rare complications of MI, occurring in < 1% of
PPCI patients, usually within 1 week of the infarct. Mortality ranges between 50% and 80%. Diagnosis
can be difficult to make and usually requires multimodality imaging (e.g. ECHO, ventriculography, CT,
CMR) before surgical repair. Because of its high spatial resolution, CMR can be used to clarify the detailed
structure of these lesions. CMR accurately identifies the location, size and tissue margins of VSD and is
useful for detecting apical defects, which are not easily identified by ECHO. CMR measurements may also
be used to determine the size of the ventricular patch required to close the VSD, which avoids the inflation
of a sizing balloon in friable infarcted tissue.119 These features, together with other CMR markers of
damage (e.g. infarct size, MVO, LV dysfunction) are useful for guiding optimal management of patients
with post-infarct VSD. Similarly, CMR can differentiate between the different types of impending free wall
rupture (i.e. acute, subacute and chronic), which may be helpful in planning surgical management.119
Statement 5. In patients with a ‘normal’ (unobstructed) coronary angiogram,
cardiovascular magnetic resonance can differentiate patients who have had a myocardial
infarction with spontaneous reperfusion or distal embolisation from patients with a
non-ischaemic diagnosis (e.g. myocarditis, Takotsubo cardiomyopathy, aortic dissection),
resulting in a patient treatment plan appropriate for the definitive diagnosis
The incidence of unobstructed coronary angiogram in patients who activate the PPCI pathway is
between 5% and 12%. In these patients, the lack of an accurate diagnosis may result in inappropriate
or unnecessary treatment and/or follow-up and a poorer prognosis.19 CMR facilitates differential diagnosis
in the context of an unobstructed coronary angiogram, providing a definitive diagnosis (e.g. myocardial
infarction, myocarditis, Takotsubo cardiomyopathy) in 65–90% of these patients.20,23 In patients with
myocarditis, LGE on CMR may predict long-term adverse outcomes.26 In the context of MI without an
angiographic lesion, CMR can locate the culprit infarct-related artery in patients with spontaneous
reperfusion or with distal embolisation.
Statement 6. Compared with echocardiography, cardiovascular magnetic resonance
after primary percutaneous coronary intervention better identifies patients at high risk
of sudden cardiac death who would benefit most from an implantable cardiac device
(e.g. implantable cardiac defibrillator, cardiac resynchronisation therapy)
About 6% of heart attack patients subsequently die suddenly from a presumed cardiac cause. Current
guidelines recommend the use of ICD to prevent sudden cardiac death in patients who have a low LV EF
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
after a heart attack. EF is used in clinical practice to make decisions about ICD implantation, but it has a
low predictive value and many patients with an ICD will never benefit from it.120 EF is most commonly
measured by ECHO, but CMR is now considered the gold standard for EF measurement because it is more
reproducible than ECHO.112 CMR has been shown to be better than ECHO for selecting patients for ICD
implantation when strict EF thresholds are used to guide implantation.121 The extent of myocardial scar
characterised by LGE CMR may also be used to predict whether or not ICD implantation is appropriate in
this patient group.122 Furthermore, LGE CMR can guide placement of the LV lead away from scarred
myocardium, which results in a better clinical outcome after cardiac resynchronisation therapy (CRT).123
Statement 7. Compared with echocardiography, cardiovascular magnetic resonance
after primary percutaneous coronary intervention better identifies patients who would
not benefit from cardiac resynchronisation therapy
Cardiac resynchronisation therapy (or biventricular pacing) uses a specialised pacemaker to resynchronise
the beating of the two ventricles by pacing both simultaneously, which improves the contraction of the left
ventricle and the overall efficiency of the heart. It is used in patients with systolic ventricular dysfunction
and heart failure. However, about 30% of patients who meet the inclusion criteria for CRT do not respond
to it.124 CMR assessment of mechanical dyssynchrony and myocardial scar provides additional value over
ECHO for identifying responsive patients.125,126 Myocardial scar is an important feature of non-response to
CRT127,128 and LGE CMR accurately differentiates between transmural, mid-myocardial, epicardial and
subendocardial scar.
Statement 8. Compared with stress echocardiography or single-photon emission
computed tomography, cardiovascular magnetic resonance after primary percutaneous
coronary intervention in patients with multivessel disease better assesses ischaemia and
viability of the myocardium to optimise the revascularisation strategy for the patient
and avoid additional diagnostic tests
Between 40% and 65% of the patients who activate the PPCI pathway have multivessel disease.
Adequate assessment of residual ischaemia in non-culprit arteries post PPCI is important for effective
management because this patient group has an adverse prognosis. Various techniques are currently used
to assess the need for additional revascularisation, including stress ECHO, SPECT and stress-perfusion CMR.
Stress CMR has excellent prognostic value129 and better diagnostic accuracy than SPECT130,131 or stress
ECHO132 for detecting angiographically significant coronary artery disease.
Statement 9. Compared with echocardiography, cardiovascular magnetic resonance
after primary percutaneous coronary intervention better identifies patients with left
ventricular thrombus for treatment with anticoagulation therapy
Left ventricular thrombus is a serious complication of acute MI. It increases the risk of thromboembolic
events, particularly stroke. LV thrombus develops in up to 10% of patients with anterior wall infarctions
after PPCI. Although ECHO is most commonly used to detect LV thrombus and to assess its shape and
size, between 10% and 46% of echocardiograms are inconclusive.133 LGE CMR is considered the gold
standard for detecting LV thrombus, because it detects thrombus based on tissue characteristics rather
than anatomic appearance. Fewer thrombi are detected by contrast-ECHO than by LGE CMR.134 CMR has
a higher sensitivity (88%) than contrast (61%) and non-contrast (< 33%) ECHO.134,135
Statement 10. Compared with other imaging modalities, in patients with multivessel
disease, cardiovascular magnetic resonance after primary percutaneous coronary
intervention better identifies the artery that caused the myocardial infarction and
guides the subsequent treatment plan in relation to additional revascularisation
(percutaneous coronary intervention or coronary artery bypass graft surgery)
In patients with multivessel disease presenting with acute MI, the culprit artery is not always easy to identify
as more than one artery could be responsible. CMR has higher spatial resolution than SPECT, allowing easy
identification of the infarct-related artery and non-culprit territory stenosis in PPCI patients,136 and, hence,
appropriate risk-stratification of patients with multivessel disease for planning their future treatment.137
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Statement 11. Compared with echocardiography, cardiovascular magnetic resonance
after primary percutaneous coronary intervention better identifies incidental cardiac
findings that may need further investigation and treatment
Compared with ECHO, CMR provides versatile imaging planes, superior tissue contrast and advanced
tissue characterisation, allowing a comprehensive assessment of cardiac anatomy, function and flow, and
imaging of the great vessels (including venous return), the pericardium and suspected cardiac tumours.138
As such, CMR can identify congenital coronary anomalies, cardiac masses, coronary artery aneurysms,
valvular heart disease, thoracic aortic disease, and so forth. CMR can adequately differentiate benign
from malignant tumours in the heart.139
Statement 12. Compared with echocardiography, cardiovascular magnetic resonance
after primary percutaneous coronary intervention identifies significant incidental
non-cardiac findings (e.g. oesophageal and lung tumours, pulmonary embolus, aortic
aneurysm) that may need further investigation and treatment
Unlike ECHO, which provides limited imaging of mediastinal and extra-cardiac structures, CMR images a
substantial part of the thorax and abdomen in the field of view, which may potentially contain non-cardiac
abnormalities. The prevalence of non-cardiac findings on CMR is up to 80% (with up to 30% of these
representing potentially significant findings), depending on the characteristics of the population examined.140–142
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Appendix 5 Cardiovascular magnetic resonance
questionnaire for cardiologists
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Appendix 6 Recorded causes of death for deaths
within 1 year of index admission
Cause of death n (%)
Acute MI, unspecified 14 (26)
Acute or chronic renal failure 1 (2)
Aortic (valve) stenosis 1 (2)
Atrial fibrillation and flutter 1 (2)
Bronchopneumonia 1 (2)
Cardiogenic shock 1 (2)
Chronic ischaemic heart disease, unspecified 5 (9)
Community-acquired pneumonia 1 (2)
Congestive cardiac failure 2 (4)
Heart failure 1 (2)
Intentional self-harm by hanging, strangulation and suffocation 1 (2)
Intentional self-harm by other specified means 1 (2)
Intercerebral bleed 1 (2)
Ischaemic bowel 1 (2)
Ischaemic cardiomyopathy 2 (4)
Ischaemic colitis 1 (2)
Ischaemic heart disease 2 (4)
Malignant neoplasm of bronchus and lung 3 (6)
Malignant neoplasm of other and unspecified parts of mouth 1 (2)
Metastatic adenocarcinoma of lung 1 (2)
Multiple myeloma 1 (2)
MI 4 (7)
Other interstitial pulmonary diseases with fibrosis 1 (2)
Pulmonary embolism 1 (2)
Pulmonary embolism without mention of acute cor pulmonale 1 (2)
Severe LV failure 1 (2)
Small-cell lung cancer 1 (2)
Squamous cell carcinoma of the lung 1 (2)
Urinary tract infection, site not specified 1 (2)
Total 54
Cause of death was unavailable for one participant.
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113

Appendix 7 Supporting tables for consensus
process
TABLE 31 Original statements generated for consensus process
Number Statement
Coronary artery disease positive
1 Multivessel disease – CMR assessment of ischaemia and viability to guide further PCI either as inpatient or
outpatient
2 Multivessel disease – CMR assessment of ischaemia and viability to guide CABG
3 PPCI with discordance between ECG and angiographic findings? New/old infarct? Territory of infarct? Was the
culprit artery successfully treated?
4 Chronic multivessel disease with no clear culprit lesion? Clarify diagnosis/guide further therapy
5 Assess the significance of bystander coronary artery disease (which will influence the need of further elective
PCI to other vessels)
6 CMR can differentiate between acute and chronic MI (important when the cause of cardiac dysfunction is
unclear despite angiography or ultrasound)
7 In patients with multivessel disease in whom the culprit artery cannot be identified, CMR can identify the
infarct-related artery and guide (1) targeted PCI and (2) viability of CABG
8 Assessment of LV function to guide AICD implantation (primary prevention)
9 CMR is more effective than ECHO at identifying STEMI patients who are at risk of sudden arrhythmic death
(consequence: early implantation of a cardioverter defibrillator?)
10 OHCA with ambiguous anatomy? Primary arrhythmia or acute MI – defibrillation or revascularisation?
11 Assessment of LV thrombus to guide possible anticoagulation
12 CMR can accurately diagnose LV thrombus (unlike ECHO) (consequence: possible anti-coagulation therapy with
vitamin K antagonist?)
13 Assessment of pericardial effusion
14 CMR markers: MVO, oedema, scar size, haemorrhage, etc. Good prognostic indicators but no/little current
evidence that they are used to change patient management at the moment
15 Impact on the length of stay (if CMR does not show very poor EF, very large area of MVO, impending cardiac
rupture)
16 CMR can accurately diagnose LV thrombus (consequence: possible anti-coagulation therapy with vitamin K
antagonist?)
17 CMR can identify impending cardiac rupture (consequence: cardiac operation or ventricular patch if needed)
18 More aggressive medical treatment in those with large infarcts and large MVO?
19 Closer medical follow-ups in those with large infarcts and large MVO?
20 Potential to change/optimise/maximise pharmacological treatment
21 Assessment of LV function to guide more aggressive medical therapy/secondary prevention
22 CMR has prognostic importance – follow-up patients in clinic more or less often depending on how good or
bad the CMR is. Secondary prevention needed?
23 Identify complications of acute MI (e.g. impending cardiac rupture and act on it, e.g. surgery)
continued
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115
TABLE 31 Original statements generated for consensus process (continued )
Number Statement
Coronary artery disease negative
24 In STEMI patients with atypical angiographic characteristics (in whom the culprit artery cannot be identified) CMR
may identify the MI location and infarct-related artery (consequence: revascularisation of appropriate artery)
25 PPCI with ‘normal’ coronaries – is it infarct with spontaneous reperfusion?
26 PPCI with ‘normal’ coronaries – is it myopericarditis?
27 PPCI with ‘normal’ coronaries – is it cardiomyopathy (dilated, hypertrophic, Takotsubo, etc.)?
28 In patients with chest pain, elevated troponins and unobstructed coronary arteries, CMR can rule out any significant
pathology (e.g. patients with spontaneous reperfusion) (consequence: early discharge? Any follow-up for these
patients?)
29 Equivocal ST elevation and angiographic findings? Alternative diagnosis e.g. pulmonary emobolus, aortic dissection
30 PPCI with ‘normal’ coronaries – impact on the length of stay (early discharge)
31 PPCI with ‘normal’ coronaries – impact on medical treatment and no secondary prevention medications
32 PPCI with ‘normal’ coronaries – impact on the patients’ quality of life (of having this diagnosis as opposed to
the diagnosis of a MI) (impact on insurance, mortgage, etc.)
33 Impact on the length of hospital stay (shorter bed stay if CMR does not show major abnormalities)
Incidental findings
34 Assessment of other incidental valvular heart disease findings
35 Assessment of mitral regurgitation – is it ischaemic, dilated annulus, native valve disease?
36 Incidental findings on CMR (e.g. valve disease, congenital anomalies) that will be subsequently treated/monitored?
37 Potential for CMR to be a ‘one-stop shop’ for imaging procedures
AICD, automated implantable cardioverter defibrillator; ECG, electrocardiogram.
TABLE 32 Examples of draft statements and reworded statements
Subgroup Draft statements Reworded statements
Unobstructed
arteries on
angiogram
PPCI with ‘normal’ coronaries – is it infarct with
spontaneous reperfusion?
In patients with a normal coronary angiogram,
CMR can identify a heart attack with spontaneous
reperfusion or distal embolisation for treatment
with medical therapy for secondary preventionEquivocal ST elevation and angiographic findings?
Alternative diagnosis, for example pulmonary
embolus, aortic dissection?
PPCI with ‘normal’ coronaries – is it cardiomyopathy
(e.g. dilated, hypertrophic, Takotsubo)
In patients with a normal coronary angiogram,
CMR can provide a new diagnosis (e.g. myocarditis,
Takotsubo cardiomyopathy, aortic dissection)
resulting in a different patient treatment planPPCI with ‘normal’ coronaries – is it myopericarditis?
Multivessel
disease
Multivessel disease – CMR assessment of ischaemia
and viability to guide further PCI either as inpatient
or outpatient
In patients with multivessel disease, CMR after PPCI
assesses ischaemia and viability of the heart tissue
to optimise the treatment for the patient
Assess the significance of bystander coronary artery
disease (which will influence the need of further
elective PCI to other vessels)
In patients with multivessel disease, CMR after
angiography identifies the artery that caused the
heart attack, and guides the appropriate therapy
(PCI or CABG surgery)
Chronic multivessel disease with no clear culprit
lesion? Clarify diagnosis/guide further therapy
LV thrombus
after MI
Assessment of LV thrombus to guide possible
anticoagulation
CMR after PPCI clearly identifies patients with LV
thrombus for treatment with anticoagulation
therapy
CMR can accurately diagnose LV thrombus
(unlike ECHO)
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TABLE 33 Examples of supporting paragraphs
Statement 5 The incidence of normal coronary angiogram in patients who activate the PPCI pathway is between 5%
and 12%. In these patients, the lack of an accurate diagnosis may result in inappropriate or unnecessary
treatment and/or follow-up and poorer prognosis.19 CMR facilitates differential diagnosis in the context
of a normal coronary angiogram, providing a definitive diagnosis (e.g. MI, myocarditis, Takotsubo
cardiomyopathy) in 65–90% of these patients.20,23 In patients with myocarditis, LGE on CMR may predict
long-term adverse outcomes.20,23 In the context of MI without an angiographic lesion, CMR can locate the
culprit infarct-related artery in patients with spontaneous reperfusion or with distal embolisation
Statement 8 Between 40% and 65% of the patients who activate the PPCI pathway have multivessel disease. Adequate
assessment of residual ischaemia in non-culprit arteries post PPCI is important for effective management
because this patient group has an adverse prognosis. Various techniques are currently used to assess the
need for additional revascularisation, including stress ECHO, SPECT and stress-perfusion CMR. Stress CMR
has excellent prognostic value129 and better diagnostic accuracy than SPECT130,131 or stress ECHO132 for
detecting angiographically significant coronary artery disease
Statement 9 LV thrombus is a serious complication of acute MI. It increases risk of thromboembolic events, particularly
stroke. LV thrombus develops in up to 10% of patients with anterior wall infarctions after PPCI. Although
ECHO is most commonly used to detect LV thrombus and to assess its shape and size, between 10% and
46% of echocardiograms are inconclusive.133 LGE CMR is considered the gold standard for detecting LV
thrombus, because it detects thrombus based on tissue characteristics rather than anatomic appearance.
Fewer thrombi are detected by contrast-ECHO than by LGE CMR.134 CMR has a higher sensitivity (88%)
than contrast (61%) and non-contrast (< 33%) ECHO134,135
TABLE 34 Examples of respondents’ comments for the three statements in consensus (3, 5 and 9) and the three
statements not in consensus (1, 2 and 8)4
Statement 3 Importance of management change
CMR differentiates causes of cardiomyopathy (IHD vs. not). We use it regularly in patients post OHCA
I have seen many cases of OHCA in which the use of CMR has made a diagnosis or significantly
altered the diagnosis. Diagnostic refinement in the light of CMR findings also frequently results in
changes in drug or device treatment, and often highlights the need for family screening. The
improved anatomical, morphological and tissue characterisation that CMR allows drives the benefit
of CMR over ECHO and allows better identification of the cause of out-of-hospital arrest
Quality of supporting evidence
I don’t think it has been proved that clinical outcomes are better with a CMR strategy
CMR is unlikely to alter the immediate management of these patients. However, if the cause is
unclear after ECHO and enzymes, then CMR is helpful but I am not aware of any studies specifically
assessing this
Statement 5 Importance of management change
Agree. Unobstructed coronaries with elevated troponin need diagnostic resolution and CMR is helpful
These patients are difficult to manage and often given incorrect diagnosis and especially different
theories by different doctors during same admission
I have direct experience of the benefit of CMR in this area. Therefore, I strongly agree with statement 5.
CMR with LGE is especially useful and I have seen many instances when CMR after acute MI with
‘normal’ coronary arteries has helped diagnosis, differentiating between distal vessel occlusion, LV clot,
myocarditis and Takotsubo cardiomyopathy. The results of CMR in this patient group have also directly
affected my management of this group of patients including drugs used and length of stay
MRI is clinically useful in this situation in my experience and occasionally makes a very useful change
to management
Quality of supporting evidence
Unfortunately, again no RCT to indicate benefit of CMR
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TABLE 34 Examples of respondents’ comments for the three statements in consensus (3, 5 and 9) and the three
statements not in consensus (1, 2 and 8)4 (continued )
Statement 9 Importance of management change
Thrombus is poorly assessed by ECHO with many inconclusive reports in my experience locally
I strongly agree with this statement as I have experience of many patients in which ECHO
demonstrated no LV thrombus that was subsequently found on CMR. This personal experience
correlates with the studies quoted in the text of the statement
Quality of supporting evidence
This statement is true but whether this leads to better patient outcomes is uncertain
Statement 1 Importance of management change
All patients who have suffered an acute MI and subsequently undergone PPCI should receive
aggressive secondary prevention. Thus, even though CMR can help refine prognosis, I do not feel
that this additional information would lead to any significant changes to prescribing for secondary
prevention. Enhanced confidence in CMR findings (compared to ECHO) and refinement of prognosis
with respect to infarct size, MVO and MSI may help physicians discharge/follow up patients more
appropriately
All patients should have aggressive secondary prevention
Quality of supporting evidence
Whilst I agree with the evidence presented, there is no evidence to support the assertion the CMR
findings lead to better outcomes for patients, as there have been no trials assessing this
I don’t think it has been proved that CMR compared with ECHO leads to improved patient outcomes
While MVO and MSI are markers of prognosis, LV systolic function remains the most important
prognostic factor, which can be assessed with ECHO. We need interventions based on CMR
parameters which improve prognosis
Cost of CMR in relation to perceived benefit
Agree, but not sure current restricted availability and high cost and only modest anticipated change
in clinical action justifies wholesale change from ECHO that also predicts risk well
Statement 2 Importance of management change
PPCI patients are already discharged early and often have little follow-up
CMR has more reproducible results than ECHO for measuring cardiac function. When this
reproducibility is combined with additional measurements that can further indicate good prognosis,
this should aid physicians’ confidence in earlier discharge and appropriate timing of follow-up
Also agree, but if good LV on ECHO and no clinical heart failure then discharge is safe. Unaware if
that can be accelerated further by CMR
Quality of supporting evidence
I don’t think it has been proved that clinical outcomes are better with a CMR strategy
Although this could be used in clinical practice, there are no studies that I am aware [of] that have
assessed such a strategy
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TABLE 34 Examples of respondents’ comments for the three statements in consensus (3, 5 and 9) and the three
statements not in consensus (1, 2 and 8)4 (continued )
Statement 8 Importance of management change
I’d accept perfusion scanning or DSE as adequate tests for ischaemia and would really only
specifically request CMR if there were additional diagnostic questions
Total revascularisation at one sitting with FFR guidance may render this unnecessary
Stress CMR in my experience is better than SPECT or stress ECHO. This is because the improved
prognostic and diagnostic accuracy helps physicians manage, with confidence, non-significant
coronary disease medically rather than invasively. There are also additional benefits of CMR, for
example definition of scar for CRT implant or for VT ablation. It can be helpful to ‘archive’ this
information for latter use if the patient is going to receive a device such as an ICD that may preclude
latter CMR scanning
Quality of supporting evidence
Evidence shows improved diagnostic accuracy compared to SPECT and DSE, but not in this
specific cohort
The evidence for ischaemia testing in the PPCI era does not really exist. There are no studies
comparing MRI in this context with other modalities and definitely no RCT comparing CMR versus
another modality
DSE, dobutamine stress echocardiography; IHD, ischaemic heart disease; MRI, magnetic resonance imaging; MSI, myocardial
salvage index; VT, ventricular tachycardia.
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Appendix 8 Modified survey (statements,
supporting paragraphs and references)
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Appendix 9 Primary diagnoses in medical notes
and Hospital Episode Statistics admissions data set
for patients initially identified as having ‘unobstructed
coronary arteries’ from hospital A
Summary from medical notes Primary diagnoses (HES) Frequency
Culprit lesion found, PCI Pain in throat and chest 1
Culprit lesion found, no PCI Acute MI 1
Culprit lesion found, no PCI Acute MI and stroke, not specified as haemorrhage
or infarction
1
Culprit lesion found, no PCI Atrial fibrillation and flutter 1
Culprit lesion found, no PCI Chronic ischaemic heart disease 2
Other/unknown problem Cardiac arrest 1
Other/unknown problem Pain in throat and chest 2
Unobstructed arteries Other diseases of pericardium 1
Unobstructed arteries Pain in throat and chest 1
Unobstructed arteries Syncope and collapse 1
Unobstructed arteries and other cardiac cause Acute MI 1
Unobstructed arteries and other cardiac cause Acute MI and other diseases of pericardium 1
Unobstructed arteries and other cardiac cause Acute pericarditis 1
Unobstructed arteries and other cardiac cause Atrial fibrillation and flutter 3
Unobstructed arteries and other cardiac cause Atrial fibrillation and flutter and other cardiac
arrhythmias
1
Unobstructed arteries and other cardiac cause Atrioventricular and left bundle-branch block 1
Unobstructed arteries and other cardiac cause Chronic ischaemic heart disease 1
Unobstructed arteries and other cardiac cause Non-rheumatic aortic valve disorders 1
Unobstructed arteries and other cardiac cause Other diseases of pericardium 4
Unobstructed arteries and other cardiac cause Other diseases of pericardium and atrial fibrillation
and flutter
1
Unobstructed arteries and other cardiac cause Pain in throat and chest 3
Unobstructed arteries and other cardiac cause Paroxysmal tachycardia 1
Unobstructed arteries and other cardiac cause Pneumonia, organism unspecified and acute renal
failure
1
Unobstructed arteries and other cardiac cause Pulmonary embolism 1
Unobstructed arteries and other/unknown problem Acute MI 2
Unobstructed arteries and other/unknown problem Chronic ischaemic heart disease 1
Unobstructed arteries and other/unknown problem Other chronic obstructive pulmonary disease 1
Unobstructed arteries and other/unknown problem Pain in throat and chest 5
Unobstructed arteries and other/unknown problem Pain in throat and chest and acute MI 1
Unobstructed arteries and other/unknown problem Pain in throat and chest and cerebral infarction 1
Unobstructed arteries and other/unknown problem Pneumonia, organism unspecified 2
Unobstructed arteries and other/unknown problem Syncope and collapse 1
DOI: 10.3310/hsdr07240 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 24
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131

Appendix 10 Data sources and definitions
used for identifying changes in management up to
12 months after the index admission
Important change in
management resulting
from CMR (identified in
formal consensus)
Patient
subgroup Data source
ICD-10 diagnosis codes and OPCS
procedure codes (up to 12 months
after the index admission)
New diagnosis
(non-ischaemic)
Unobstructed
coronary arteries
HES/PEDW admission data Any record of the following:
l Takotsubo cardiomyopathy (I42.8
AND F43.8)
l Myocarditis (I51.4)
l Pericarditis (I30 OR I31.0 OR I31.1
OR I31.9 OR I32.0 OR I32.1 OR I32.8
OR I01.0 OR I02.0 OR I09.2)
l Endocarditis (I33.9)
l Coronary spasm (I20.1)
Changes in medication All subgroups Not available Not available
Additional diagnostic tests All subgroups HES/PEDW admission data
and outpatient data
Any record of the following:
l PET scans (U10.4 OR U21.3
OR U36.2)
l ECHO (K58.5 OR U20.1 OR U20.3
OR U20.4 OR U20.5)
l IVUS (K51.2 OR L726)
l Pressure wire [(K63.4 OR K63.5 OR
K63.6) AND K51.8 AND Y44.2
AND Y53]
l Radionuclide
angiocardiography (U10.5)
l CT angiography (U10.2)
l SPECT (U21.4)
Implantation of devices l PPCI
l OHCA
HES/PEDW admission data Any record of the following:
l CRT (K60.7 OR K61.7 OR K59.6)
l ICD (K59 OR K72)
Revascularisation (PCI or
CABG) within 3 months
Multivessel
disease
HES/PEDW admission data Any record of the following (up to
3 months after the index admission):
l PCI (K49 OR K50 OR K75)
l CABG (K40 OR K41 OR K42 OR K43
OR K44 OR K45 Or K46)
Frequency of cardiology
outpatient appointments
All subgroups HES/PEDW outpatient data Rate of outpatient visits attended (count
of visits divided by follow-up time) where
the treatment specialty in which the
consultant responsible was working
during the period of care was cardiology
(code = 320)
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